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1 | General introduction
As newer and more intensive cancer therapies improve survival in patients with malignant
diseases, issues relating to quality of life and cognitive functioning are becoming more prominent.
Long-term survival depends on intensive and aggressive combined therapies for many
malignancies, but this treatment can come at a price. For many years treatment modalities have
been extensively investigated for their general and neurotoxic side-effects.1-5 Though, far less is
known about potential cognitive dysfunction associated with cancer therapy, and formal neuro-
psychological evaluation is rarely used as an outcome measure in clinical trials of anticancer
agents. 
Patients with cancer who are treated with systemic chemotherapy, cranial irradiation or
combined modality treatment often report difficulties with memory, attention, new learning,
and other higher cognitive processes.6,7 These problems - commonly referred to as ‘chemobrain’
or ‘chemofog’ by long-term cancer survivors - only recently have been getting the attention
they deserve. There is at present a growing awareness of potential cognitive side-effects of
cancer treatment, but as yet, research in this field has not yielded conclusive data that could
influence treatment decisions or development of new treatment strategies. In addition, still too
many oncologists, and other clinicians and professionals are unaware of the impact of potential
cognitive deficits on patients’ daily functioning and quality of life. Conceivably, even minimal
and subtle cognitive dysfunction may be profoundly disturbing to patients, especially when it
involves the inability to maintain or advance professional careers, academic performance, or to
take part in social or familial activities. Recovery to their baseline (or so called premorbid) state of
function is therefore crucial for most patients undergoing cancer treatment. 
The available literature on the potential cognitive side-effects of cancer and cancer treatment
has expanded in the last decade.8-11 The majority of these studies and review articles have
focused on patients with breast cancer or brain tumors,12-17 although patients with other cancer
diagnoses are also at risk and require further investigation. The aim of this thesis is to study the
cognitive sequelae of intensive or combined treatment regimens for hematological malignancies,
focusing on patients treated with bone marrow or hematopoietic stem cell transplantation
(HSCT), and patients who received treatment for primary central nervous system lymphoma
(PCNSL). 
The impetus for our investigations was derived from cognitive complaints that were frequently
reported by cancer patients after their treatment during clinical consultations by their physician.
As a result, several research projects have been initiated and undertaken by the Departments of
Neuro-oncology, Hematology, Radiotherapy and Psychiatry of the Erasmus MC – Daniel den
Hoed Cancer Center over the last eight years. The additional goals of these projects were to
study the effect of cognitive impairment on general health-related quality of life (QOL), and to
study its relation to subjective cognitive complaints and psychological functioning.
This thesis begins with an overview of potential neurotoxic complications observed after cancer
treatment and its effect on cognitive functioning (chapter 2). Two chapters with an extensive
literature review on cognitive dysfunction in HSCT patients (chapter 3) and in PCNSL patients
(chapter 4) follow. The next four chapters describe a series of investigations on the cognitive
sequelae and quality of life (QOL) in patients treated with or undergoing HSCT. It starts with the
results of a retrospective study in long-term survivors of HSCT in chapter 5. The preliminary
findings of a pilot study with a one year follow-up in patients scheduled to undergo HSCT are
presented in chapter 6. The next two chapters describe the pre-treatment baseline findings
(chapter 7) and the follow-up results (chapter 8) of our large-scale longitudinal prospective study
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in patients with hematological malignancies treated with HSCT, or with systemic chemotherapy
and/or involved-field radiotherapy. Chapter 9 presents the results of our neuropsychological
study, including a neuroradiological evaluation, in PCNSL patients treated with combined
modality treatment within a phase II trial of the European Organization for Research and
Treatment. In chapter 10 the main findings are summarized and discussed, followed by recom-
mendations for future research. 
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2 | The neurotoxic side-effects 
of cancer treatment 
Neurotoxic complications of cancer therapy are an increasingly important concern in patient
management. Because advances in cancer therapies have brought prolonged survival, toxicities
with a delayed onset now become manifest when in the past patients did not survive long
enough to be affected by them. In addition, improvement in systemic therapies and the use of
local treatments to target specific tumor sites have resulted in an increased incidence of central
nervous system (CNS) toxicity. For example, advances in supportive measures such as stem cell
rescue technology, have enabled the possibility of high-dose chemotherapy. Although these
supportive measures reduce systemic toxicity, they do not protect the CNS, and the same
cytotoxic agent that at low doses cannot adequately cross the blood-brain barrier (BBB) may
cause significant toxicity to the CNS when administrated in intensified doses. The main long-term
CNS toxicities observed after cancer treatment are discussed in this chapter. 
Radiotherapy and the nervous system
Radiotherapy plays a central role in cancer treatment as it continues to be the most widely used
treatment for most cancers. Radiotherapy can produce a variety of adverse side-effects on the
central and peripheral nervous system. Patients are exposed to radiotherapy-induced brain
injury either directly when they receive cranial irradiation (CRT) for primary or metastatic brain
tumors or as prophylactic treatment to prevent CNS cancers (eg, in small cell carcinoma of the
lung and leukemia), or incidentally when treated for head, neck and pituitary tumors or other
non-CNS tumors and nervous tissue is included within the radiation fields. The individual tolerance
for radiation damage is quite variable and may be influenced by several factors; including
volume (eg, whole brain or partial brain), total dose, dose per fraction, and duration of treatment.
Neurological complications associated with radiotherapy are usually classified according to the
time of onset after radiotherapy and include acute, early-delayed (or sub-acute), and late-
delayed (or delayed) complications.1 Acute complications occur days to weeks after radio-
therapy and usually involve constitutional symptoms such as headache, fatigue, and general
malaise. Early-delayed injury arises one to six months after therapy, whereas late-delayed
effects occur by more than six months after treatment and may be delayed for many years. Late-
delayed complications differ from the former effects as the damage is in most cases irreversible
and progressive.2,3 Four major clinical syndromes have been described in relation to
radiotherapy-induced CNS injury: encephalopathy, cranial neuropathy, myelopathy, and
peripheral neuropathy. The two main late-delayed effects will be described in the next section.
The development of radiation-induced leukoencephalopathy or diffuse radiation injury is the
most frequent complication in long-term survivors of CRT. Neuroimaging shows diffuse white
matter lesions (with preservation of the gray matter) associated with cortical and subcortical
atrophy, and ventricular enlargement. It may be clinically asymptomatic, but may also present
with progressive cognitive impairment, ranging from mild dysfunction to severe dementia.
Other clinical manifestations include gait abnormalities, fatigue, personality and emotional
changes, apathy, and eventually ataxia, incontinence, and sometimes akinetic mutism. Impro-
vement of clinical manifestations is rarely seen, and an ongoing deterioration is the rule. The
incidence and potential risk of this radiotherapy-induced complication is directly related to
several predisposing factors, including old age (ie, over 60 years), more than 2 Gy dose per
fraction, higher total dose, greater volume of brain irradiated (ie, whole brain radiotherapy),
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shorter overall treatment time, and concomitant or subsequent use of chemotherapy.4
In addition, CRT can cause focal areas of necrosis within six months of treatment.5 Most areas
develop within the white matter of the forebrain, and their occurrence is depending on the
dosage delivered. It is infrequent after standard radiotherapy to a dosage of 60 to 65 Gy in
fractions of 1.8 to 2.0 Gy, but it is more frequent after stereotactic radiosurgery and especially
after interstitial brachytherapy. It is commonly referred to as delayed cranial irradiation necrosis
or cerebral radionecrosis. Symptoms involve headache, personality change, focal neurological
deficits (eg, dysphasia, hemiparesis) or seizures.2 Patients may present with a clinical picture of a
growing intracranial mass lesion that is indistinguishable from tumor recurrence on CT or MRI. It
may however be entirely asymptomatic. The diagnosis can be established by brain biopsy, and
surgery may be indicated in patients in whom signs and symptoms cannot be easily controlled
with steroids.
Cognitive side-effects after radiotherapy to the brain have come increasingly into the focus of
interest because of their influence on quality of life in long-term disease-free patients.
Numerous reports have been published on cognitive decline following CRT for primary brain
tumors or metastases, and following prophylaxis for leukemia and small cell carcinoma of the
lung.6-10 This research has shown distinctive patterns in the clinical presentation of CRT induced
cognitive deficits. Most studies demonstrated deficits in memory functions (eg, memory
retrieval), motor functions (eg, fine motor control, neurobehavioral slowing) and executive
functions (eg, mental flexibility) during or after treatment, whereas other cognitive skills like
visual-perceptual skills, language, and abstract reasoning remained relatively stable. In addition,
there is evidence of more pronounced cognitive impairment after whole brain irradiation
compared to focal irradiation.11 Most studies showed that cognitive decline occurs more than
one year after treatment, with a peak of cognitive dysfunction approximately 24 months after
treatment.12-14 
It is unknown whether this cognitive deterioration is entirely due to the therapeutic procedure.
A recent study has shown that cognitive deterioration can actually predict tumor progression,
and even may precede radiographic evidence of progression by more than 3 months.15 Others
have shown that there are substantial differences in cognitive performance between long-term
survivors (patients who lived more than three years) and those who died between 20 and 36
months after treatment; patients who lived longer demonstrated significant better cognitive
function.16 So, even in patients with stable disease, the tumor itself may exert a significant
negative impact on cognitive function, and this seems especially the case for aggressive brain
tumors, such as high-grade gliomas. In sum, it appears that cognitive deterioration in tumor
patients can be attributed to multiple causes: direct and indirect tumor effects as well as side-
effects of the therapeutic procedure. 
Chemotherapy and the nervous system
Chemotherapy regimens involve the use of antineoplastic agents administered orally,
intravenously, intratumorally, or intrathecally (directly into the cerebral spinal fluid). Chemo-
therapy is associated with acute and rather persistent adverse effects on the nervous system
which generally depend upon the dosage and type of drugs, the route of administration, and
the presence of other treatment. The BBB plays a key role in the prevalence of neurotoxicity. It
is a barrier system that protects the brain from harmful substances in the blood, while supplying
12 |  COGNITIVE SEQUELAE OF INTENSIVE TREATMENT FOR HEMATOLOGICAL MALIGNANCIES
the brain with the required nutrients for proper function.17 It strictly limits transport into the
brain through both physical (tight junctions) and functional (transport proteins) barriers. It is the
rate-limiting factor in the penetration of many compounds into the brain. 
Many cytotoxic agents do not readily cross the BBB in conventional doses. Hence, most drugs
do not cause significant CNS side effects. But, many drugs that if given in low dosage are not
toxic to the CNS, may induce long-term neurotoxic complications if the BBB is disrupted, or
when the drug is delivered intrathecally or in high doses. For example, a variety of neurological
complications have been described for high-dose or intrathecal administration of cytosine
arabinoside (ARA-C) or methotrexate (MTX), whereas these drugs are not toxic for the CNS if
given in more ‘standard’ dosages.18,19
The neurotoxic potential of MTX, an antimetabolite used for chemotherapy of various malignant
diseases, is more widely recognized than that of any other cytotoxic agents. MTX is poorly
transported across the BBB, but significant concentrations can be achieved when the drug is
administered intrathecally or intravenously in high doses. The major delayed complication of
systemic high-dose MTX therapy is leukoencephalopathy manifested by symptoms similar as
radiotherapy-induced leukoencephalopathy.3,20 The course may progress to a permanent
vegetative state or death, although the majority of patients experience partial or complete
recovery when MTX is withdrawn. Leukoencephalopathy especially occurs if high-dose intra-
venous MTX is combined with radiotherapy to the brain, in particular when CRT is administered
before or during MTX therapy. Aseptic meningitis is the most common acute manifestations of
CNS toxicity from intrathecal MTX administration, but that treatment may also rarely give rise to
an ascending and often fatal myelopathy.21
Ara-C is another frequently used drug for hematological malignancies that has little neuro-
toxicity when used systemically at conventional doses.21 High-dose Ara-C may cause a usually
reversible cerebellar syndrome.22 It is also commonly used in intrathecal cancer treatment,
which use may cause an aseptic meningitis and rarely an irreversible myelopathy and encep-
halopathy. 
Many other agents used in the treatment of cancer may cause CNS toxicities, but these are
usually transient (eg, high-dose ifosfamide, 5-FU, cyclosporine). Most research on potential
side-effects of chemotherapy for solid tumors has been performed in patients receiving
chemotherapy for breast cancer in the adjuvant setting. Relatively few literature data exist on
possible late cognitive sequelae of chemotherapy, which is in part, due to small sample sizes of
studies, relatively high rates of attrition in longitudinal studies, and the administration of several
tests in a relatively small sample thereby increasing the risk of a Type I error.23 The interpretation
of data from cross-sectional study designs is troublesome because of inevitable differences
between the chemotherapy treated groups and the control groups, comprising for instance
differences in age, in use of hormonal therapy and in rates of (premature) menopause. Chemo-
therapy and hormonal therapy for breast cancer can induce premature menopause and induce
long-term complaints of fatigue. Hormonal changes might affect the regulation of mood and
anxiety as well as vigor, thereby in combination with factors underlying fatigue, affecting both
objective and subjective measures of cognition.24
Although high rates of cognitive dysfunction have been found in breast cancer patients before
the administration of chemotherapy, several cross-sectional studies using objective measures
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for cognitive function found impairment in the groups treated with chemotherapy compared
with control groups.25-28 Since two recent longitudinal studies on cognition in breast cancer
patients treated with adjuvant chemotherapy in the majority of women did not observe clear
impairments , it is difficult to draw definitive conclusion.25,29 Still, in both studies in a subset of
women an association between chemotherapy and cognitive impairment appeared to be
present. Meta-analyses of these studies showed small to moderate associations between
chemotherapy and cognitive impairment, with a magnitude of impairment of –0,03 to –0.51 SD
compared with matched controls.23,30,31 In addition, the need for more longitudinal research was
emphasized to the characteristics of chemotherapy-induced cognitive impairment and to
determine the clinical significance of cognitive deficits in patients’ daily-life functioning.
Effects of combined treatment and the nervous system
Multimodality treatment has become standard therapy for many cancer patients. However, a
greater efficacy in treating disease is frequently associated with greater toxicity, and it is not
surprising that neurotoxic effects of combined treatment are more profound than those of
single modality treatment, and may even be synergistic especially if chemotherapy is combined
with CRT.22 The sequence of treatment is here of clinical relevance. When MTX and CRT are
delivered sequentially, neurotoxicity appears to be less if chemotherapy is the initial treatment
modality and a suitable time break is allowed between administration of chemotherapy and the
start of radiotherapy. The administration of CRT prior to or concomitant with MTX, however,
predisposes patients to a higher incidence of delayed leukoencephalopathy.32 This seems in
part due to a disturbance of the BBB by CRT, resulting in an increased penetration of drugs into
the CNS. In children, the incidence and potential risk for the development of this delayed
syndrome was found directly related to the total dose of CRT, systemic and intrathecal
administration of MTX, and the sequence of their combined administration. Estimated
incidence ranges from less than 1% to 45%, depending on the mode of therapy.33
Small cell lung cancer patients may be treated with prophylactic RT after a complete systemic
response to chemotherapy is obtained. Despite the treatment of these patients with whole
brain radiotherapy, the impact of delayed leukoencephalopathy seems limited. Remarkably,
most studies have failed to demonstrate major effects on cognition in these patients.34,35
Effects of immunotherapy 
In the last two decades there has been an increase in the use of biological therapies for cancer
patients. One of these therapies involves immunotherapy with cytokines, also designated as
biological response modifiers which is utilized for a number of malignancies, including hairy-cell
leukemia, chronic myelogenous leukemia, non-Hodgkin’s lymphoma, multiple myeloma, and
melanoma.36 Cytokines are regulatory molecules that allow communication among cells of the
immune system. Immunotherapy focuses on the patients’ immune system in an effort to
enhance its ability to identify cancer cells and to support the organism’s ability to destroy these
cells. The most frequently used cytokines are interferon-alpha (IFN) and interleukin-2 (IL-2).
Cytokine-induced changes in brain function are well documented. Cytokine receptors are found
in many other organs, including the brain. Cytokine produced in the periphery can possibly
cross the BBB and act directly in the CNS or can transmit signals to the CNS through visceral-
neuronal and humoral pathways. 
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IFN therapy is characterized by a wide range of adverse effects. Almost all patients experience a
‘flu-like’ syndrome within hours after the first administration. Symptoms include fever, chills, and
nausea, and generally abate after a few weeks of treatment. Other adverse effects reflect
hematological, hepatic, renal, cardiovascular, pulmonary, and endocrine dysfunctions.37 Severe
neurological manifestations are uncommon despite the fact that IFN affects the CNS and the
peripheral nervous system. Neurotoxicity tends to be dose-related and more common in older
patients. Higher cumulative doses of IFN can cause headaches, confusion, lethargy, halluci-
nations, and seizures, and these symptoms are usually reversible. Furthermore, a growing
number of studies have observed mood and cognitive changes after administration of pro-
longed IFN.3,38,39 Changes include symptoms of depression, anxiety and fatigue and impairment
of attention, memory, motor and executive functions.40-43 Data show that these neuropsychiatric
effects are suggestive of frontal-subcortical dysfunction, supported by EEG studies that showed
notable slowing of frontal lobe waveforms in patients receiving high-doses of IFN.44,45
IL-2, a cytokine used to boost immune response in cancer therapy, has also been associated
with neurotoxicity. Neurobehavioral complications are observed in 30 to 50% of patients that
use IL-2. These symptoms usually include delusions, hallucinations, and depression. The
cognitive changes associated with IL-2 are similar to those of IFN, and involve a triad of
impaired memory, motor, and executive functioning in the context of preserved intellectual
abilities.46,47
Effects of adjunctive medications
In addition to the neurotoxic effects of primary cancer treatment, adjuvant medications such as
corticosteroids, other immunosuppressive agents, and anticonvulsants may also cause
neurobehavioral symptoms. Corticosteroids are widely used in cancer therapy. They are a part
of the anticancer therapy for a variety of tumors, including brain tumor (to control increased
intracranial pressure) and hematological malignancies. In this latter patient group they are
mainly used for their oncolytic effect. In patients treated with allogeneic HSCT, corticosteroids
are administered for their immunosuppressive effects to control graft-versus-host disease. One
of the most common neurological complications of corticosteroids is myopathy.48 Cognitive and
affective side effects are also common. Corticosteroids, amongst others, act at receptors in the
hippocampus and can play a role in memory deficits after chemotherapy.49 There is evidence of
reduced hippocampal volume and declarative memory deficits after chronic corticosteroid
exposure.50 In addition, CNS infections may arise due to the immune suppressive action of
corticosteroids.
Mechanisms of treatment-related neurotoxicity
Many parts of the precise pathogenesis of CNS complications associated with cancer treatment
are still unknown. Complications may arise from direct toxic effects of treatment on the CNS,
indirectly from metabolic abnormalities or cerebrovascular disorders induced by the treatment
regimen, or from other additional factors. For radiation injury to the CNS two hypotheses have
been proposed. The vascular hypothesis speculates radiation-induced vascular injury, accelerated
atherosclerosis and mineralizing microangiopathy, resulting in vascular insufficiency and
infarction. The glial hypothesis speculates radiation-induced ablation of glial precursors and
resultant demyelinative necrosis.1 In the more severe cases, obvious vascular damage and
demyelination contribute to neurological deficits; these injuries may be amplified by an
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extensive neural progenitor dysfunction that includes the more radioresistant glial and vascular
progenitor cells.
The assumed underlying mechanisms for chemotherapy-induced neurotoxicity are similar to
those of radiation-induced injury. Three mechanisms are commonly proposed: 1) direct
neurotoxic injury to the cerebral parenchyma, including the microglia, oligodendrocytes, and
neuronal axons, producing demyelination or altered water content; 2) secondary inflammatory
response, an immunologic mechanism including allergic hypersensitivity and autoimmune
vasculitis; and 3) microvascular injury leading to obstruction of small- and medium-sized blood
vessels, spontaneous thrombosis, ischemia/infarction, and parenchymal necrosis.51-53
Other additional mechanisms involve altered neurotransmitter levels, particularly brain amines
and metabolites, indirect chemical damage and oxidative damage, and indirect effects such
anaemia or a reduction in hormone concentrations.54-56 Last of all, CNS effects and subsequent
cognitive impairment can also be increased by factors that normally confer increased vulnerability
to cognitive dysfunction after any type of CNS injury, in particular older age. 
Distinguishing treatment-induced toxicity from the numerous of other possible causes of the
same symptoms is a difficult process, but also an important challenge in patient care and
management. This may in particular be relevant in patients with CNS localizations of their
malignancy. Therefore, the cause-and-effect issue remains a key subject when dealing with
individual patients, in particular those with primary brain tumors.
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3 I Literature review of cognitive functions 
in HSCT patients
COGNITIVE SEQUELAE OF INTENSIVE TREATMENT FOR HEMATOLOGICAL MALIGNANCIES |  21
Bone marrow or hematopoietic stem cell transplantation (HSCT) can be defined as an
intravenous infusion of hematopoietic stem cells collected from bone marrow, peripheral blood,
or umbilical cord blood. It is used as a procedure to re-establish hematopoietic and immune
function in patients with damaged or defective bone marrow or immune systems. Significant
advances in the development of HSCT were made in the late 1960s. These days, worldwide
more than 45.000 patients annually receive HSCT, and this number continues to increase by 10-
20% each year.1,2
HSCT is in particular a potentially curative treatment for hematological malignancies or
disorders. High-dose chemotherapy and autologous stem cell rescue are considered standard
therapies for relapsed Hodgkin disease and relapsed non-Hodgkin’s lymphomas, and they are
increasingly applied as part of initial therapy for patients with non-Hodgkin Lymphoma (NHL),
multiple myeloma, and germ cell tumors. Allogeneic HSCT is potentially curative for acute and
chronic leukemia, myleodysplastic syndromes, NHL, and multiple myeloma. Experimentally,
HSCT is used for disorders such as multiple sclerosis, primary systemic amyloidosis, and primary
brain tumors.3-5
The transplant procedure is generally divided in the following phases: conditioning, bone
marrow or stem cell infusion, neutropenic phase, engraftment phase, and post engraftment
period. The most common conditioning regimens include total body irradiation (TBI) and cyclo-
phosphamide, or busulfan and cyclophosphamide. In allogeneic HSCT, bone marrow or stem
cells from a HLA-matched or mismatched related donor, or an unrelated donor are utilized. 
For many diseases, the curative potential of allogeneic HSCT is only in part due to the
myeloablative conditioning regimen. A major therapeutic effect of allogeneic transplantation is
related to an immune mediated graft-versus-malignancy effect (GVM), which is the alloreactive
response of donor-immune cells against the host’s tumor. Consequently, recipients of allografts
have reduced rates of relapse compared to recipients of autografts.6 Another type of HSCT is an
autologous transplant, in which the patient’s peripheral blood stem cells are harvested at an
earlier timepoint in the course of the disease and reinfused following myeloablative therapy. No
GVM effect ensues autologous HSCT, and, as a result the therapeutic efficacy exclusively results
from the high-dose cytotoxic regimen. 
Transplant-related complications
HSCT is associated with significant morbidity and mortality, which is evident throughout the
course of treatment, beginning with induction therapy and continuing in the post-transplantation
recovery phase. The severe toxicity of the preparative conditioning regimens, acute and chronic
graft-versus-host-disease (GVHD), and infectious complications related to the immunodeficient
state remain major obstacles of the HSCT procedure, especially in recipients of allografts.
GVHD is the clinical manifestation of an immunological attack by donor lymphocytes on host
tissues, and generally involves the skin, gastrointestinal tract, and the liver. By definition, acute
GVHD occurs within the first 100 days of transplantation, and consists of a syndrome of
dermatitis, enteritis, and hepatitis. The incidence and severity of acute GVHD varies and is
directly correlated with HLA subtype mismatching and use of adequate prophylaxis. Chronic
GVHD develops after day 100 and consists of an autoimmune-like syndrome directed towards
multiple organs and organ systems. Chronic GVHD arises in 15-50% of patients who survive
three months after transplantation, and commonly evolves as a transition from acute GVHD,
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although it can occur de novo in 20-30% of patients. The primary cause of morbidity related to
chronic GVHD is global immune dysfunction and organ malfunction. To prevent GVHD, patients
receive a variety of immunosuppressive drugs, including cyclosporine, low-dose methotrexate
(MTX), and corticosteroids. Many of these immunosuppressive drugs (in particular cyclosporine,
tacrilomus, and corticosteroids) have neurological side-effects, mainly central nervous system
(CNS) disorders, and they increase the risk of CNS infections.7,8 Autologous HSCT has a lower
frequency of complications, because it does not cause GVHD and does not require post-
transplant immunosuppression. The risk of regimen-related toxicity and GVHD increases with
advanced age, limiting standard HSCT to younger patients (below 60 years) who are in a good
general condition. Reduced-intensity or nonmyeloablative conditioning regimens are alternative
therapeutic options for elderly, and for patients who require a second transplant.9
Infectious complications arise during several stages of the transplant procedure. Especially
during the first months after transplant patients are at high risk of fungal, bacterial and viral
infections due to neutropenia and damage to mucosal barriers. But, even in the late engraft-
ment period patients are at risk to develop infectious despite a slow recovery of immunity.
HSCT patients who survive the early phase after transplant and who remain disease-free are still
at risk to develop late side-effects, even years after the HSCT procedure. Much of the research
on late effects has focused on major medical events, in particular late deaths and secondary
malignant diseases. Still, several non-malignant physical complications, as late ocular effects
(eg, cataract), pulmonary late effects, liver complications (eg, hepatitis), musculoskeletal problems
(eg, necrosis of bone, osteoporosis), and fertility problems may significantly impair the health-
related quality of life (QOL) of long-term survivors.10-12
Neurological Complications of HSCT
The neurological and central nervous system (CNS) complications following HSCT not only
affect survival,13,14 they may also affect cognitive functioning of long term survivors. The nervous
system is exposed to multiple sources of injury following HSCT, including the effects of pre-
transplant conditioning, of immunodeficiency resulting from GVHD, and of immunosuppressive
drugs.8,15 Neurological complications following HSCT have been reported in up to 70% of
patients.16,17 Allogeneic HSCT has generally been reported to lead to more frequent neuro-
logical complications than autologous HSCT.13
Neurological complications predominantly involve encephalopathy, CNS infections, and
cerebrovascular disorders.18 Diffuse generalized encephalopathy may be a side-effect of drugs
used in the conditioning regimen, like cytarabine, busulfan, ifosfamide, and cyclosporine. 
It may also be the result of concurrent liver, lung and kidney dysfunction. Approximately 2% of
HSCT recipients develop an infection of the CNS (eg, cerebral aspergillus, herpes zoster,
toxoplasmosis).19 The nature and severity of CNS infections are dependent on several factors,
including donor histocompatibility, GVHD prophylaxis, concurrent viral infections, and presence
of GVHD. Particularly, patients with persistent immunodeficiency (chronic GVHD, prolonged
immunosuppressive drugs) are at continued and increased risk of infection. 
Lastly, cerebral hemorrhages, including subarachnoid hemorrhage and subdural hematomas are
relatively rare complications in HSCT patients.20 The underlying disease may play a role in the
development of these specific complications, as subarachnoid hemorrhages and subdural
hematomas are more frequently observed in patients with relapsed leukemia or leukemic
infiltration. 
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All these potential sources of CNS damage can affect cognitive functioning and pose significant
problems for patients who attempt to resume their day-to-day lives after this intensive treatment.
HSCT treatment has been extensively investigated for its physical toxic or acute neurological
side-effects, but far less is known about late cognitive deficits related to HSCT. Several uncon-
trolled studies suggest that cognitive problems are not rare in HSCT patients, which would be
an important concern of the QOL in this group of cancer patients.
This chapter reviews the results of studies on cognitive functioning in HSCT recipients. A
bibliographic search of articles was conducted that included reports using formal neuro-
psychological evaluations, or self-report measures. The purpose of this review is to syste-
matically assess and summarize what is known about cognitive functioning in patients prior to
and following HSCT. 
LITERATURE OVERVIEW OF COGNITIVE STUDIES
A systematic MEDLINE search was performed to identify key literature. Only articles published
in English were included. Case-reports, pediatric studies, and studies which did not present
their results in full detail were excluded. The electronic search was supplemented by a manual
review of the bibliographies of the references retrieved. Articles were reviewed with respect to
important psychometric issues related to cognitive functioning, including the cohort of patients,
the neuropsychological measures utilized, the definition of cognitive impairment used, and
observed cognitive dysfunction and, if presented, potential confounding factors related to
cognitive functioning and implications for QOL. 
The search identified 12 articles, seven of which have been published in the past decade, since
1989. Almost all studies were designed specifically to investigate cognitive functioning in HSCT
patients before or following treatment. Two reports focused on the neurological effects of
HSCT, including neuroradiological examination, and combined their evaluation with a neuro-
psychological assessment.14,15 Three studies used either a relatively brief cognitive evaluation, a
structured interview, or a self-reported measure to assess cognitive functioning.15,21,22 In all other
studies, formal neuropsychological testing was performed. Table 1 lists the neuropsychological
instruments used to assess cognitive functioning. 
The majority of studies concerned patients with a hematological malignancy, predominantly
leukemia. In two studies the clinical diagnosis was not specified,23,24 and two studies used a
mixed group of hematological and breast cancer patients.25,26 Seven studies reported solely on
either autologous or allogeneic recipients. Sample sizes ranged from 14 to 65 patients in cross-
sectional studies. In prospective studies, sample sizes ranged from 12 to 142 patients at
baseline before HSCT conditioning, and from 11 to 54 patients at follow-up. One study
included both pediatric and adult patients,23 in all other studies, patients were between 16 and
63 years old. The review results are discussed by study design (see Table 2 and 3 for a detailed
overview).
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Results of prospective studies
Eight articles described the results of prospective longitudinal studies on cognitive functioning
in HSCT patients.14,22-25,27-29 The first study was carried out by Parth et al23 to assess whether
intensive chemoradiotherapy was related to cognitive deficits, and if improvement after
recovery of treatment occurred. Serial neuropsychological assessment up to one year after
treatment was performed in 11 patients and three controls. Between-group differences, in
particular with regard to perceptual speed and reasoning, were found at all time points apart
from one year after treatment. The authors concluded that slight changes in neuropsychological
capacity were seen compared to controls, especially near the beginning of treatment. 
Meyers et al followed a mixed group of 61 hematological patients scheduled to undergo
HSCT.22 Serial cognitive screening using the Dementia Rating Scale, was performed in 21
patients up to eight months following HSCT. Results showed that 20% of patients experienced
mild cognitive dysfunction prior to HSCT, and nearly 40% had significant anxiety. Short-term
memory deficits nearly doubled at follow-up. Pre-transplant emotional and cognitive functioning
were important determinants of long-term outcome. 
Ahles et al examined psychological and cognitive functioning in 54 patients with a hema-
tological disorder or breast cancer undergoing autologous HSCT.25 Serial evaluations before
and following transplant, and at pre-discharge were available for 34 patients. No effect of prior
Attention and Executive Function
Trailmaking Test A and B
Ruff Two and Seven Test 
Digit Span Testb
D2 Test
Stroop Color Word Test
Wisconsin Card Sorting Test
Language
Controlled Oral Work Association
Verbal Fluency Test
Intelligence
Raven Standard Progressive Matrices
WAIS-R, short version
Information Testb
Similarities Testb
National Adult Reading Test
Memory
Buschke Selective Reminding Test
Benton Visual Retention Test 
Verbal Learning Test
Non-Verbal Learning Test
Hopkins Verbal Learning Test-revised
Temporal Orientation Subtest 
Subtests Wechsler Memory Scale-reviseda
Visuospatial Visual Function
Block Design Testb
Picture Completion Testb
Fragmented Figures Recognition Test
Psychomotor function
Grooved Pegboard Test
Finger Oscillation Test
Vienna Determination Test
Hand Dynamometer Test 
Digit Symbol Test
Table 1 Overview of neuropsychological measures
a Visual Memory Span Test, Visual Reproduction, and Logical Memory; b Wechsler Adult Intelligence Scale
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CNS treatment (eg, intrathecal chemotherapy and cranial irradiation) was found at baseline. The
authors concluded that both groups demonstrated a general decline in cognitive performance
over time. 
The acute and delayed neurotoxic effects of low doses of hyperfractionated TBI (12 fractions of
1.2 Gy) in adults undergoing autologous HSCT were investigated in a series of studies of Wenz
et al24,27 and Peper et al.28 The extent to which these three studies have an overlap of patients is
unclear. Two of the three studies used small control groups of cancer patients who received
radiotherapy on the pelvis, patients with renal insufficiency, and patients undergoing dental
surgery. The first study examined 40 patients before and immediate after the first fraction of
TBI.24 Baseline results were within normal limits, and no decrease in functioning was observed.
Attention functions improved as a result of practice effect of repeated testing. A long-term
follow-up assessment at a median of 27 months following TBI was performed in 21 recurrence-
free survivors, and revealed no deterioration of test results in intelligence, attention or
memory.27 The last study in the series compared three subgroups of patients, including a control
group, and assessed 12 long-term survivors more than seven years after treatment. Patients
underwent a neuropsychological, neurological, and neuroradiological examination. Results
showed moderate brain atrophy in some survivors, and a mild decrease in memory function.
The authors concluded that cognitive decline in individual patients was associated with CNS-
treatment prior to HSCT, and that the incidence of long-term neurobehavioral toxicity was very
low. 
In the study of Sostak et al, patients treated with allogeneic HSCT were evaluated with
neurological and neuroradiological examinations, and underwent a neuropsychological
assessment.14 Almost half of the 71 patients developed mild neurological abnormalities that
primarily affected the peripheral nervous system with minor consequences for cognitive and
neuroradiological outcome. Subclinical neurological abnormalities, cognitive deficits (mainly
within the domain of executive function) and white matter lesions were detected in a small
subgroup of patients following HSCT. The main risk factors related to these CNS changes were
severe GVHD and prolonged immunosuppression. 
Recently, Syrjala et al reported results of the first large-scale longitudinal study in recipients of
allogeneic HSCT with serial assessments at 80 days and one year.29 Complete follow-up was
performed in 54 of the 142 patients who participated in the pre-transplant baseline assessment.
Before transplant, patients performed comparable to normative data in all areas except motor
dexterity, verbal fluency and verbal memory. A significant reduction in performance on all
neuropsychological tests was found at 80 days, with improvement to pre-transplant levels at
one year on all measures except grip strength and motor dexterity. Performance on tests of
verbal fluency and verbal memory were significantly lower than normative data on all time
points. Patients without pre-transplant chemotherapy (other than hydroxyurea) and patients
without chronic GVHD medication at one year demonstrated a lower risk of cognitive
impairment. The authors concluded that long-term cognitive deficits are only infrequently
directly derived from HSCT.
Results of cross-sectional studies
Four studies used a cross-sectional design to examine cognitive functioning in HSCT patients.
The time between transplant and the neuropsychological assessment ranged from 5 to 120
months in three studies,15,21,26 while one study investigated pre-transplant cognitive functioning
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only.30 Andrykowski et al studied a cohort of 30 leukemia patients who received allogeneic
transplant at a mean time of 47 months after HSCT using two standardized self-report
measures.21 Long-term impairments reported by HSCT survivors involved primarily slowed
reaction time, reduced attention, and difficulties with problem-solving and reasoning. An
increased dose of TBI was associated with increased cognitive dysfunction, even when controlling
for psychological distress. In another study, Andrykowski et al demonstrated by formal neuro-
psychological testing that cognitive impairment was apparent before undergoing transplant in
56% of 55 HSCT candidates.30 Performance in memory was most likely to be impaired, followed
by performance in motor function, and complex attention function (eg, cognitive flexibility). Test
performance was associated with specific disease and treatment factors: cranial irradiation and
CNS involvement in conjunction with intrathecal chemotherapy were predictors of poor
performance. 
Other risk factors for cognitive impairment following HSCT were identified by Padovan et al.15
Neurological, neuropsychological, and neuroradiological findings were examined seven to 120
months after transplantation. Cognitive functioning was evaluated in 46 long-term survivors by
using a structured interview. Cognitive deficits, particularly reduced memory function, were
reported by 37% of patients. Impairment was related to neurological abnormalities, long-term
cyclosporine medication and age. 
Very recently, Booth et al investigated the relationship between objective cognitive impairment
and subjective cognitive complaints six months following HSCT.26 The majority of the 65
patients was female, diagnosed with breast cancer, and had received autologous HSCT.
Moderate to severe cognitive impairment was found in 28% of patients. Deficits in psychomotor
speed and executive function were most profound. Impaired function was predominantly found
in patients who were older, male, less educated, and had lower estimated intelligence. Subjective
cognitive complaints reported by the patients failed to reflect their cognitive performance, as
they were unrelated to overall cognitive functioning assessed with an extensive neuro-
psychological test battery. The authors concluded that patients who report cognitive deficits
may not be the same as those who experience an actual decline following HSCT.
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Parth et al 1989 23
Objective
To assess whether
intensive chemoradio-
therapy results in
cognitive performance
deficits and whether
changes recover after
treatment
Neuropsychological tests
/ Additional measures
Locally developed
(computerized) test
battery assessing
information processing,
memory, reasoning,
spatial function,
perceptual speed, fine
motor skills and
vigilance / -
Meyers et al 1994 22
Objective
To evaluate cognitive
and emotional
functioning of patients
scheduled to undergo
HSCT
Neuropsychological tests
/ Additional measures
10 / IV,V,VI,VII
Design
Prospective design with
assessment pre-HSCT, at
discharge (50 days), at
100 days and at 1 year
post-HSCT
Impairment definition
Mean raw scores over
time were compared to
control group 
Cut-off for impairment
not specified
Design
Prospective design with
assessment pre-HSCT,
after 2 weeks, at
discharge (29 days) and
at 8 months post-HSCT
Impairment definition
Impairment defined as
total score was ≥ 2 SD
below mean of healthy
elderly subjects
Sample characteristics
Mixed sample HSCT
patients (n=44) and
healthy controls (n=42);
medical diagnosis
unknown
Age 8-44 Serial NPA in
11 HSCT patients and 3
controls
Remarks and
Conclusion
Between-group
differences on tasks
before treatment:
perceptual speed,
spatial function and fine
motor skills Between-
group differences at
discharge and 100 days,
not at 1 year
Sample characteristics
Hematological patients
(n=61), mainly leukemia;
no CNS disease Age 19-
63; mean 38
Remarks and
Conclusion
20% mild impairment
and 40% anxiety pre-
HSCT; short-term
memory deficits nearly
doubled at follow-up; no
problems on attention
subtest at any time
point; outcome
unrelated to IFN, type of
HSCT or age
Treatment
CP (60 mg/kg for 2 days)
followed by TBI (15 Gy
in 6 fractions)
Type of HSCT not
specified
Remarks and
Conclusion
Slight decrement on
perceptual speed and
reasoning in patient
group at start of
treatment
Treatment
IFN pre-HSCT (n=22);
HSCT conditioning
regimens not specified
Type of HSCT:
autologous (n=19), MRD
(n=25), MUD (n=17)
Remarks and
Conclusion
Cognitive and emotional
functioning pre-HSCT
related to long-term
outcome
Depression increased at
hospitalisation, and
decreased at follow-up;
anxiety decreased at
follow-up and remained
low
Table 2 Overview of prospective studies of cognitive functioning and HSCT
Ahles et al 1996 25
Objective
To evaluate psycholo-
gical and neuropsycho-
logical functioning of
autologous HSCT
patients
Neuropsychological tests
/ Additional measures
4,6,11,12 / I (brief
version), IV, VIII, IX
Wenz et al 1999 24
Objective
To investigate acute
CNS toxicity of low
radiation doses in adults
undergoing TBI
Neuropsychological tests
/ Additional measures
9,14,15,16,17,18 / X
Design
Prospective design with
assessment pre-HSCT,
mid-treatment (1-3 days
following reinfusion), 1-2
days before discharge
Impairment definition
Between (patient) group
comparisons of mean
test scores
Design
Prospective design with
assessment 1 day before
TBI and 1 hour after first
dose of TBI
Impairment definition
Comparison to
normative data
Test scores over time
were compared within
patient groups
Sample characteristics
Mixed group of
hematological (n=27)
and breast cancer
patients (n=27); 
Age mean 39; majority
(78%) female
Serial NPA in 34 patients
Remarks and
Conclusion
No effect of prior CNS
treatment at baseline
Decreased performance
over time for both
groups in higher order
cognitive processing
Sample characteristics
Patients in CR (n=58)
diagnosis not specified;
no CNS disease; mean
age 43 ± 10; serial NPA
in 40 patients
Control group: cancer
patients (no CNS
disease) undergoing RT
to pelvis (n=31), patients
undergoing dental
surgery (n=7); mean 
age 53 ± 15
Remarks and
Conclusion
TBI patients showed
normal baseline results
in intelligence and
attention
No decline in results
after 1.2 Gy TBI
Improvement in
attention attributed to
practice effects of
repeated testing
Treatment
Various pre-treatment
regimens, including CRT
and/or IT-CT (n=11)
Various HSCT induction
regimens (CP, VP-
16,BCNU,CA ,CY,CIS,TH)
and TBI (n=5) ; all
autologous HSCT
Remarks and
Conclusion
Hematological patients
showed more psycho-
logical distress at
baseline
Psychological status
generally improved over
time for both groups
Treatment 
Previous treatment not
specified
TBI (1.2 Gy in 1 fraction;
total dose not
specified); HD-CT (CP)
after completion TBI
All autologous HSCT
Remarks and
Conclusion 
TBI patients showed less
positive feelings before
start treatment
No differences in mood
states compared to
control groups
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Wenz et al 2000 27
Objective
To evaluate delayed
CNS toxicity of TBI
using neuropsycholo-
gical testing of
intelligence, attention
and memory
Neuropsychological tests
/ Additional measures
9,14,16,17,18,19,20 / X
Peper et al 2000 28
Objective
To investigate neuro-
behavioral, neurological
and neuroradiological
effects of TBI in treat-
ment of hematological
malignancies
Neuropsychological tests
/ Additional measures
3,4,5,6,9,21,22,23,24,25,2
6,27,28,29, 30,31 /
VIII,X,XI
Design
Prospective design with
assessment 1 day before
TBI, 1 hour after first
dose of 1.2 Gy TBI and
after a median of 27
months (range 6-36)
Impairment definition
Comparison to
normative data
Test scores over time
were compared for the
patients tested at all
time points (n=21)
Design
Cross-sectional study (I)
with pre-TBI and post
TBI group (I9-65 months
post-TBI, mean 32) and
prospective study (II)
with mean long-term
follow-up of 9 years after
TBI (range 7-11)
Impairment definition
Comparison to normative
data (z-score < -1.28
borderline or impaired)
Between-group com-
parisons of mean test
scores and comparison
of mean test scores over
time
Sample characteristics
Mixed group of
hematological patients
(n=58); no CNS disease
Age 20-59; mean 43
Serial NPA in 21 patients
Remarks and
Conclusion
Pre-HSCT results within
normal limits apart from
visual memory;
improvement in all tests
after first TBI dose; no
deterioration at follow-
up and significant
improvement in attention
and non verbal memory
Sample characteristics
Study I: Pre-TBI group
(n=14) and post-TBI
group (n=20); age 16-52,
mean 36.5 and matched
controls with renal
insufficiencies (n=11;
age 20-52, mean 38)
Study II: survivors pre
and post-TBI groups
(n=12; age 23-59, 
mean 45)
Remarks and
Conclusion
Study I: scores within
normative limits
Post-TBI group showed
subtle reduction (1 SD)
in memory 
Cognitive decline
associated with pre-TBI
CRT or IT-CT
Treatment
Various pre-treatment
cytotoxic regimens
HSCT regimen consisted
of TBI (12 fractions of 1.2
Gy in 4 days) and CP
followed by autologous
HSCT
Remarks and
Conclusion
Influence of practice
effects (acute phase)
and improvement in
mood state (chronic
phase)
No effects of age at TBI,
gender or length of
follow-up
Treatment
Previous CNS treatment
(n=4)
HSCT induction regimen
consisted of TBI (12
fractions of 1.2 Gy in 4
days) and CP followed
by autologous HSCT
Remarks and
Conclusion
Study II: no clinical signs
of dementia and stable
intellectual abilities
Slight increase in
memory, verbal concept
formation and attention
Improved emotional
state
Sostak et al 2003 14
Objective
To determine the risk
and time course of
neurologic sequelae
after allogeneic HSCT to
establish the risk profile
Neuropsychological tests
/ Additional measures
5,8,9,13,25,30 / -
Syrjala et al 2004 29
Objective
To examine
neurocognitive changes
over the first year in
recipients of allogeneic
HSCT
Neuropsychological tests
/ Additional measures
1,6,9,11,21,32,33,34 (6
tests administered at all
time points) / -
Design
Prospective design with
assessment 2 ± 4
months pre-HSCT and
14 ± 3 months after
HSCT
Impairment definition
Comparison to
normative data
Impaired functioning
defined as total score
was 1 SD below mean;
dementia defined as
total score of structured
interview was ≤ 32
Design
Prospective design with
assessment pre-HSCT, at
80 days and 1 year after
HSCT
Impairment definition
Comparison to
normative data
Impairment was defined
as test score ≥ 1 SD
below normative mean
Summary impairment
scores were calculated
based on the number of
impaired tests
Sample characteristics
Mixed group of
hematological patients
(n=71), mainly leukemia
patients
Age 17-58; mean 37
Serial NPA in 55 patients
Remarks and
Conclusion
Abnormal results in 58%
pre- HSCT and 51% after
HSCT (executive
function) 
17/32 HSCT improved
post treatment,
associated with female
sex, shorter disease
duration and stable
disease stage at HSCT
Sample characteristics
Mixed group of
hematological patients
(n=142), mainly leukemia
Age 22-61; mean 41
Serial NPA in 54 patients
Remarks and
Conclusion
Pre-HSCT function
comparable to norms
except for motor dex-
terity, verbal fluency and
verbal memory; reduction
at 80 days on all tests
with return to pre-HSCT
levels at 1 year, except
for motor dexterity and
grip strength
Treatment
Various pre-HSCT
cytotoxic regimens: 
CNS treatment (n=11)
Conditioning regimen
consisted of CP
combined with TBI
(n=46) or Bu, VP-16,
BCNU, MPD; IT-CT post
HSCT (n=8)
Remarks and
Conclusion
5 deteriorated, 4 had
neurological
abnormalities
Neurological outcome
negatively affected by
unrelated donor status,
TBI, IT-MTX, disease
duration, disease stage,
aGVH and
immunosuppression
Treatment
Various pre-HSCT
cytotoxic regimens CNS
treatment (n=16), IFN
(n=17)
HSCT conditioning
regimen: HD-CT alone
(n=53) or combined with
TBI (n=89) followed by
allogeneic HSCT
Remarks and
Conclusion
Impairment pre-HSCT
increased risk (6.3) 
at 1 year
Lower risk in patients
not treated with CT (or
only hydroxyurea) pre-
HSCT; cGVHD treatment
increased risk of motor
dexterity impairment 
at 1 year
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Andrykowski et al 1990 21
Objective
To investigate long-term
cognitive dysfunction in
adult survivors of
allogeneic HSCT in
relation to TBI dose
Neuropsychological tests
/ Additional measures
Measure of cognitive
functioning based on
self-report measures / -
Andrykowski et al 1992 30
Objective
To identify the nature,
extent and correlates of
neuropsychological
impairment in HSCT
patients before
undergoing treatment
Neuropsychological tests
/ Additional measures
1,2,3,4,6,7,8,9 / I (brief
version)
Design
Retrospective design
Time interval 12-96
months post-HSCT;
mean 47 months
Impairment definition
Intercorrelations
between subscales and
total scores on
subjective measures
were compared to
demographical, disease
and treatment variables
Design
Cross-sectional
assessment before
HSCT treatment
Impairment definition
Summary z-scores 
were calculated
Comparison to
normative data
Definite impaired ≥ 2 SD
below norms; probable
impairment ≥ 1.5 SD
below norms
Sample characteristics
Chronic and acute
leukaemia patients
(n=30)
Age 18-51; mean 34
Remarks and
Conclusion
Mild to moderate self-
reported cognitive
impairment
independent of
concurrent distress
Increased dose of TBI
was associated with
increase in cognitive
dysfunction
Sample characteristics
Patients with hemato-
logical disorders (n=55),
including CNS disease
(n=9) 
Most patients (n=42)
had leukemia
Age 19-53; mean 36
Remarks and
Conclusion
56% impaired (> 1.5 SD)
on at least 2 of 11 test
indices
Memory most likely 
to be impaired (33%),
attention least likely (6%)
No relation with
psychological distress
Treatment
HD-CT (CP, VP-16,
BCNU, Ara-C, MPD)
followed by TBI (5.5 to
14 Gy)
3 patients received 
HD-CT alone
Type of HSCT: MRD
83%; haplo-identical
partially MMR (17%)
Remarks and
Conclusion
TBI-related cognitive
impairment involved
slowed reaction time,
reduced attention and
concentration,
difficulties in reasoning
and problem solving
Treatment
Pre-HSCT treatment
consisted of
chemotherapy alone
(n=39) or combined with
localized RT (n=7), CRT
(n=8) or TBI (n=1); CNS
treatment (n=9); CNS
prophylaxis (n=27)
Remarks and
Conclusion
Impairment associated
with CRT, HD Ara-C and
IT-CT for CNS disease
Risk impairment
increased as disease
and treatment risk
factors increased
Table 3 Overview of cross-sectional studies of cognitive functioning and HSCT
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Padovan et al 1998 15
Objective
To assess neurological,
neuropsychological and
neuroradiological
findings in long-term
survivors of HSCT
Neuropsychological tests
/ Additional measures
Cognitive functioning
evaluated with
structured interview (13),
including items of
orientation, memory and
reasoning / -
Booth-Jones et al 2005 26
Objective
To measure the
prevalence of and
relationship between
subjective complaints
and objective cognitive
impairment following
HSCT 
Neuropsychological tests
/ Additional measures
1,5,6,8,9,11,25,28,29,34,3
5,36 /
XII,XIII,XIV, XV
Design
Retrospective design
Time interval 7-120
months post-HSCT,
mean 34 months
Impairment definition
Total scores compared
to demographic, disease
and treatment variables
Total score ≤ 49 out of
55 defined as mild
cognitive impairment;
total score ≤ 32 cut off
for dementia
Design
Retrospective design 
Assessment 6 months
(range 5-10) post-
discharge from HSCT
Impairment definition
Comparison to
normative data
Summary z-scores were
calculated by averaging
test scores
Mild impairment
defined as score > 1 SD
and < 1.5 SD below
norms; moderate to
severe impairment
defined as score ≥ 1.5
SD below norms
Sample characteristics
Mixed group of
hematological patients
(n=66), mainly leukemia
Age 19-59; mean 40
NPA in 46 patients
Remarks and
Conclusion
Cognitive impairment in
17 patients, 3 (7%)
fulfilled criteria
dementia 
16/17 mildly impaired
patients had abnormal
neurological functioning
Deficits more frequent in
cGVH evolving from
aGVH
Sample characteristics
Group of hematological
(n=21) and breast cancer
patients (n=44) 
Age 23-63, mean 47;
majority (n=51) female
Remarks and
Conclusion
51% mild impairment,
28% moderate-severe
impairment ≥ 1 domain;
most prevalent in
psychomotor speed and
executive function
Negative influence of
older age, male sex, low
education and low IQ
Treatment
Various pre-treatment
cytotoxic regimens,
including IFN (n=15)
HSCT regimens: CP
followed by TBI (n=33);
HD-CT (CP, BCNU) only
(n=33); IT-CT (n=8)
Type of HSCT: MRD
(n=50), MUD (n=9),
autologous (n=7)
Remarks and
Conclusion
Impairment associated
with long term CyA use
(> 1 year) and age 
(> 40 years)
Long-term CyA use,
cGVH and steroids
affected neurological
status and MRI results
Treatment
Treatment regimens not
specified
Autologous HSCT(n=52)
and allogeneic HSCT
(n=13)
Remarks and
Conclusion
Younger patients had
more complaints
(memory, attention and
language)
No relation cognitive
complaints (total or
domains) and objective
cognitive functioning
Objective and subjective
cognitive complaints
related to depression
and fatigue
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Abbreviations
NPA:neuropsychological assessment CT:chemotherapy HD-CT:high-dose chemotherapy IT-CT:intrathecal
chemotherapy RT:radiotherapy CRT:cranial radiation TBI:total body irradiation CNS:central nervous system
CP:cyclophosfamide Ara-C:cytosine arabinoside VP-16:etoposide MPD:methylprednisolone BCNU: 1,3-bis(2-
chloroethyl)-1-nitrosournea BU:busulfan MTX:methotrexate CA:carmustine CY:cytarabine CIS:cisplatin TH:thiotepa
MRD:matched related donor MMR:mismatched related donor MUD:matched unrelated donor IFN:interferon-alfa
CyA:cyclosporine aGVH:acute graft versus host disease cGVH:chronic graft versus host disease 
Neuropsychological tests
1:Grooved pegboard test 2:Finger oscillation test 3:Buschke selective reminding test 4:Benton visual retention
test 5:Trailmaking test A 6:Trailmaking test B 7:Ruff two and seven test 8:Digit span test WAIS 9:Digit symbol test
WAIS 10: Dementia rating scale 11: Controlled oral work association 12:Temporal orientation subtest 13:SIDAM
14:Standard progressive matrices, 15:WAIS-R short version 16: Zahlenverbindungstest (modified Trailmaking A)
17:D2 test 18:Complex stimulus reaction task (Vienna determination test) 19:Verbal learning test 20:Non-verbal
learning test 21:Information test WAIS 22:Similarities test WAIS 23:Block design test WAIS 24:Picture completion
test WAIS 25:Stroop colour word test 26:Digit span test WMS-R 27:Visual memory span test WMS-R 28:Logical
memory WMS-R 29:Visual reproduction WMS-R 30:Verbal fluency test 31:Fragmented figures recognition test
32:Hand dynamometer test 33:Hopkins verbal learning test-revised 34:Wisconsin card sorting test 35:National
adult reading test 36:Hopkins verbal learning test
Additional measures
I:Profile of mood states II:Psychological adjustment to illness scale III:Sickness impact profile IV:State-trait anxiety
inventory V:Zung depression inventory VI:Internal-external locus of control scale VII:Norbeck social support
questionnaire VIII:Beck depression inventory IX:Psychiatric diagnostic interview X:Eigenschaftwörterliste
(assessment of mood state) XI:Freiburg personality inventory XII:Center for epidemiological studies depression
scale XIII:Medical outcome SF-36 health survey measure XIV:Fatigue symptom inventory XV:Multiple abilities
questionnaire
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SUMMARY AND CONCLUSIONS
Cognitive outcome associated with HSCT was reported in 12 published studies involving a total
of 720 patients, including a possible overlap of data in 162 patients.24,27,28 Only three studies,
however, compared HSCT patients to a control group of healthy controls23 or other patient
groups, including cancer patients treated with radiotherapy to the pelvis.24,28 In no less than 10
trials out of the 12 studies summarized in Table 2 and 3 cognitive dysfunction was noted. The
incidence of cognitive impairment (if indicated in the paper) before HSCT ranged from 20% to
58%; the incidence of impairment after transplant varied from 37% to 79%. Most studies
showed significant differences to published test norms. In two reports, cognitive performance
was within the normal range when compared with norms of healthy individuals, both before and
after conditioning with low doses of TBI.24,27 The results of the reviewed studies demonstrate
that patients undergoing HSCT for hematological malignancies experience cognitive deficits
that affect several cognitive domains.
Cognitive domains affected by HSCT
Although the available evidence suggests a fairly diffuse pattern of cognitive dysfunction
following HSCT, some cognitive domains seem to be preferentially affected. Most published
studies revealed deficits in motor, executive and memory function.14,15,21,22,26,27,29,30 Other
cognitive problems associated with HSCT involved poor performance in perceptual speed,
reasoning, and problem solving.21,23 One study reported a general cognitive decline after
HSCT.25 Cognitive impairment occurred in HSCT patients at different time points. Some studies
demonstrated that cognitive impairment is evident before conditioning.14,22,27,29,30 This is in line
with research on cognitive functioning in patients who received standard systemic chemo-
therapy for lymphoma or breast cancer which observed cognitive dysfunction after standard-
dose chemotherapy.31-34 
Following transplant, most prospective reports indicated a mild to moderate decrease in
functioning. One report revealed a transient reduction on all neuropsychological tests within
three months after transplant, with return to pre-transplant levels at one year.29 Only few studies
observed an increase in test scores in the period immediately following HSCT. However, the
authors suggested that this was related to practice effects of repeated testing, as the time
between assessments was only a few days.24,27,28
Subjective cognitive impairment
Patients who received chemotherapy often report problems regarding their memory and
concentration.35,36 Only one study assessed subjective cognitive functioning in HSCT patients in
addition to objective testing.26 In this retrospective study, 50% of 65 patients reported up to 11
complaints, on a 48-item self-report questionnaire of subjective cognitive function in routine
daily-life activities across six cognitive domains. The most common complaints were in the
domains of remote memory, attention, and language. Younger patients made significantly more
complaints. No correlation was found between objective and subjective cognitive functioning,
which suggests that complaints about cognitive function after transplantation may be an
indicator of emotional distress rather than factual cognitive deficits assessed by formal testing.
Evidence of correlations between higher rates of complaints and respectively greater depressive
symptomatology, more severe daily fatigue, and greater interference of fatigue, underline this
assumption.
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Assessment of confounding factors and QOL
Research examining psychological distress has reported that clinically significant levels of
emotional distress are observed in roughly one-third of mixed oncology patients.37-40
Undoubtedly, in HSCT patients these rates are higher as a result of the stressful situation before
the initiation of treatment.41,42 Emotional status can affect cognitive functioning, and may
therefore contribute to the differences seen in cognitive functioning either before or following
transplant. Seven of the reviewed studies used self-report questionnaires to assess
psychological functioning and mood states, and have therefore controlled adequately for these
potential confounding factors.22,24-28,30 In short, their results on this issue vary from no relation
between cognitive functioning and psychological distress at baseline and follow-up30, to a
strong association between pre-transplant anxiety and poorer cognitive performance at follow-
up.22 Most studies found a high prevalence of psychological distress before HSCT and during
hospitalization, and decreased levels of distress at discharge.22,25 Further results illustrate a
general trend toward improved emotional functioning over time.22,24,25,27 Lastly, differences in
mood states between HSCT patients and control groups were not observed.24
Although assessment of potential confounding factors was performed in just over half of the
studies, only one trial investigated the consequences of cognitive dysfunction on health-related
QOL.26 This study showed that cognitive performance was not associated with overall physical
QOL, but a trend towards higher levels of performance and better mental QOL was observed.
This area of research, and in particular the consequences of treatment-related cognitive
dysfunction at QOL, requires further attention in future trials. 
Risk factors of cognitive impairment following HSCT
Some of the studies under review performed a risk factor analysis to determine if demographic
and/or disease-related factors were associated with cognitive functioning.14,15,21,25,26,28-30
Although the data of this review suggest that some individual HSCT patients might be more
vulnerable for cognitive problems than others, generally spoken, heterogeneous results were
observed. With regard to demographical variables, relations between lower cognitive outcome
and older age,15,26 male gender,14,26 low educational levels and low estimated intelligence
scores IQ26 were observed. 
Analyses of disease- and treatment factors suggest that impairment prior to HSCT and
diminished performance over time were associated with cranial irradiation and intrathecal
chemotherapy for CNS disease.28,30 This was not evident in all studies, Ahles et al25 found no
effect of prior CNS treatment on cognitive functioning at baseline. Other pre-transplant factors
related to cognitive outcome were a history of previous chemotherapy, disease duration, and
disease stage at the time of transplant. Syrjala et al found a lower risk of cognitive impairment in
patients not treated with chemotherapy (or hydroxyurea only) before undergoing transplant
compared to patients treated with chemotherapy or interferon.29 In another study, patients with
a prolonged disease duration (over 20 months) and patients with a progressive disease stage at
transplant, demonstrated no improvement in functioning following HSCT, in contrast to patients
with a short disease duration and a stable disease stage.14
Potential risk factors related to the HSCT conditioning regimen were total dose of TBI and
GVHD factors. One study demonstrated that an increased dose of TBI was related to an
increase in cognitive dysfunction.21 In line with this report a series of studies found no significant
evidence of cognitive impairment or cognitive changes after low radiation doses.24,27,28 Lastly,
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cognitive deficits were more frequently observed in patients with chronic GVHD evolving from
acute GVHD15, and in patients exposed to long-term chronic GVHD treatment like the use of
cyclosporine for more than one year.29
Limitations of the studies under review
A number of methodological issues limit the applicability of available research. Many studies
have used a small sample size, particularly following the transplant procedure. Small sample
sizes are a common problem in HSCT research due to high morbidity and mortality rates, which
consequently affects the power to permit conclusions. Only one study used a sufficient large
group of HSCT patients at baseline and follow-up.29 Yet, this recent report is lacking measures
of psychological functions and QOL, therefore it does not control adequately for potential
confounding factors. 
In addition to small sample size, some patient samples were diverse in diagnosis or in HSCT
treatment (eg, mixed group of allogeneic and autologous patients), and accordingly significant
differences in treatment regimens were seen either before or during HSCT. Differences in
treatment regimens may of course be associated with distinctive side-effects with a different
impact on cognitive functioning. Given the more intensive treatment of and the different
hematological diagnoses for which allogeneic transplant is used, it is possible that allograft
patients will show a different cognitive outcome. Furthermore, two studies included a mixed
group of patients with hematological malignancies and breast cancer.25,26 Comparison with the
other studies is difficult because of possible contributory effects of chemotherapy-induced
menopause and the use of adjuvant hormonal therapy (eg, tamoxifen) in breast cancer
patients.43,44
Cross study comparisons are also problematic because different studies used diverse criteria for
cognitive impairment and measured patients at different time points. Some studies identified
cognitive impaired patients as those who had an average score of at least one standard
deviation below published norms, while others used deviated scores of at least two standard
deviations below published norms as cut-off point. Differences in impairment rate across the
reviewed studies may be partly due to these differing criteria. Additionally, there was a wide
variance in the timing of the neuropsychological assessment in relation to previous treatment or
HSCT. Most studies used uniform time points for their follow-up, but these time points ranged
from one to 80 days following HSCT, with regular follow-ups till one year. In cross-sectional
studies, patients were assessed between six months to approximately 10 years after completion
of treatment. Straight forward conclusions about cognitive functioning remain therefore
difficult. 
Lastly, the lack of an appropriate control group is another major limitation in research on
cognitive outcome of HSCT. The majority of studies used published norms rather than matched
control groups, and only one study used a small control group of cancer patients who received
less toxic treatment than HSCT. The use of control group of patients with hematological
malignancies is essential for the interpretation of effects related to previous treatment before
undergoing HSCT and the potential additional effects of HSCT conditioning regimens. 
In conclusion, so far only a few studies with a relatively modest number of patients and several
methodological biases have addressed the issue of possible cognitive dysfunction associated
with HSCT. Results of this review suggest that HSCT causes cognitive deficits in a significant
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number of patients. The existing studies indicate that the cognitive domains most affected by
HSCT include motor and executive function, and memory. Several demographical and disease
and treatment-related factors influence the prevalence and severity of cognitive outcome. Still,
most studies have major methodological limitations which limit the conclusions that can be
drawn. 
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4 I Cognitive functions in primary CNS
lymphoma: literature review
Primary central nervous system lymphoma (PCNSL) is a non-Hodgkin’s lymphoma (NHL) that
appears solitary or multifocal within the brain, leptomeninges, spinal cord or eyes in the
absence of systemic disease. Most PCNSLs are histologically high-grade and arise from B
lymphocytes.1 In the past, it was considered a rare disorder, accounting for 1-2% of all extra-
nodal lymphomas and fewer than 5% of all cases of primary intracranial neoplasm.2,3 Its
incidence has been increasing steadily in the last three decades in both immunocompromised
groups (eg, patients with acquired immunodeficiency syndrome and transplant recipients) and
in the general population, in the latter for unknown reasons. PCNSL has been described at all
ages, but it is more common in the elderly. Most cases arise in the sixth decade, with a median
age of 55 years and male to female ratio of around 1.5.4,5 The prognosis of PCNSL is still
considered poor, despite new therapeutic approaches which improved outcome. In patients with
severe immunodeficiency, treatment options and survival are heavily influenced by the under-
lying disease. Therefore, this review is restricted to immunocompetent patients with PCNSL. 
Clinical features and treatment modalities
PCNSL is frequently a multifocal disease that involves deep brain structures (eg, supratentorial
sites and periventricular location). Angiotropism and diffuse infiltrating growth are main
characteristics of PCNSL. Primary symptoms may result from local mass effect due to raised
intracranial pressure, from ocular involvement, or from focal deposits on cranial or spinal nerve
roots. Initial symptoms include aspecific neurological deficits, seizures, mental status changes
(including behavioural changes) and signs of increased intracranial pressure, like blurred vision,
headache, vomiting and nausea. On MRI PCNSL lesions are usually homogeneously enhancing
lesions, often localised near the ventricles. Despite the typical appearance of most lesions, MR
findings are not specific. In about 10% of lesions no enhancement is present. Diagnosis is
achieved by surgical resection or stereotactic biopsy techniques and by cerebrospinal fluid
(CSF) cytology.
Due to the infiltrating growth pattern and the frequently multifocal presentation, local treatment
is not curative. A resection does not contribute to disease control and after surgery only a
median survival of 3 to 5 months is achieved. Although most PCNSL are sensitive to
corticosteroid treatment, the disease usually recurs within months in patients receiving steroids
only. Historically, treatment for this malignancy consisted of whole-brain radiotherapy (WBRT) in
combination with corticosteroids. This therapy frequently produced a complete tumor response
and ameliorated symptoms in most patients, but responses to WBRT are generally short-lived.
The overall median survival of patients with PCNSL treated with initial WBRT is less than 18
months from the time of diagnosis, and the 5-year survival rate is less than 5%. A major
improvement of the outcome of PCNSL patients was obtained by adding high-dose metho-
trexate (MTX) chemotherapy to WBRT.6
The benefits of chemotherapy in PCNSL were initially observed by studies evaluating treatment
options for patients with recurrent disease after initial radiotherapy.7 Standard systemic NHL
regimens (in particular the CHOP regimen) have been unsuccessful for PCNSL, presumably
because many of these drugs do not penetrate through an intact blood brain barrier (BBB).8 The
single most active and commonly used agent for PCNSL is MTX administered by intravenous
systemic administration in high doses (> 3 g/m2).2 With this dosage, cytotoxic concentrations
of MTX are achieved within the CNS even if the BBB is intact.4 Currently, the treatment of choice
is high-dose MTX-based chemotherapy alone or in combination with other agents as cytosine
COGNITIVE SEQUELAE OF INTENSIVE TREATMENT FOR HEMATOLOGICAL MALIGNANCIES |  43
arabinoside (Ara-C), cyclophosphamide, thiotepa, nitrosourea and procarbazine. Many
physicians advocate the use of WBRT after treatment with high-dose intrathecal and systemic
MTX-based chemotherapy, but others feel that this may contribute to late neurotoxicity.
Whether intrathecal chemotherapy with MTX and/or ARA-C adds to the outcome is not clear,
but it is often used. 
Another therapeutic approach for PCNSL incorporates blood-brain barrier disruption (BBBD)
chemotherapy. This approach aims at the delivery of chemotherapeutic agents past the BBB
where potentially microscopic disease resides. Endothelial tight junctions of the BBB are
disrupted by an intra-arterial infusion of hypertonic mannitol, allowing for increased drug
penetration in the brain. BBBD is preceded by systemic cyclophosphamide and followed by
intra-arterial MTX in combination with procarbazine and dexamethasone. This regimen is usually
administered each month for about one year, and radiotherapy is not administered except at
progression. Several reports confirm that this procedure results in high response rates and
improved survival, with acceptable complication rates and low incidence of neurotoxicity.9,10
A recent development in the treatment of PCNSL is the use of intensified chemotherapy
supported by autologous hematopoietic stem cell transplantation (HSCT). A number of preliminary
trials have been carried out in either newly diagnosed PCNSL or relapsed disease.11 Results are
encouraging, but the role of HSCT as part of first line treatment needs further investigation.
Treatment-related neurotoxic complications
As the survival rates in PCNSL have improved, there is a need to address the potential long-
term effects of therapy, in particular the risk of delayed neurotoxicity. Leukoencephalopathy is
the main long-term treatment-related toxicity observed in PCNSL, and this often permanent
and progressive.12 The use of radiotherapy, intrathecal drug delivery, age over 60 years, and
combined modality treatment (particularly when chemotherapy is administered after
radiotherapy) are the major risk factors of delayed neurotoxicity. 
Over 90% of the long-term survivors older than 60 years at the time of treatment with the
combination of chemotherapy and WBRT will develop leukoencephalopathy, clinically
characterized by behavioural changes, mental slowing, dementia, gait ataxia, and urinary
incontinence.13,14 Late-delayed complications usually appear 1-2 years after the completion of
treatment, but in some patients symptoms and signs of leukoencephalopathy develop within
months.15,16 Mechanisms underlying delayed neurotoxicity are still poorly understood.
Neuroimaging studies in PCNSL patients show diffuse white matter disease, cortical-subcortical
atrophy, and often hydrocephalus.16-19 Autopsy data reveal demyelination, axonal loss, gliosis,
and thickening of the small vessels.15,16 Vascular injury mediated by brain irradiation clearly is a
component in the development of CNS damage in PCNSL patients. The tumor may also play a
critical part, since even in complete responders residual parenchymal lesions (‘scarring’) may
remain present.
In most clinical trials in PCNSL, treatment-related neurotoxicity is assessed clinically or based on
global ratings, like performance status. Most of these methods lack sensitivity to detect
cognitive dysfunction in patients, whereas objective and quantitative testing would reveal more
subtle neurocognitive deficits and give a better picture about patients’ functioning in daily life
after completion of treatment.
This chapter presents a literature overview of studies that have addressed cognitive functions in
adult PCNSL survivors. A bibliographic search of articles was conducted that included formal
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neuropsychological evaluations or evaluations using mental status examinations. Case-reports,
studies based on performance status or clinical observations, and studies which did not present
their results in full detail were excluded. The criteria for inclusion of articles for this review were
chosen with the aim to examine the full body of data available in the literature on assessment of
cognitive functions in PCNSL survivors. 
LITERATURE OVERVIEW OF COGNITIVE STUDIES IN PCNSL
A MEDLINE search of articles published in English, covering the period from January 1991 to
December 2005, identified a total of 21 published studies including a brief communication of
preliminary results. Table 1 lists a detailed chronological overview of data. The studies under
review show a wide range of variance regarding patient selection, study design and
psychometric methods. In the majority of these studies, cognitive functioning was assessed
prospectively as a routine examination of treatment-related neurotoxicity within an ongoing
clinical trial. Data of serial neuropsychological assessment is in some studies only available for
small samples, ranging from seven to 32 patients. Few studies were specially designed to
investigate disease-related cognitive impairment and changes in cognitive function associated
with received treatment for PCNSL.20-26 Seventeen studies used a prospective design and four
studies used a retrospective design. The review results are discussed by treatment modality.
Results of studies with WBRT alone or with high-dose chemotherapy
Six studies have examined cognitive functioning in patients who received either WBRT alone or
in combination with high-dose MTX-based chemotherapy administered before or after cranial
irradiation (Table 1).18,22,27-30 These studies included a total of 296 patients, although in three
studies (226 patients) only a brief mental status evaluation was used.27,28,30 Two studies did not
report methods or test scores in full detail.18,29
Pels et al evaluated treatment-related neurotoxicity in different therapeutic modalities with
WBRT in a consecutive group of 28 patients, of which half had a complete response to
treatment.18 The authors concluded that WBRT, either alone or combined with high-dose
chemotherapy, was associated with cognitive deterioration. Three of thirteen patients who
received chemotherapy alone showed white matter abnormalities in absence of cognitive
decline. Pöttgen et al performed serial neuropsychological testing in only two of initially 14
patients.29 Both patients were fully working, and one patient showed mild impairment in verbal
memory, visual memory, and speed of information processing. Correa et al performed a
detailed study on 14 PCNSL patients that included formal neuropsychological testing at
baseline, a quality of life (QOL) assessment and comparison between different treatment
modalities.22 The authors concluded that WBRT alone or combined with high-dose
chemotherapy was associated with more pronounced cognitive impairment than chemotherapy
alone, regardless of time since treatment completion. Impairment was found in the following
domains: attention and executive function, memory, psychomotor speed, and language. QOL
assessment showed no differences according to treatment modality. Half of patients were either
unemployed or worked at a lower capacity due to tumor or treatment-related effects.
Three studies reported on cognitive functions using the Mini Mental Status Examination
(MMSE).31 O’Neill et al assessed the consequences of survival in an intergroup phase II trial of
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combined modality therapy for PCNSL.27 Median MMSE score at study entry was above cut-off
point (ie, ≥ 24 points), but nearly all patients who were alive more than one year after study
entry had a demonstrable decline in cognitive function. Declines occurred before disease
progression and in patients without evidence of disease progression. Of note, missing data
(MMSE scores of only eight patients were available at one year) created difficulties in
interpreting outcome. DeAngelis et al observed delayed neurotoxicity in 15% of 98 patients
who received combined modality treatment.28 Median baseline MMSE score was above cut-off
point, but unfortunately follow-up scores were not reported. A recent study performed by
Fisher et al evaluated whether a lower dose of hyperfractionated WBRT reduces neurotoxicity
for PCNSL patients receiving combined modality treatment (patients received 45 Gy in 25
fractions or 36 Gy in 30 fractions).30 Only complete responders to treatment and with baseline
MMSE scores above ≥ 24 points were included in the analysis. A drop below the cut-off point
was observed for some patients at eight months after pre-treatment baseline assessment, but
no significant differences were found between patient groups.
Results of studies with high-dose chemotherapy alone
A total of seven studies evaluated cognitive functioning in PCNSL patients who only received
high-dose, MTX-based chemotherapy (Table 1).23,25,32-36 Baseline assessment was completed by
a total of 190 patients, although some studies report on the results of the same patients.23,25,35
Psychometric tests and/or test scores were not specified in three studies.32,34,35
Guha-Thakurta et al assessed 31 PCNSL survivors almost two years after diagnosis in a study
with a retrospective design.33 Patients were evaluated with two brief mental status examinations
and QOL questionnaires. Results showed preserved cognition and memory with no evidence of
leukoencephalopathy. Sandor et al conducted serial neuropsychological evaluations in a small
group of 14 PCNSL patients and observed cognitive and motor decline subsequent to
treatment in two of seven patients with serial measurements; both patients were over 65
years.32 Schlegel et al found no evidence of treatment-related cognitive impairment in a study
on 20 patients, with serial assessment on ten patients, eight of whom had a complete
response.34 The test scores remained stable or improved at the last follow-up evaluation which
was performed between 15 and 41 months post-treatment. Pels et al evaluated 22 patients with
serial assessments after systemic and intraventricular chemotherapy with deferred radio-
therapy.35 They observed no cognitive decline in any patients who had either partial or
complete response to therapy. Older patients had lower test scores, but overall cognitive
performance post-treatment showed no significant differences between patients younger than
60 years and those older than 60 years. Fliessbach et al reported on ten patients with durable
complete response who had serial measurements up to 96 months after treatment.23 Cognitive
impairment prior to treatment was found, with improved functioning at four months after
treatment completion, in particular in attention and verbal memory. Patients who were not
impaired at baseline remained stable at follow-up. At the last follow-up, a small decline was
observed in written phonemic verbal fluency and memory. Neuropsychological test scores were
impaired in patients who relapsed, or who received adjuvant WBRT or ocular radiotherapy. No
influence of age was observed. In a recent study, Fliessbach et al assessed tumor and
treatment-related effects on long-term cognition and QOL in survivors of PCNSL.25 An overall
improvement was observed in 21 of 23 patients, although scores remained in the low average
range on tests of attention, executive function, and non-verbal memory. Diminished functioning
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on QOL questionnaires was reported by 17% of patients. The authors suggested that cognitive
deficits in PCNSL patients were caused primarily by tumor because no treatment-related
cognitive decline was observed. Recently, Herrlinger et al performed cognitive evaluations in a
small group of six PCNSL patients at least 48 months post-treatment.36 All patients showed
impaired attention and four patients had impaired memory. Moderate to marked restrictions
with regard to QOL were found in four patients. The authors concluded that high-dose MTX
with deferred radiotherapy had only moderate efficacy and was associated with significant
neurotoxicity in long-term surviving patients. 
Results of studies with BBBD chemotherapy
Seven studies measured cognitive outcome of BBBD chemotherapy in adults with
PCNSL.10,20,21,26,37-39 In each study, neuropsychological assessment was performed before the
onset of chemotherapy, and follow-up evaluations were conducted at least one year after
treatment completion. Three studies included subgroups of patients who received initial
treatment with WBRT prior to BBBD chemotherapy,10,37,38 and one study included patients who
received previous chemotherapy.20 A large number of patients appear in several of these
studies which precludes an accurate calculation of the total number of patients assessed.10,21,37
The first study on cognitive functioning in PCNSL patients was performed by Neuwelt et al.10
A small group of 12 patients who received WBRT and BBBD chemotherapy was followed before
and one year after treatment. Stable or improved functioning compared to results of the
baseline assessment was found in the majority of patients not treated with WBRT. At completion
of treatment, most test scores were within the normal range. In contrast, nearly half of patients
who received WBRT showed significant declines in overall cognitive functioning. Similar
findings were reported by Dahlborg et al who followed the majority of these patients over
time.37 Stability or improvement in cognitive functioning following BBBD chemotherapy without
WBRT was found in all age groups, including patients over 60 years. A decline in functioning
was observed for some patients treated with WBRT. Two years later, Dahlborg et al reported on
a mixed group of young adults with non-glial intracranial tumors, including seven young PCNSL
patients (mean age was 24 years).38 Test scores in PCNSL patients were mildly impaired at
baseline, and remained stable or improved at follow-up. It remains unclear whether both
studies show an overlap of data.
Four studies report data of the effects on cognition of administration of BBBD chemotherapy
without prior or subsequent WBRT (yet again, some of these studies may report on the same
patients). Crossen et al demonstrated significant impairment on mental flexibility, memory, and
fine motor skills at baseline.39 There was no evidence of treatment-related decline at follow-up.
Patients either remained stable or improved significantly. Roman-Goldstein et al observed no
change in overall cognitive functioning after treatment completion in a mixed group of patients
with CNS tumors, including nine adults diagnosed with PCNSL.20 However, performance on
tests of attention and fine motor skills declined in one individual patient. McAllister et al
demonstrated improvement in overall cognitive functioning at completion at treatment, while
scores of verbal memory, mental flexibility and motor function remained stable.21 Lastly, in a
recent study, Neuwelt et al observed an improvement in overall cognitive functioning from
baseline in a small group of 16 PCNSL patients.26 Follow-up data of recurrence-free survivors
two years after initial diagnosis showed, again, no significant declines in overall performance.
The authors concluded that cognitive loss at baseline is associated with enhancement of tumor.
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Results of studies with high-dose chemotherapy followed by HSCT
Only one study reported preliminary results of research on cognitive functions in 14 PCNSL
patients who were assessed with a neuropsychological test battery and the MMSE, prior and
subsequent to treatment with high-dose MTX-based induction chemotherapy followed by
myeloablative chemotherapy with autologous stem cell rescue.24 At baseline, impaired
performance was found in attention and executive function, psychomotor speed, memory and
language. Improvement was observed in seven patients available for post-induction follow-up,
and was most profound in attention and executive function, and language. Cognitive
performance remained stable at 18 months post-transplant. Of note, the sensitivity of the
MMSE was too low to detect cognitive impairment in this patient population.
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Neuwelt et al 199110
Objective
To evaluate the efficacy
of BBBD chemotherapy
in PCNSL patients
Neuropsychological tests
/ Additional measures
1,2,3,4,5,6,7,8,9 / -
Crossen et al 199239
Objective
To evaluate the risk of
neurotoxicity in PCNSL
survivors treated with
BBBD chemotherapy
Neuropsychological tests
/ Additional measures
1,2,3,4,5,6,7,8,9 / -
Design
Prospective design
Prior to BBBD
chemotherapy, at
completion of treatment
at 1 year and at annual
intervals post-treatment
(ranged from 1 to 7
years)
Impairment definition
Comparison to
published norms
Summary z-scores were
calculated by averaging
test scores
Mild impairment score ≥
1 SD below norms;
moderate impairment
score ≥ 2 SD below
norms
Design
Prospective design with
assessment prior to
therapy and post-
treatment (at 1-7 years,
mean 2.6 years)
Impairment definition
Comparison to
published norms
Changes in summary z-
scores (average change
in z-scores from baseline
to follow-up) were
reviewed
Impairment defined as
decline > 1 SD
compared to baseline 
z-score
Sample characteristics
PCNSL patients (n=30)
with CR 
Group 1 (n=13): referred
after PD; mean age 43
Group 2 (n=17): referred
following diagnosis;
mean age 54
Serial NPA in 12 patients
Remarks and Conclusion
Preservation of cognitive
functioning (stable or
improved) in 6 patients
without WBRT (n=7); z-
scores -1.0 to .05; 1
patient declined and
showed severe
impairment)
Sample characteristics
PCNSL patients (n=8)
with CR after 1 year of
BBBD
Age 37-69, mean 56
Remarks and Conclusion
Summary z-scores at
baseline -2.16 to .13; 4
patients showed overall
cognitive impairment; at
baseline significant
impairment in mental
flexibility, learning and
memory and fine motor
skills
Treatment
BBBD chemotherapy
with CP, MTX, PC 
Group 1: received initial
treatment with WBRT
pre-BBBD 
Group 2: received
subsequent WBRT post-
BBBD for PD
Remarks and Conclusion
Patients treated with
WBRT (n=5) had
average test results (z-
scores -1.0 to .05); 1
patient (WBRT prior to
BBBD) declined with
evidence of radiation
necrosis; 1 patient
(WBRT post-BBBD)
showed decline to lower
normal limits
Treatment
BBBD chemotherapy
with CP, MTX, PC 
No WBRT
Remarks and Conclusion
Changes in summary z-
scores -.60 to 1.53; 2
patients improved, 6
patients remained stable
Follow-up assessment
revealed stability of
intelligence, learning
and memory
Absence of
characteristics of
dementia
Table 1 Overview of studies on cognitive functions associated with PCNSL
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To evaluate whether
BBBD chemotherapy is
associated with
abnormalities diagnosed
by MRI or detected by
cognitive testing
1,2,3,4,6,7,8,9 / -
To evaluate tumor
response and survival in
patients receiving MTX-
based chemotherapy
with BBBD with or
without antecedent CRT
1,2,3,4,6,7,8,9 / -
Prospective design
Prior to BBBD
chemotherapy, at
completion of treatment
at 1 year and at yearly
intervals
Comparison to
published norms
Summary test scores
over time were
compared for each
individual patient
Impairment or
improvement defined as
a 1 SD change from
baseline performance
Prospective design
Prior to BBBD
chemotherapy, at
completion of treatment
at 1 year and at yearly
intervals
Comparison to
published norms
Summary z-scores were
calculated by averaging
test scores; mild
impairment score ≥ 1 SD
below norms; moderate
impairment score ≥ 2 SD
below norms; downward
change in scores > 1 SD
interpreted as decline
Mixed group of brain
tumor patients with CR
(n=15; age 6-66),
including 9 adults with
PCNSL (age 24-68)
Summary z-scores
(PCNSL) at baseline -
2.15 to .62 (mean -.94);
post-treatment change
in z-scores -1.46 to 1.06
(mean -15)
No evidence of global
decline in cognitive
functioning after
treatment
PCNSL patients with CR
(n=58; 30 previously
reported10
Group 1 (n=19): referred
after PD; mean age 46;
Group 2 (n=39): referred
following diagnosis;
mean age 52
Serial NPA in 23 patients
No cognitive decline in
patients without WBRT
(n=15) 
Summary z-scores
decreased (from .86 to
1.07) in 3/8 WBRT
patients
Two BBBD
chemotherapy regimens
with CP, MTX, PC or VP-
16 and CPL
No WBRT
Significant decline in
attention and grip
strength in 1 PCNSL
patient
4/9 PCNSL patients
showed new MRI
changes; MRI changes
not associated with
decline in cognitive
functioning 
BBBD chemotherapy
with CP, MTX, PC
Group 1 received initial
treatment with WBRT
pre-BBBD; Group 2
received subsequent
WBRT post-BBBD for 
PD only
Stability or improvement
in cognitive functioning
following BBBD
chemotherapy was seen
in all age groups,
including patients older
than 60 years
Neuropsychological tests
/ Additional measures
Impairment definition Remarks and Conclusion Remarks and Conclusion
Objective Design Sample characteristics Treatment
Roman-Goldstein et al 199520
Objective Design Sample characteristics Treatment
Dahlborg et al 199637
Neuropsychological tests
/ Additional measures
Impairment definition Remarks and Conclusion Remarks and Conclusion
To evaluate tumor
response and survival in
children and young
adults with non-glial
intracranial tumors
receiving carboplatin- or
MTX-based
chemotherapy with
BBBD
Battery of neuro-
psychological tests
(measures not specified)
assessing intelligence,
concentration, short-
term memory, visual
perception and fine
motor skills (motor
dexterity and grip
strength) / -
To define the toxicity
and efficacy of high-
dose MTX-based
chemotherapy regimen
used as a single
modality treatment of
PCNSL and IOL
1,3,4,10,11,12,13,14,15,
16,17,18 / I,II
Prospective design
Prior to BBBD
chemotherapy and post-
treatment evaluation
(time between baseline
and post-treatment
evaluation ranged from
12 to 60 months, mean
22 months)
Comparison to
published norms
Summary z-scores were
calculated by averaging
test scores
A change of 1 SD was
interpreted as a change
from baseline levels
Prospective design with
baseline assessment
prior to treatment and
regular follow-up
evaluations after
completion of treatment
Not specified 
Mixed group of patients
(n=34) with non-glial
intracranial tumors with
CR; age 1-30, mean 18
(7 adult PCNSL patients;
mean age 24)
Serial NPA in 32 patients
7 patients scores > 1 SD
below normative data at
baseline; no distinctive
pattern of global
impairment; 1 patient
declined at follow-up;
individual test scores
remained stable or
improved 
Mixed group of PCNSL
and IOL patients (n=14);
age 34-69; CR in 11
patients
Individual test scores
not available
Test results of 5 patients
who underwent serial
NPA (n=7) remained
stable; 2 showed severe
cognitive and motor
decline post-treatment
Two BBBD
chemotherapy
regimens:
CP, MTX with/without
PC (replaced by VP-16
latter), or CPL, VP-16 (CP
added latter)
10 patients initial WBRT,
18 CT
Prior WBRT in 3
patients, 1 post-WBRT
Overall data of
paediatric and adult
PCNSL patients
(separation not possible)
demonstrated complete
and durable response
(5/9 PCNSL patients)
without cognitive loss
Serial NPA in 7 patients
Chemotherapy with HD
MTX, TH, VI and IT Ara-
C and MTX
Prior WBRT in 2 patients
Severe clinical
deterioration in 1
patient (not tested) 
who received MTX 
and WBRT
All cognitive impaired
patients (3/14) were > 
65 years
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Objective Design Sample characteristics Treatment
Dahlborg et al 199838
Neuropsychological tests
/ Additional measures
Impairment definition Remarks and Conclusion Remarks and Conclusion
Objective Design Sample characteristics Treatment
Sandor et al 199832
Neuropsychological tests
/ Additional measures
Impairment definition Remarks and Conclusion Remarks and Conclusion
52 |  COGNITIVE SEQUELAE OF INTENSIVE TREATMENT FOR HEMATOLOGICAL MALIGNANCIES
To evaluate response,
survival and QOL in
patients with PCNSL
who received high-dose
MTX chemotherapy
No neuropsychological
tests /
III,IV,V,VI,VII,VIII
To assess the
consequences of
survival in a completed
phase II trial of
combined modality
therapy
No neuropsychological
assessment /III
Retrospective design;
QOL assessed at a
median of 22 months
after diagnosis
Comparison to
normative data
Prospective design with
baseline assessment
prior to study entry and
regular (quarterly)
follow-up evaluations
after completion of
treatment
MMSE score < 24 used
as a measure of
dementia
PCNSL patients (n=31;
CR in 20); age 35-87;
median 63
QOL assessment only in
patients with CR (n=11;
age 45-78, median 56)
Mental status
questionnaires indicated
preserved cognition and
memory
No evidence of MTX-
induced
leukoencephalopathy
PCNSL patients (n=53);
median age 60 
46 patients underwent
cognitive evaluation at
baseline, and 8 at 52
weeks
Failure to obtain MMSE
scores through study
(13% at baseline and
66% at follow-up)
Median MMSE at
baseline above cut-off
point (score = 26)
Chemotherapy with HD
MTX (IV)
Patient without initial CR
received additional RT
and/or other therapies
Psychosocial
adjustment, well-being
and stress coping
abilities comparable 
to normative data;
moderate rate of
depression and anxiety
Chemotherapy with CP,
VI and AD followed by
WBRT, and HD Ara-C
Long-term decline in
cognitive function
Decline may occur
before PD or in occur 
in patients without
evidence of PD
Objective Design Sample characteristics Treatment
Guha-Thakurta et al 199933 
Neuropsychological tests
/ Additional measures
Impairment definition Remarks and Conclusion Remarks and Conclusion
Objective Design Sample characteristics Treatment
O’Neill et al 199927
Neuropsychological tests
/ Additional measures
Impairment definition Remarks and Conclusion Remarks and Conclusion
COGNITIVE SEQUELAE OF INTENSIVE TREATMENT FOR HEMATOLOGICAL MALIGNANCIES |  53
To evaluate the efficacy
of chemotherapy in
PCNSL and the
frequency of treatment-
related neurotoxicity in
different therapeutic
modalities
Standardized
neuropsychological
testing (tests not
reported) / -
To evaluate response,
survival rate and
cognitive outcome in
patients who received
MTX-based
chemotherapy in
conjunction with
osmotic BBBD therapy
for PCNSL
1,2,3,4,6,7,8,9 / -
Prospective design with
regular follow-up
evaluations ranging
from 1 to 95 months
(intervals not specified)
Not specified
Prospective design with
baseline assessment
prior to treatment and
regular follow-up
evaluations from 6
months to 16 years after
completion of treatment
(mean 16.5 months)
Comparison to
published norms
Summary z-scores were
calculated by averaging
test scores
A core change of 1 SD
was interpreted as a
change from baseline
levels
Consecutive group of
PCNSL patients (n=28);
14 with CR
Age 27-74, mean 59
Test results not reported
9 patients treated with
WBRT alone or
combined with CT
showed cognitive
decline at follow-up (1-
95 months), while 2
patients who received
CT alone declined at
follow-up (10-38 months) 
PCNSL patients (n=74;
39 were previously
reported37
Age < 60 years n=36, ≥
60 years n=38
Serial NPA in 23 patients
Summary z-scores
improved in post-
treatment assessment
for all patients 
z-scores of verbal
learning, memory,
mental flexibility and
motor tasks remained
stable
Various treatment
regimens:
WBRT alone; CT
(systemic, IVT) alone;
WBRT with HD MTX,
Ara-C or Ara-C alone
WBRT (alone or
combined n=13); 1
patient received steroids
only
WMA and severe
cognitive dysfunction in
patients who received
WBRT alone or
combined with CT
3/13 patients treated
with CT alone showed
WMA without cognitive
dysfunction
Two BBBD
chemotherapy
regimens:
1. MTX, PC, VP-16 or CP
(n=44)
2. MTX, VP-16, CP
(n=30)
No WBRT
2 patients showed
cognitive decline at
baseline and achieved z-
scores within normal
limits at follow-up
Objective Design Sample characteristics Treatment
Pels et al 200018
Objective Design Sample characteristics Treatment
McAllister et al 200021
Neuropsychological tests
/ Additional measures
Impairment definition Remarks and Conclusion Remarks and Conclusion
Neuropsychological tests
/ Additional measures
Impairment definition Remarks and Conclusion Remarks and Conclusion
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To evaluate response
rate, response duration
and toxicity after
systemic and
intraventricular
chemotherapy in PCNSL
Detailed
neuropsychological
evaluation assessing
attention, verbal and
non-verbal memory,
verbal fluency and
visuoconstruction
(measures not reported)
/ -
To study the use of
combination
chemotherapy plus
cranial irradiation in
newly diagnosed
patients with PCNSL
No neuropsychological
assessment /
III
Prospective design with
baseline and regular
follow-up; NPA at
therapy, at 4 months, 
12 months and at 15 to
41 months
Comparison to
normative data
Global index score was
calculated by averaging
means of test scores
(with 100 as a reference
value for average
cognitive function)
Prospective design with
assessment prior to
treatment and regular
follow-up
MMSE score < 24 used
as a measure of
dementia
Consecutive group of
PCNSL patients (n=20) 
Age 27-71, mean 59
Serial NPA in 10 patients
(8 with CR)
Preserved or improved
cognitive function after
therapy and during
follow-up 
Median global index
scores was 95 (range 89-
107) at last follow-up
Patients with PCNSL
(n=98)
Median age 56.5 (42% ≥
60 years)
Delayed neurological
toxicities (mainly
leukoencephalopathy)
after RT in 15% No
influence of age
Chemotherapy regimen
consisted of MTX, Ara-C
(systemic, IVT) and VI, IF,
CP, VNS
Severe cognitive
dysfunction, possibly
due to treatment, was
seen in 1 patient (not
tested) after additional
ocular RT and combined
CT for relaps
Systemic chemotherapy
with MTX, VI, PC and IVT
HD MTX followed by
WBRT, followed by HD
Ara-C; (WBRT n=82)
Baseline median MMSE
score was 26.5 Follow-
up data MMSE not
reported
Objective Design Sample characteristics Treatment
Schlegel et al 200134
Neuropsychological tests
/ Additional measures
Impairment definition Remarks and Conclusion Remarks and Conclusion
Objective Design Sample characteristics Treatment
DeAngelis et al 200228
Neuropsychological tests
/ Additional measures
Impairment definition Remarks and Conclusion Remarks and Conclusion
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To determine whether
HD MTX-based
chemotherapy results in
cognitive impairment
and/or changes
detectable by MRI
during long-term follow-
up
19,20,21,22,23 / -
To address response
rate, response duration,
overall survival and
toxicity in PCNSL after
systemic and
intraventricular
chemotherapy with
deferred radiotherapy
19,20,21,22,23
Prospective design with
baseline assessment
prior to treatment, after
completion of treatment
at 4 months, 12 months
and at most recent
follow-up (ranging from
21 to 69 months, mean
43 months)
Comparison to norma-
tive data
Summary score was
computed by averaging
mean test scores (mean
100, range 90-110)
Changes in performance
were analyzed by calcu-
lating reliable change
indices for each test
score in every patient
(compared with extent
of changes expected 
to occur in healthy
population)
Prospective design with
baseline assessment
prior to treatment, after
completion of treatment
at 4 months, 12 months
and one additional time
point (ranging from 19
to 82 months, median 33
months)
Not specified
Consecutive group of
PCNSL patients (n=20,
some data published
previously34) 
Age 27-67, median 60
Serial NPA in 10 patients
with durable CR
Cognitive impairment in
5/8 patients prior to
therapy; 3 scored within
normal range at 4-
months follow-up;
improvement most
profound in attention
and verbal memory
Patients with normal
cognitive performance
at baseline showed
preserved or stable
functioning at follow-up
No influence of age
PCNSL patients (n=65;
20 were previously
reported34
Age 27-75; median 62
Serial NPA in 22
patients; 15 had durable
CR and were re-
evaluated 
Test results not reported
No cognitive decline at
serial testing
No differences between
patients older and
younger than 60 years
Chemotherapy regimen
consisted of MTX and
Ara-C (systemic, IVT), VI,
IF, CP, VNS
MRI revealed treatment-
induced WMA in 4/10;
changes not related to
cognitive functioning
1 patient had WMA 
(with severe cognitive
dysfunction) prior to
therapy and showed
progression with therapy
Chemotherapy regimen
consisted of MTX and
Ara-C (systemic, IVT), VI,
IF, CP, VNS
2 patients showed
cognitive decline (asso-
ciated with leukoen-
cephalopathy or WMA)
due to tumor relapse or
residual tumor
Objective Design Sample characteristics Treatment
Fliessbach et al 200323
Objective Design Sample characteristics Treatment
Pels et al 200335
Neuropsychological tests
/ Additional measures
Impairment definition Remarks and Conclusion Remarks and Conclusion
Neuropsychological tests
/ Additional measures
Impairment definition Remarks and Conclusion Remarks and Conclusion
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To analyze long-term
results following WBRT
with sequential IT Ara-C
with or without systemic
Ara-C in PCNSL patients
3,4,11,13,22,24,25,26,27
To study cognitive
functions in PCNSL
patients treated with HD
MTX and Ara-C followed
by myeloablative
chemotherapy with
autologous stem cell
rescue
Standardized battery of
neuropsychological tests
(measures not specified)
assessing attention and
executive function,
psychomotor function,
memory, language and
visuoconstruction / III
Cross-sectional
assessment after
treatment completion (>
12 years post treatment
in 2 tested patients)
Not specified
Prospective design,
baseline assessment at
diagnosis and follow-up
at completion of
treatment, at 6, 12 and
18 months after
treatment
Comparison to
normative data
Impairment defined as
z-score of > 2 SD below
mean of normative
sample means
PCNSL patients (n=14)
Age 20-73; mean 54
Serial NPA in 2 patients
Test results not reported
Mild impairment (34
percentile) in verbal
learning and memory,
visual reproduction and
speed of information
processing in 1 patient
Newly diagnosed
PCNSL patients (n=14);
Mean age 59
Serial NPA in 7 patients
with long-term follow-up 
Performance in impaired
range at baseline in all
domains apart from
visuoconstruction
Improvement after
treatment (n=7), in
particularly in attention
and executive function
and language 
IT Ara-C (pre- and post-
RT), WBRT with or
without additional
systemic Ara-C
Both patients fully
working
No signs of leuko-
encephalopathy on MRI
Induction with HD MTX
and Ara-C (IV) followed
by BEAM chemotherapy
and autologous stem
cell rescue
Cognitive performance
stable (ie, within 1 SD
below normative mean)
at long-term follow-up 
Baseline MMSE scores
mildly reduced (mean
25); sensitivity MMSE
too low to detect
cognitive impairment
Objective Design Sample characteristics Treatment
Pöttgen et al 200329
Neuropsychological tests
/ Additional measures
Impairment definition Remarks and Conclusion Remarks and Conclusion
Objective Design Sample characteristics Treatment
Correa et al 200324
Neuropsychological tests
/ Additional measures
Impairment definition Remarks and Conclusion Remarks and Conclusion
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To assess cognitive
functions and QOL in
PCNSL survivors treated
either with WBRT with or
without MTX-based
chemotherapy or with
chemotherapy alone
3,4,17,25,28,29,30,31,32,
33,34 / I,V
To determine whether
hyper-fractionated
WBRT reduces CNS
morbidity without
compromising survival
for PCNSL patients
receiving combined
modality treatment
No neuropsychological
assessment / III
Retrospective design
with post-treatment
baseline-evaluation and
an 8-month follow-up
evaluation 
Time interval of months
after combined modality
treatment and 18
months after CT alone
Comparison to normative
data Mild impairment
defined as z-score
between 1.4 - 1.9 SD
below normative mean;
moderate impairment as
z-score ≥ 2 SD below
normative mean
Composite scores were
calculated by averaging
z-scores within cognitive
domain
Prospective design with
pre-treatment
evaluation and regular
follow-up evaluations
(including pre-radiation
and post-treatment)
Cognitive decline
(dementia) was defined
as a drop of MMSE
score below 24 in
patients with a baseline
score ≥ 24
PCNSL patients with CR
(n=28)
Age 36-85; mean 60
Serial NPA in 14 patients
No cognitive decline 
at follow-up Patients
treated with WBRT
alone or combined with
CT displayed more
pronounced cognitive
dysfunction, in attention,
executive function,
memory, psychomotor
speed, and language
(associated with
extensive WMA)
PCNSL patients who
received CT and RT
(n=82)
Only patients with CR to
CT and baseline MMSE
score ≥ 24 included
(n=29; 20 WBRT, 9 HFX;
age unknown
Median baseline MMSE
score was 26.5
At 8 months, mean
MMSE scores improved;
drop below cut-off in
8/20 WBRT and 2/9 HFX
(not significant)
Various treatment
regimens:
HD MTX alone or with
Ara-C (n=10), WBRT
alone (n=1), WBRT and
combined CT, including
MTX, Ara-C, PC, VI and
other agents (n=17)
Patients treated with CT
alone had moderate
impairment in
psychomotor speed
QOL-assessment
showed no difference
according to treatment
modality
50% unemployed or
worked at lower capacity
due to tumor and
treatment 
Systemic chemotherapy
with MTX, VI and PC; IVT
HD MTX followed by
WBRT and HD Ara-C
RT-dose modified
through study: patients
with CR had reduced
dose
Significant between-
group difference in
MMSE scores ≥ 24 was
found at 2 years (89%
HFX vs. 70% WBRT)
Leukoencephalopathy
occurred at later stage
in HFX group
Objective Design Sample characteristics Treatment
Correa et al 200422
Neuropsychological tests
/ Additional measures
Impairment definition Remarks and Conclusion Remarks and Conclusion
Objective Design Sample characteristics Treatment
Fisher et al 200530
Neuropsychological tests
/ Additional measures
Impairment definition Remarks and Conclusion Remarks and Conclusion
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To assess the impact of
the tumor itself and its
treatment with HD MTX-
based chemotherapy on
long-term cognition and
QOL in patients with
PCNSL
3,4,8,19,21,22,23,25,35,3
6,37,38,39 / I,IX
To explore the efficacy
of HD MTX alone in
PCNSL patients
2,26,40,41,42,43,44,45 /
III,IX,X
Prospective design with
assessments prior to
treatment, 3 - 4 months
after completion of
treatment and at last
available follow-up
(ranging from 17 to 96
months after diagnosis,
median 44 months)
Comparison to
normative data
Impairment within
domains: mild z
between -1.5 and -1.9;
moderate z between -2
and -2.9; severe z ≥ -3
Overall: mild than
mild/moderate impair-
ment in 1 domain;
moderate than mild/
moderate impairment in
> 1 domain or severe in
1 domain; severe as
there was impairment 
in > 1 domain
Cross-sectional
assessment after
treatment completion
(ranging from 55 to 69
months after treatment,
mean 61.8 months)
Comparison to
normative data
Overall scores for
attention and memory
were calculated
Reduced performance
was defined as a score <
25th percentile of
normative data
PCNSL patients with CR
(n=23)
Age 28-68; mean 54
Serial NPA in 14 patients
83% impaired (at least I
domain) prior to treat-
ment, most in word
fluency, attention and
executive function and
memory
After completion of
treatment 59% impaired;
z-scores improved in
59% or remained stable;
at long-term follow-up
48% impaired; 2 patients
declined in motor speed
and fluency
PCNSL patients with CR
(n=37)
Serial NPA in 6 patients;
age 56-63; mean 60
Mild to moderate
cognitive impairment in
all 6 patients, especially
in attention and memory
General cognitive
functioning reduced in 
2 patients
Chemotherapy regimen
consisted of MTX, Ara-C
(systemic, IVT) and VI, IF,
CP 
Overall cognitive
functioning 
correlated to subjective
cognitive and global
functioning
In 35% WMA (developed
during treatment);
associated with age, 
not with cognitive
performance
Overall, no long-term
decline; impairment
related to residual
effects of tumor
HD MTX (IV) and
second-line therapy with
either PCV or WBRT
Deficits most
pronounced in 2
patients with marked
leukoencephalopathy
Increased or stable
MMSE
Markedly affected QOL
in 1 patient
Objective Design Sample characteristics Treatment
Fliessbach et al 200525
Neuropsychological tests
/ Additional measures
Impairment definition Remarks and Conclusion Remarks and Conclusion
Objective Design Sample characteristics Treatment
Herrlinger et al 200536
Neuropsychological tests
/ Additional measures
Impairment definition Remarks and Conclusion Remarks and Conclusion
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Abbreviations 
NPA:neuropsychological assessment BBBD:blood brain barrier disruption PD:tumour progressive or recurrence
CR:complete tumor response IOL:intraocular lymphoma MRI:magnetic resonance imaging CT:chemotherapy
HD:high-dose IV:intravenous IT:intrathecal IVT:intraventricular RT:radiotherapy CRT:cranial radiation irradiation
WBRT:whole brain radiotherapy HFX:hyperfractionated CNS:central nervous system WMA:white matter
abnormalities/changes QOL:quality of life CP:cyclophosfamide MTX:methotrexate Ara-C:cytosine arabinoside
PC:procarbazine CPL:carboplatin VP-16:etoposide TH:thiotepa VI:vincristine AD:Adriamycin IF:Ifosfamide
VND:vindesine BEAM:carmustine, etoposide, cytarabine and melphalan PCV:procarbazine,lomustine,vincristine) 
Neuropsychological tests
1:Wechsler adult intelligence test-revised 2:Wechsler memory scale-revised 3:Trailmaking test A 4:Trailmaking
test B 5:Rey auditory verbal learning test 6:California verbal learning test 7:Rey complex figure test 8:Finger
tapping test 9:Grip strength test 10:Mental control WMS 11:Logical memory WMS 12:Visual reproduction WMS
13: Paired association WMS 14:Peabody picture vocabulary test - revised 15:Wide range achievement test-
revised 16:Raven standard progressive matrices test 17:Grooved pegboard test 18:Hand dynamometer test
19:Number connection test (analogous to Trailmaking A) 20:Controlled oral work association 21:Verbal learning
and memory test (analogous to Rey auditory verbal learning test) 22:Benton visual retention test 23:Block design
test WAIS 24:subtests WAIS measuring intellectual function 25:Digit span test WAIS 26:Divided attention test
27:Thurstone cognitive ability test 28:Brief test of attention 29:Stroop color word test 30:Phonemic verbal fluency
test 31:Hopkins verbal learning test-revised 32:Boston naming test 33:Category fluency test 34:Clock drawing
test 35:Short test for cerebral insufficiencies (symbol counting, interference inhibition) 36:Written phonemic
fluency test 37:Corsi block tapping test 38:Semantic oral word association task 39:Reaction times test (Vienna
determination test) 40:German leistungsprüfsystem-50+ test 41:Simple reaction time test 42:Aachen aphasia test
43:Bell’s test 44:Letter cancellation task 45:Drawing geometrical figures and pictures
Additional measures
I:Beck depression inventory II:Spielberger inventory for anxiety III:Mini mental state examination (MMSE) IV:Short
test of mental status V:Functional assessment of cancer therapy scale-brain subscale VI:Symptom questionnaire
VII:Scale for social-adjustment by self-report VIII:Problem solving inventory IX:EORTC Quality of life questionnaire
(EORTC QLQ C30) X:EORTC Brain cancer module
To examine the
correlation between MRI
changes in the brain and
cognitive outcome after
BBBD-enhanced
chemotherapy for
PCNSL
1,2,6,7,8,9 / -
Prospective design with
baseline assessment
prior to treatment, at
end of treatment and at
yearly intervals (range
22-71 months, mean 40
months)
Comparison to
published norms
Summary z-scores were
calculated by averaging
test scores
A z-score change of 1
SD was interpreted as a
decline in cognitive
functioning
PCNSL patient with CR
(n=16) 
Age 10-68; mean 47.7
(one child included)
Serial NPA in 9 patients 
Mean baseline summary
z-score -1.1;
improvement at end of
treatment (mean z-score
= -.35)
No cognitive decline at
long-term follow-up
(range of change -.37 to
.71)
BBBD chemotherapy
regimen with MTX, VP-
16 and CP
No additional treatment
Cognitive dysfunction
prior to treatment
correlated to abnormal
signal intensity around
enhanced tumor; no
association after
treatment Cognitive loss
at baseline due to
enhancing tumor
Objective Design Sample characteristics Treatment
Neuwelt et al 200526
Neuropsychological tests
/ Additional measures
Impairment definition Remarks and Conclusion Remarks and Conclusion
SUMMARY AND CONCLUSIONS
The reviewed studies on cognitive functioning in PCNSL show, despite a considerable hetero-
geneity, that patients treated for PCNSL suffer from a broad range of cognitive deficits.
Cognitive domains most likely to be impaired include attention and executive function,
memory, language, and psychomotor speed. The studies using additional QOL measures
showed a moderate rate of depression and anxiety.33 Diminished QOL was observed in a
minority of evaluated patients, with no effect of treatment modality on overall QOL.22,25,36
The findings on cognitive outcome in PCNSL patients treated with combined modality therapy
suggest more pronounced cognitive impairment than in patients treated with chemotherapy
alone. The findings are consistent with the literature on treatment-related cognitive dysfunction
in glioma patients who are usually treated with fractionated partial-brain radiotherapy,
sometimes combined with systemic chemotherapy. These studies suggest that not all patients
are equally affected and that cognitive impairment can occur at different time points. Deficits
are fairly diffuse, but attention and executive functions, learning and retrieval of new
information, and motor function are preferentially affected.40-42 The adverse effects of the tumor
itself on cognition should not be underestimated in brain tumor patients. Some studies show
that in particular the brain tumor itself has a detrimental effect on cognitive functioning with
only additional effects of cranial irradiation, if applied in high fraction doses (ie, 2 Gy or
larger).43
The studies that reported the cognitive impact of treatment for PCNSL with high-dose MTX-
based chemotherapy alone or with BBBD chemotherapy were mostly prospective. Several
studies documented cognitive impairment at baseline (prior to all therapies) in the areas of
attention, executive functions, memory, language, and psychomotor speed. Follow-up
assessments after completion of treatment show, generally, either stable or improved cognitive
performance. Only in a small number of patients a decline in memory, psychomotor speed, and
word fluency was observed. These findings seem to be in line with previous research on the
cognitive effects of systemic chemotherapy in patients with malignancies. Again, deficits are
widespread with most apparent declines in memory, executive function, and motor function.44-47
Though, a comparison between PCNSL patients and other patient groups is complicated due to
the differences in chemotherapeutic regimens and the route of administration. For instance,
many PCNSL patients will have received intrathecal or intraventricular chemotherapy.
There are several problems involved in interpreting the current findings and comparing the
severity of cognitive dysfunction across reports. Several series show an overlap of data, and may
be in fact redundant publications.10,21,23,34,35,37 Extracting these cases, as an attempt not to
duplicate data, is not possible. Another problem is the absence of precise and detailed
information; in particular, the failure to present used psychometric measures, and numerical
data of neuropsychological test scores. In addition, some studies used insensitive and invalid
measures (eg, assessment with the MMSE only).8,27,30,33
Other problems concern the methodological shortcomings of the studies examined. There are
considerable differences between the reviewed studies in selection of patient population,
sample size, assessment time, selection of measures, and the definition of cognitive
impairment. The composition of patient groups varies with regard to type of malignancy,
disease status at the time of the assessment, and age. Three studies also enrolled patients with
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other CNS tumors or with intraocular lymphoma.20,32,38 Although most other studies included
either newly diagnosed PCNSL patients, in some studies patients were included who received
treatment for recurrent disease. Moreover, some studies included patients with only partial
response to treatment, or even with disease progression. Inclusion of these patients obviously
limits the ability to distinguish tumor from treatment effects on cognitive functioning.
There is also a wide variance in age of patients between the reviewed studies, in particular
among studies evaluating cognitive functioning following BBBD chemotherapy. In these series,
the patient age is substantially younger (with an average age of approximately 46 years) than
that of the average PCNSL patient. High age (> 60 years) is clearly a very important risk factor
for the development of leukoencephalopathy after high-dose MTX chemotherapy and WBRT.
Three reports included a small subgroup of children from one year onwards.20,26,38 This variance
in age limits the generalization of results to the older population and this places the lower
neurotoxicity rates in younger patients treated with BBBD in a different perspective.
Almost all of the reviewed studies are limited by their small sample size and by substantial
differences in follow-up intervals. Apart from two studies using mental status evaluations,28,30 all
involved a relatively small number of patients (n < 35; not including the redundant or duplicate
publications). The number of assessed patients ranged from eight to 65 patients at baseline, six
to 32 patients at completion of treatment, and, in some cases, only three patients at long-term
follow-up. Most published reports used a baseline assessment (prior to treatment), and at
completion of treatment at four months and one year after treatment. The duration of long-term
follow-up ranges from six months to 16 years after completion of treatment.21,29 The small
number of long-term survivors with a complete response and adequate testing, and the
heterogeneous follow-up intervals, both limit the power to determine late sequelae of
treatment.
Most studies were embedded in ongoing clinical trials evaluating therapeutic options for
PCNSL, and almost all used an extensive neuropsychological test battery covering a wide range
of cognitive domains. Noteworthy, four studies used self-report questionnaires of QOL and/or
measures of potential confounding factors (eg, anxiety, depression, and fatigue) in combination
with a neuropsychological assessment.22,25,32,36 Additional use of QOL or psychological
measures is an encouraging new trend in the more recent studies, which helps to determine the
impact of possible cognitive impairment on QOL and daily-life functioning.
Lastly, the definition of cognitive impairment varies considerably across studies. Although some
reports lack a specific definition of impairment, most compare patient data with published
normative data. However, the criteria for impairment vary, as a general rule, from one to over
two standard deviations below the mean of standardized normative data, causing significant
difficulties in interpreting current findings.
In conclusion, all these limiting factors together preclude the assessment of the specific
contributions of tumor and the delayed effects of treatment on cognitive functioning in PCNSL
patients. Given the present state of literature on cognitive functioning in PCNSL, it appears that
WBRT and combined modality therapy have a greater impact on cognitive functioning
compared to chemotherapy alone. There is a need for further systematic and large-scale clinical
studies using standardized methods of neuropsychological assessments and, preferably, a
control group to determine if this can be solely attributed to the neurotoxic effects of treatment.
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ABSTRACT
Background: The late neurotoxic effects of bone marrow transplantation on cognitive func-
tioning and quality of life were investigated in a consecutively treated cohort of long-term adult
survivors. 
Methods: Progression free patients treated with bone marrow transplantation or peripheral
stem cell graft for a hematological malignancy at least 2 years before study participation were
examined with a comprehensive battery of neuropsychological tests and questionnaires for
quality of life and mood states. The results of the neuropsychological tests were compared to
healthy population norms.
Results: Forty patients were included, 87.5% had undergone an allogeneic transplantation. All
received total body irradiation up to 12 Gy (in 2 fractions). Assessment took place 22 to 82
months after BMT. Mild to moderate cognitive impairment was found in 24 patients (60%).
Compared to healthy population norms, selective attention and executive function, information
processing speed, verbal learning, and verbal and visual memory were most likely to be
affected. 
The mean score for the total patient group revealed that these patients scored significant lower
on the information processing speed task compared to expected scores obtained from the
normal population.
The main predictors for poor neuropsychological performance were fatigue, global health, and
educational level. Other correlations with moderate to severe cognitive impairment were
subjective cognitive complaints, physical functioning, social functioning, overall mood states
and employment status. 
Conclusions: These data indicate that bone marrow transplantation may lead to cognitive
complaints and late cognitive deficits in adult long-term survivors. Cognitive functioning should
therefore be used as an outcome parameter in bone marrow transplantation studies.
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INTRODUCTION 
Autologous or allogeneic bone marrow or stem cell transplantation (BMT) has become standard
treatment for a variety of hematological malignancies. This treatment is curative for an
increasing number of patients, and attention has turned to the long-term effects of BMT.
Unfortunately, the BMT procedure carries still a considerable morbidity as a consequence of
acute and delayed disease and treatment-related complications. Patients have a risk of
developing neurological complications and delayed encephalopathies, which are associated
with the BMT conditioning regimen.1-7 The BMT conditioning regimen involves high-dose
chemotherapy, often combined with total body irradiation (TBI). Both high-dose chemotherapy
and radiation therapy to the brain are known causes for delayed central nervous system (CNS)
toxicity.8-11 Other potential severe treatment-related complications are opportunistic infections
related to immunosuppression, extensive acute or chronic graft versus host disease (GVHD),
side-effects of immunosuppressive therapy (cyclosporin, methotrexate or corticosteroids) or
major organ failure. These may give rise to a variety of severe neurological complications, in
particular (drug-induced) encephalopathies and opportunistic CNS infections.6 Prior or post
BMT intrathecal chemotherapy or whole brain irradiation as treatment or prophylaxis for CNS
disease may also induce a delayed leukoencephalopathy.12,13 The presence of this combination
of many potential risk factors for late neurological sequelae makes the BMT procedure unique
compared to other potentially neurotoxic forms of cancer treatment. The impact, however, of
the mentioned risk factors on cognitive functioning in long-term survivors is not well
documented. Neuropsychological studies in cancer patients treated with only one of the
treatment forms used in the BMT conditioning regimen showed evidence of cognitive
impairment.14-18 The few previous reports on the specific neurocognitive side effects of BMT
suggest that these patients are at risk to develop cognitive deficits.5,19-26 Only five studies
focused upon the late side effects but methodological shortcomings, such as lack of neuro-
psychological testing, small sample size or selection of patients, preclude reliable con-
clusions.5,19,20,25,26 We have, therefore, assessed cognitive functioning and quality of life (QOL) in
a consecutively treated cohort of long-term adult survivors of BMT. A minimum time interval of
2 years post treatment was used to elude influence of acute side effects of BMT.
MATERIALS AND METHODS
Patient selection
Patients treated with BMT for hematological malignancies 2 to 7 years before the time of this
study were selected from the BMT database of the Department of Hematology. In this 5-year
period a total of 141 patients were treated with a BMT conditioning regimen involving both
high-dose chemotherapy and TBI. Of these, a cohort of 61 consecutive long-term survivors was
identified.
Patients eligible for our study had to meet the following inclusion criteria: 1) no evidence of
recurrent disease, 2) no previous neurological or psychiatric disorders, 3) no use of psychoactive
drugs or medication known to affect cognitive functioning, 4) no history of, or current substance
abuse, 5) basic proficiency of the Dutch language, 6) between 18 and 65 years of age. 
68 |  COGNITIVE SEQUELAE OF INTENSIVE TREATMENT FOR HEMATOLOGICAL MALIGNANCIES
Measures
Cognitive performance was assessed by a comprehensive battery of standardized neuro-
psychological tests. Prior to testing the patients were interviewed with regard to cognitive
problems experienced in their daily-life routine. The extent of the problems was rated by the
neuropsychologist on a 4-point Likert-type scale (0= no problems, 1= mild problems, 2=
moderate problems, 3= severe problems.27 In addition, a set of self-administered question-
naires was applied to collect data on quality of life and mood states. Ratings of a widely used
mental status screening test, the Mini Mental State Examination (MMSE), and the Karnofsky
performance status scale were obtained before the assessment.28,29
The neuropsychological evaluation consisted of eleven internationally used psychometric tests
selected for validity and availability of normative data. The battery was designed to assess
several cognitive functions: general intelligence and conceptual reasoning, verbal function,
memory, attention functions and concentration, executive functions, visuospatial and visuocon-
structive ability, psychomotor function, and speed of information processing. 
The Groninger Intelligence Test, short form (GIT-V)
The GIT-V30 measures actual general intelligence level. The test consists of three subtests for
respectively spatial ability, abstract reasoning and arithmetic. The scores of the three subtests
are transformed into an intelligence quotient (IQ) based on age and gender. 
The National Adult Reading Test (NART)
The (NART)31 estimates premorbid intelligence based on verbal ability. This is mea-sured by the
ability to read aloud correctly a list of phonetically irregular words and accuracy of oral
pronunciation is scored. Premorbid intelligence can be estimated by this test as vocabulary
level and related verbal skills correlate with overall ability level.32
Wordfluency Test 
The Wordfluency test30 evaluates language processing by naming as many words as possible
belonging to two word categories. The score is the sum of words produced in each trial.
California Verbal Learning Test (CVLT)
The CVLT33 assesses verbal memory capacities. The test consists of five presentations with recall
of a 16-word list, one presentation of a second 16-word list and recall, followed by a short-term
free recall and cued recall of the first list. Retention is tested 20 minutes after learning by
delayed free recall, delayed cued recall and recognition. The CVLT provides also information on
learning strategies, and retroactive and proactive interference tendencies. 
Rey Complex Figure Test (CFT)
The CFT34 measures both visuospatial organization and visual memory. The patient is asked to
copy a complex figure. Immediate recall is assessed 3 minutes after copying. Evaluation of the
immediate recall is obtained by using scores based on a unit scoring system referring to specific
details of the figure. 
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Digit Span of the Wechsler Adult Intelligence Scale
Digit span35 assesses immediate recall and attention. The patient is asked to repeat successive
series of digits in two conditions, forward and backward.
Trailmaking Test (TMT)
The TMT36 measures psychomotor speed and attention. The test consists of small randomly
printed consecutively numbered circles (part A) and consecutively numbered and lettered
circles (part B). The patient has to draw lines to connect the circles, and in part B alternating
between the two sequences is required. Slow performance on one or both parts of the test
indicates cognitive deterioration. 
Stroop Color Word Test (SCWT)
The SCWT37 determines selective attention and executive functions. In part A and B, the time
needed to complete reading 100 color names and naming 100 colored rectangles is recorded.
Part C involves 100 color names in different printing ink than the color name; the speed at
which the color of the printing ink is named is taken as the test variable. is recorded. The time
taken to complete each part and the total number of failures are registered. 
The Fingertapping Task
The Fingertapping task32 measures the psychomotor speed. The patient is asked to press a
marked button with the index finger of each hand separately as fast as possible for one minute.
The number of hits in the first and second half (30 seconds) of the test and the number of total
hits is recorded. 
The Reaction Time Task
The Reaction time task38 measures speed of information processing in two single stimuli tasks
(visual and acoustic) and two complex binary choice tasks. The use of a rest button and reaction
button enables breakdown into decision-making time and motor time. Decision time, motor
time and the number of missing, incorrect or incomplete responses are scored. 
Questionnaires of QOL and Mood States
QOL was measured with the European Organization for Research and Treatment of Cancer
(EORTC) QLQ-C30.39 This instrument includes five domains that assess functioning (physical,
role, cognitive, emotional, social) by using multi-item scales, two domains assessing global
health status and global QOL, and nine multi-item scales or single items assessing sym-
ptomatology. In conjunction with the EORTC QLQ-C30, we used the EORTC brain cancer
module (BCM 20) to screen for neurological dysfunction.40 The BCM 20 contains four multi-item
scales (future uncertainty, visual disorder, motor dysfunction, and communication deficit) and
seven single items.
A questionnaire of mood states was administered to distinguish between cognitive deficits
related to BMT treatment or to additional psychological distress. The brief version of the Profile
of Mood States (POMS) was used as a summary measure.41,42 The POMS has separate subscales
for five dimensions of general psychological distress: depression, tension, anger, fatigue and
vigor. In total there are thirty-two items to be scored on a 5-point Likert-type scale format,
ranging from 0 to 4. 
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Procedure
The study was approved by the institutional ethics and scientific committee and written
informed consent was obtained from all patients. The medical records of the patients were
examined by a physician to record information regarding patients' current medical status
(including current medication use) and history of disease and treatment (eg, cytotoxic treatment
and complications of the BMT conditioning regimen). All psychometric tests were administered
in the same order for all patients and scored by an experienced neuropsychologist. The assess-
ment took approximately two and half-hours to complete.
Statistical Methods
The questionnaires were transformed into scores according to standard procedures. Before
computing a total score for overall psychological distress, the total POMS score, the scores of
the positive psychological distress subscale Vigor were transformed so they were in line with the
scores of the negative psychological distress subscales. The total POMS score was computed by
summing up the standard z-scores for each subscale and then dividing this score by the number
of subscales. The total POMS score was considered aberrant when the score was 2 standard
deviations (z ≤ -2.0) below the mean of the healthy population norms.41 The raw data of each
neuropsychological test (or test indices) were converted into standard scores (z-scores) and
percentile scores by using age and gender corrected healthy population norms. Patients were
classified according to the commonly accepted standard criteria of each test (ie, impaired either
when test scores were 2 standard deviations (z ≤ -2.0) below the mean of the standard scores
(z=0) or below percentile 10). General intelligence was considered to be aberrant if the
difference between the estimated premorbid intelligence quotient and the actual intelligence
quotient was more than 20 points (z ≤ -2.0), taking into account that the NART underestimates
premorbid intelligence by 15 IQ points.31,43 A composite score for cognitive impairment was
computed for each individual by counting all test indices on which the patient was impaired. 
The mean score of each neuropsychological test was computed after transforming all test
scores into percentile scores (to ease interpretation). In a normal population a percentile score
of 50 means that the patient has an average test result; the standard deviation is 34. The
differences between the distribution of the observed frequencies and the distribution of the
expected frequencies were tested with a chi-square test (X2 for trend). The distribution of the
expected frequencies was calculated using the scores of the normal population as reference
group.30,32-38 The upper and lower cells were collapsed so that the percentage of cells with an
expected count less than 5 did not exceed the limit of 20%.
Descriptive statistics were performed for all variables. Differences in individual test scores in
various patients groups defined by demographic and disease and treatment-related parameters
were analyzed by the Student's t-test. Relationships between overall cognitive performance,
psychosocial functioning and subjective measures of cognitive complaints were analyzed using
Pearson’s correlation coefficients. 
Multiple linear regression analysis was used to estimate the influence of disease and/or
treatment related variables on cognitive impairment. The set of variables to enter the analysis
were selected by the method of multiple regression; the composite score for cognitive
impairment was used as the dependent variable. The standardized regression coefficient (ß) was
used as a measure of relative importance.
Tests were two-sided and a P-value of 0.05 or less was considered statistically significant. All
data were analyzed using the Statistical Package for Social Sciences (SPSS) Windows 9.0 software.
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RESULTS
Demographic and clinical patient characteristics
Forty-two patients were eligible for study. Of these, forty patients (95%) provided written
informed consent (one patient lived abroad temporary and one patient declined to participate).
Ten patients were excluded because of recurrent disease or secondary malignancies and six
patients because of the lack of basic proficiency of the Dutch language. Two patients were
excluded due to long-term alcohol and/or drug abuse and one because of recurrent depressive
episodes and use of psychotropic drugs. Demographic and clinical information is shown in Table 1.
The two patients with aplastic anemia did not receive induction therapy prior to the BMT
procedure. CNS prophylaxis was given to eleven patients prior to BMT (4-8 injections of
intrathecal methotrexate or Ara-C), which was continued (2-3 injections) in five patients after the
BMT procedure. One patient received low dose TBI (24 x 0.10 Gy) before undergoing the BMT
conditioning regimen. Neurological complications prior to BMT were found in two patients: one
patient had CNS disease and was treated with cranial radiotherapy (16 x 1.5 Gy), another
patient had seizures related to intrathecal treatment. 
All patients underwent conditioning with high-dose chemotherapy and TBI. High-dose
chemotherapy consisted of cyclophosphamide, either alone (60 mg/kg of body weight per day
for 2 days) or in combination with cytosine-arabinoside (1000 mg/m2 per day for 2 days) or
etoposide (350 mg/m2 per day for 2 days). For the majority of patients high-dose chemotherapy
was followed by 10 or 12 Gy of TBI, administered in 2 doses of either 5 or 6 Gy in 2 days. After
the conditioning regimen most patients (87.5%) received bone marrow support from a related
or unrelated donor. 
Various regimens for prophylaxis of GVHD were utilized depending on the protocol and the
compatibility of the donor. Thirty-four patients received cyclosporin (CyA) (mean 166.2 days, SD
116.5, range 42 to 507) and T-cell depletion of the donor graft was performed in thirty-three
patients. Half of the patients received corticosteroids as immunosuppressive therapy (mean
139.8 days, SD 170.8, range 3 to 598). The median time interval between BMT and testing was
43 months.
Medical status and treatment-related neurological complications
After the BMT procedure complete remission was achieved in thirty-six patients. Four patients
with multiple myeloma were in ongoing partial remission, of which three used a maintenance
dose of interferon-alpha. Following BMT 69% of the allogeneic recipients experienced acute
GVHD (grade I to III), and 29% developed mainly limited chronic GVHD (Table 2). Four patients
had received treatment for recurrent disease (eg, donor buffy coat infusion or chemotherapy)
and were again responding. All additional therapy was given at least one year before neuro-
psychological testing.
The severe neurological complications induced by the BMT-conditioning regimen are
summarized in Table 2. A history of neurological complications such as encephalopathy, cere-
brovascular events or cerebral infections was found in almost a fourth of this cohort. Fifteen
patients underwent cranial MRI at the time of presence of clinical neurological signs. Abnormal
neuroradiological findings (eg, white matter abnormalities or focal lesions) were present in
seven patients. No current neuroradiological information was available at the time of neuro-
psychological evaluation.
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Table 1 Patient characteristics (n=40)
No. of patients Mean (SD) Range
Sex
Male 24
Female 16
Age (years) 40.8 (10.3) 18 - 60
Age at BMT (years) 37.2 (10.4) 15 - 55
Time since BMT (months) 45.1 (17.3) 22 - 82
Estimated premorbid IQ 105.3 (10.0) 84 -126
Educational level
Less than high school degree 3
High school degree 14
Vocational/trade school 10
College/bachelors degree 7
Graduate/professional degree 6
Diagnosis
Acute Lymphocytic Leukemia 8
Acute Myelogenous Leukemia 10
Chronic Myelogenous Leukemia 6
Non-Hodgkin’s Lymphoma 6
Myelodysplastic Syndrome 4
Multiple Myeloma 4
Aplastic Anemia 2
Intrathecal treatment
Yes 11
No 29
Type of BMT
Allogeneic MRD 26
Allogeneic MUD 9
Autologous 5
Conditioning regimen
CP 12
Ara-C + CP 19
VP-16+ CP 9
TBI dose
10 Gy (two fractions) 13
12 Gy (two fractions) 25
8.5 Gy (two fractions) 1
8 Gy (one fraction) 1
MRD = bone marrow transplantation; IQ = intelligence quotient MRD = matched related donor; MUD = matched unrelated donor 
CP = cyclophosphamide; Ara-C  = cytosine arabinoside; VP-16 = etoposide
Clinical performance and cognitive screening
Mean performance status (KPS) was 89.8, (SD 10.0, range 70-100); twelve patients had a clinical
performance below 90. The screening test of mental status revealed no abnormalities as all
patients scored above the MMSE cut-off score of 23 points (mean 28.3, SD 1.1, range 26-30).
Subjective cognitive problems in daily life routine
The incidence of reported subjective cognitive problems interfering with daily life routine is
shown in Table 3. Most patients reported no problems or only very mild problems. However,
almost 28% experienced moderate to severe memory problems and 17.5% showed moderate
problems in attentional functions. In most cases these patients experienced a decline in
comparison to their level of cognitive functioning prior to BMT treatment.
Table 3 Subjective cognitive problems in daily life routine a
Memory % Attention %
No problems 37.5 50
Mild problems 35 32.5
Moderate problems 25 17.5
Severe problems 2.5 -
a Information based on a short pre-test interview and rated on a scale by the neuropsychologist
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Table 2 Treatment-related complications: GVHD and neurological disorders
Acute GVHD No. of patients Chronic GVHD        No. of patients
Grade I 12 Limited 9
Grade II 6 Extensive 1
Grade III 6
Grade IV -
CyA encephalopathy 3
Hypertensive encephalopathy 1
Intracerebral hemorrhage 1
Viral-meningo encephalitis 1
Cerebral toxoplasmosis 1
Pneumococcal meningitis and 
cerebral toxoplasmosis 1
Unspecified cerebral lesion 
with seizures 1
GVHD: graft versus host disease; CyA: cyclosporine
Table 4 Neuropsychological tests: percentage of impaired patients and mean test score
Cognitive Domain Impaired patients % Mean test score (SD)a P-valueb
Neuropsychological Test
Intelligence
Groninger Intelligence Test 5 71.43 (28.22) .002
Language
Wordfluency Test 0 74.95 (20.24) .001
Memory
California Verbal Learning Test 15
- Total words 43.49 (30.97) .48
- Learning speed 41.81 (31.06) .43
- Consolidation 46.59 (29.13) 1.0
Rey Complex Figure Test-recall 20.5 50.26 (31.85) .10
Attention and executive function
Stroop Colour Word Test 23.1
- Word card 46.54 (30.89) .97
- Colour card 46.41 (29.33) .88
- Colour-word card 40.90 (27.86) .30
Digit Span 0 61.45 (23.38) .01
Trailmaking Test A 0 63.91 (23.01) .01
Trailmaking Test B 0 60.00 (24.19) .01
Visuospatial organization
Rey Complex Figure Test- copy 2.6 91.15 (20.50) .001
Psychomotor speed
Fingertapping Task 2.5
- Dominant hand 50.40 (29.51) .48
- Non-dominant hand 49.40 (29.83) .08
Speed of information processing
Reaction Time Task 32.5
- Single choice task 11.20 (15.56) .001
- Complex choice task 11.29 (20.65) .001
a In percentiles (mean=50, SD=34) 
b Compared to expected scores obtained from the reference group
Neuropsychological assessment
Only one patient could not perform all neuropsychological tests due to severe cataract. All
other patients completed the battery of neuropsychological tests including the questionnaires.
Table 4 presents the percentage of patients who performed in the impaired range of the eleven
neuropsychological tests and the mean test score for the total patient group. The distribution of
the composite score for cognitive impairment is summarized in Table 5. Sixty percent scored in
the impaired range on at least 1 neuropsychological test. Five patients (12.5%) scored on 3 or
more of the 11 tests they completed. 
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Compared to the normative data of each neuropsychological test the following domains of
cognitive functioning were most frequently impaired: selective attention and executive function
(SCWT;X 2=6.94,df=1,P=.008), information processing speed (Reaction time task;X 2=162.35,df
=1,P<.001), visual memory (Rey CFT; X 2=4.44,df=1,P=.035) and verbal learning and memory
(CVLT; X 2=25.64,df=1,P<.001). Verbal functions, intellectual functioning, motor speed,
immediate verbal memory and perceptual organization were unaffected. However, when the
distribution of the observed test scores were compared to the distribution of the expected test
scores, only the scores on the test for information processing speed were far below from those
obtained from the reference group (Table 4). The test scores on tests for verbal memory (CVLT)
and selective attention (SCWT) were slightly lower but not significant. On several neuropsycho-
logical tests the test scores were higher than the expected scores, namely on the GIT-V, the
Wordfluency Test, Digit Span, the Trailmaking A and the copy of the Rey CFT. 
A multiple linear regression analysis (adjusted for age and gender) was carried out using a selected
set of variables as covariates and the composite score for cognitive impairment as the depen-
dent variable. Examination of the standardized regression coefficients (ß) for the individual
variables indicated that the strongest predictors of the proportion of impaired tests were:
fatigue rated with the EORTC QLQ-C30 (ß=.43;P=.03), global health of the EORTC QLQ-C30
(ß=.55;P=.004) and higher educational level (ß=.29;P=.04). Other potential predictor variables
like age, the total POMS score, type of BMT, dose of TBI, use of CyA, use of T-cell depletion,
use of corticosteroids, use of interferon-alpha, time since treatment, exposure to intrathecal
treatment or treatment for recurrent disease, presence of acute or chronic GVHD, presence of
pre treatment or post treatment CNS complications, and presence of MRI-confirmed abnormal
neuroradiological findings did not account for the variance in the proportion of impaired tests.
QOL and mood states
The results of the questionnaires for QOL and psychological distress measured by the EORTC
QLO C-30 and the brief POMS are listed in Table 6. Global QOL in this cohort of patients seems
satisfactory (mean 82.5, SD 18.1). The cognitive function scale of the EORTC QLQ-C30 (Q20
and Q25) is of special interest in this study. The cognitive function scale was strongly correlated
with the symptom fatigue (r=-.55;P<.001). The composite score for cognitive impairment was
associated with several functional scales or items of the EORTC QLQ-C30: the physical function
scale (r=-0.44;P=.005), the cognitive function scale (r=-0.58;P<.001), the social function scale
(r=-0.38;P=.016) and the symptom fatigue (r=0.37;P=.02). 
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Table 5 Overall cognitive status: composite score for cognitive impairment
No. of patients (%)
No test in impaired range 16 (40)
One test in impaired range 14 (35)
Two tests in impaired range a 5 (12.5)
Three tests in impaired range 3 (7.5)
Four tests in impaired range 2 (5)
a Including the patient who completed only six neuropsychological tests
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Table 6 Scores of the questionnaires of quality of life and mood states
Mean (SD)
EORTC QLQ C-30 a
Functional scales
Physical function 80.6 (18.4)
Role function 83.8 (22.2)
Cognitive function 74.2 (22.3)
Emotional function 79.2 (24.5)
Social function 72.9 (31.3)
Global health 80.0 (17.4)
Global quality of life 82.5 (18.1)
Symptom scales and/or items
Fatigue 27.5 (18.7)
Nausea and vomiting 4.2 (11.2)
Pain 12.9 (18.3)
Dyspnea 14.2 (21.2)
Sleep disturbances 18.3 (22.6)
Appetite loss 5.8 (18.3)
Constipation 4.2 (17.2)
Diarrhea 4.2 (13.5)
Financial impact 15.0 (28.2)
EORTC BCM 20a
Multi-item scales
Future uncertainty 17.8 (19.2)
Visual disorder 11.9 (16.8)
Motor dysfunction 7.2 (10.5)
Communication deficit 17.2 (23.6)
Items
Headaches 19.2 (23.7)
Seizures 0.8 (5.3)
Drowsiness 10.8 (15.8)
Bothered by hair loss 4.2 (11.2)
Bothered by itchy skin 29.2 (32.2)
Weakness of both legs 13.3 (21.2)
Trouble controlling bladder 5.0 (14.2)
POMSb
Depression 4.3 (5.8)
Anger 8.4 (6.6)
Fatigue 6.1 (5.3)
Vigor 12.6 (3.5)
Tension 5.2 (4.9)
a EORTC QLQ C-30, EORTC BCM 20: scores range from 1 to 100; higher scores on the function scales represent a higher level of functioning;
higher scores on the symptom scales and/or items represent more perceived symptoms 
b POMS: scores range from 0 to 32 (depression), 0 to 28 (anger), 0 to 24 (fatigue and tension), and 0 to 20 (vigor); higher scores indicate
greater current mood disturbances except for the subscale vigor
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High levels of current distress (z ≤ -2.0 in comparison to healthy population norms) in one or
more subscales of the brief POMS were found in 15 patients. Most of these patients (60%) had a
high score on only one of the five subscales of the brief POMS, especially on the subscale
anger. The total POMS score was aberrant in only three patients. The total POMS score was
associated with the composite score for cognitive impairment (r=0.39;P=.02). Further analysis
showed a substantial correlation between the composite score of cognitive impairment and the
subscale fatigue (r=0.51;P<.001) and a weak correlation with the subscale tension (r=0.34;
P=.03). Absence from work or school was in particular associated with the following factors: fatigue
measured by the brief POMS (r=0.62;P<.001) and EORTC QLQ-C30 (r=0.46;P=.01), and
physical functioning (r=-0.41;P=.021).
Attendance at work or at school either full-time or part-time was established in 47% of the
patients who used to work or study prior to BMT. Forty percent of the patients were still on
disability or sickness benefit. There was a relation between employment status and the
incidence of subjective cognitive complaints measured by the EORTC QLQ-C30 (r=
-0.57;P=.001), and self reported memory problems (r=0.53;P=.002), the composite score for
cognitive impairment (r=0.42;P=.02) and the total POMS score (r=0.46;P=.003). More specific
inspection of the data showed that. 
DISCUSSION
Long-term survivors of BMT are at risk for cognitive impairment as a result of exposure to a
number of potentially neurotoxic agents, including those used in conditioning regimen (eg,
high-dose chemotherapy and TBI), as well as those used as prophylaxis or treatment of GVHD
or immunosuppression. Likewise, intrathecal chemotherapy or whole brain irradiation, often
used as prophylaxis or treatment for CNS disease involvement prior to the BMT conditioning
regimen, are risk factors for the development of cognitive deficits. In our study we analyzed
cognitive functioning in a consecutively treated sample of long-term adult survivors of mostly
allogeneic BMT with a mean time interval between treatment and neuropsychological testing of
more than 3 years. To our knowledge, this is the first study to examine long-term survivors of
BMT, who attained a survival of at least 2 years, with both an extensive battery of neuropsycho-
logical tests and measures of QOL and mood states. As anticipated, we observed late cognitive
sequelae in a significant percentage of patients. Most patients had only mild cognitive
impairment, but five patients (12.5%) showed moderate to severe decreased performance on
several neuropsychological measures compared to the normative data. Cognitive dysfunction in
these patients was most profound in visual memory, verbal learning, and verbal short-term and
long-term memory, attention or executive functions and speed of information processing. When
comparing the distribution of observed and expected test scores, a few tests had a lower mean
score than expected, but this was only significant for the speed of information processing task.
Several neuropsychological tests showed a higher mean score compared to the reference group
which is probably related to higher score on the intelligence test in this patient group. Measures
of QOL and mood states revealed that the majority of patients reported satisfactory global QOL
(median 83.3) and showed no signs of severe mood disturbances. 
Only nine studies have been published regarding cognitive functioning in BMT patients five of
which explored the neurocognitive status in long-term survivors a year or more after their
treatment.5,19-26 The first study in long-term survivors was performed by Parth et al.19 In a
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longitudinal design with a follow-up period up to a year post treatment, the cognitive and
motor performance of 44 BMT patients was compared to the cognitive status of their relatives
or donors. Cognitive changes in comparison to baseline levels and controls were most profound
near the beginning of treatment and involved associative memory, perceptual speed and logical
reasoning. These findings, however, reveal mainly the acute side effects of BMT treatment as
the sample size at the last follow-up was reduced to just 11 patients. 
Two retrospective studies with a similar time-interval between treatment and assessment to our
current study found evidence for cognitive decrement.5,20 Andrykowski et al 20 reported slowed
cognitive processing, attention problems, and difficulties in reasoning in 30 allogeneic
transplant patients and found an association with increased TBI dose. Reduced memory
function after allogeneic BMT related to older age, a longer time-interval post BMT, chronic
GvHD and long-term CyA use was found by Padovan et al.5 However, both studies lack
comprehensive neuropsychological testing as only subjective and unreliable measures (self-
report questionnaires and a structured interview) were used. Therefore, the extent of cognitive
problems could therefore be misjudged or underestimated. 
Two recent studies showed only minor cognitive problems following autologous BMT which is
contradictory to our findings.25,26 Peper et al25 used standardized neuropsychological tests in a
small cross-sectional study of 20 survivors of autologous BMT at a mean time interval of 32
months after treatment. Only a slight reduction of memory function was found but these
survivors were comparied to control patients with renal insufficiencies in which cognitive dysfunc-
tions are to be expected.44,45 The same group found normal pretreatment results and improved
test performance in a prospective evaluation of 58 autologous BMT patients with a mean
follow-up of 27 months.26 The improvement in cognitive functioning was explained by practice
effects of the repeated measurements (before treatment, the first day of TBI and 6 to 36 months
after TBI/BMT treatment), as well as by an increase of positive mood states. A possible
explanation for the inconsistency between these studies and our findings is the difference in the
type of BMT. In our study the majority of patients received allogeneic BMT, 26% of whom had
an unrelated donor. The incidence of neurological complications varies among types of BMT
with allogeneic BMT, in particular BMT with unrelated donors, carrying more treatment related
morbidity than autologous BMT.3-6 In our cohort of patients the neurotoxity and cognitive
dysfunctions will have been more severe because of their exposure to acute and chronic GVHD
and complications related to immunosuppression or immunosuppressive therapy.
Our data suggest correspondence between impaired cognitive function and educational level
especially higher educational background. Parameters such as age, gender and level of
education are known to influence cognitive functioning. Education level can in particular affect
the level of performance on tasks involving verbal skills, stored information, and other school-
related activities.32 Although the normative data usually have corrections for age and gender,
education–specific norms are not available for the majority of neuropsychological tests. Only a
longitudinal study in which patients are followed in time and are tested before treatment will
overcome this problem. 
We also collected information regarding QOL and mood states. An important finding is that
fatigue and global health are the main disease and treatment related predictors for cognitive
impairment. Our results on QOL confirm earlier studies among long-term BMT survivors in,
which, up to 10 years following treatment, a considerable percentage of patients still experience
a wide range of lingering complaints.46-48 Physical limitations or functional disability, pain, sexual
problems, fatigue, sleep disturbances and social problems were the most common reported
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complaints. Our findings show that both global QOL and fatigue were significantly associated
with depressed mood measured by the brief POMS which shows that these lingering complaints
have a great impact on patients’ daily life in general. While it is still unknown whether the
cohesion between fatigue, global health and cognitive impairment are possibly related to
another unspecified factor, it may in the meantime be worthwhile to investigate whether
intervention programs developed specifically to enhance QOL and to reduce fatigue and other
late physical effects, help patients to re-establish their daily life routine after the BMT treatment. 
Our study is the first to evaluate late cognitive side-effects using an extensive neuropsycho-
logical test battery in combination with QOL and mood states measures in long-term survivors
with a minimum survival of 2 years or more, it is preliminary and has some methodological
limitations. The sample size is relatively small due to the low survival-rates and the limited
number of disease-free survivors. Another limitation is that all patients in our study received a
conditioning regimen with high-dose chemotherapy and TBI and therefore the effects directed
to TBI only were not assessed. In addition, with this sample size we were unable to assess
whether specific chemotherapeutic agents or dosages affect cognitive functioning. Similarly, the
retrospective design and lack of pretreatment baseline assessment preclude definite
conclusions about a change in cognitive functioning over time. The best way to evaluate the
side effects of BMT treatment on cognitive functioning is through a longitudinal cohort study
using a comprehensive neuropsychological test battery instead of a cognitive screening test or
questionnaires only. Our results highlight the demand for systematic investigations on the late
neurocognitive effects of BMT treatment. We have therefore started a prospective and
longitudinal cross-sectional study to assess cognitive functioning and quality of life.
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ABSTRACT
Longitudinal data of neurocognitive functions and quality of life (QOL) were obtained for a
cohort of 25 patients followed before transplant and through the first year after haematopoietic
stem cell transplantation (SCT). A battery of neuropsychological tests and two self-report
questionnaires were used to assess neurocognitive functions, QOL and psychological
functioning. In comparison to normative data, up to one-fourth of the patients experienced
impaired functioning on several cognitive domains before SCT. Random regression modelling
revealed a slight improvement in the mean group scores of memory tasks over time, especially
for younger patients. Impairment in neurocognitive functions was positively related to
depression and anger at baseline, and to the emotional functioning scale at follow-up. These
preliminary results emphasise the significance of a pre-treatment assessment and the need of a
large baseline sample in future longitudinal studies to overcome the expected dropout-rate of
more than 50%.
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INTRODUCTION
Progress in haematopoietic stem cell transplantation (SCT) procedures and supportive care
following bone marrow and peripheral blood stem cell transplantation has resulted in higher
survival rates. As a consequence, the impact of SCT on neurocognitive functions and quality of
life (QOL) is receiving more attention. Research into the neurocognitive consequences of SCT is
critical as SCT-recipients are exposed to several potential sources of neurotoxic damage. The
pre-transplant treatment schedules followed by intensive conditioning regimens with high-dose
chemotherapy and total body irradiation (TBI), together with frequent infections, neurological
complications and long-term use of graft versus host disease (GVHD) prophylactics may well
affect the central nervous system and lead to long-term cognitive impairment. 
Previous research indeed suggested that SCT recipients develop cognitive deficits, even years
after treatment. Recently, we reported that more than half of 40 long-term survivors experienced
mild to moderate cognitive impairment and less than half were back at work at a mean time of
almost four years after SCT.1 Like the few other reports in long-term SCT survivors this study was
performed without an assessment prior to SCT.2-4 Therefore, one cannot conclude that post-
transplant cognitive impairments are directly attributable to the transplantation rather than
other factors. Study designs with a pre-treatment baseline evaluation will differentiate between
effects of previous treatment and the intensive SCT conditioning regimens or post-treatment
complications, and monitor the influence of behavioural factors and psychological adjustment.
However, longitudinal neurocognitive studies in SCT patients are problematic especially in
areas of feasibility and statistical analysis. Mortality and morbidity rates are high caused by the
toxicity of conditioning regimens, relapse, and acute or delayed treatment-related complications.
Consequently, it takes many years to obtain data from a sufficient number of long-term
survivors. The longitudinal studies performed so far investigated cognitive functions mainly in
the periods before and immediately after hospitalisation for SCT.5-8 Reports with longer follow-
up included both children and adults, used subjective psychometric methods or had widely
varying time-intervals between the assessments.9-11
The aim of the current pilot-study was to describe changes in cognitive functioning in the first
year after SCT in a group of 25 patients, and to assess the feasibility of longitudinal research of
objective neurocognitive functions and QOL methods in SCT patients.
METHODS
Patients
A total of 25 recipients of haematopoietic stem cell grafts were enrolled in the study and were
tested before hospitalisation. Patients eligible for the study had to be over age 17 years, have
sufficient knowledge of the Dutch language, and provided written informed consent. The study
excluded patients with a history or presence of psychiatric or neurological disorders, and
substance abuse. For follow-up, only patients without relapse or severe medical problems were
included. The pre-transplant medical and demographic characteristics are summarised in Table
1. Most patients (20/25) had received prior systemic chemotherapy and the last cycle of
chemotherapy was given at a median of 1.8 (range 1-14) months before baseline. Additional
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(non-cranial) radiotherapy before SCT had been given to three patients. Two patients received
intrathecal MTX chemotherapy. One patient had a subdural haematoma prior to SCT and used
anti-epileptic drugs. The study was approved by the ethical committee of our hospital.
Table 1 Pre-transplant medical and demographic characteristics (n = 25)
Male / Female, no. 16 / 9
Median age in years (range) 47 (18-56)
Median premorbid IQa (range) 104 (81-126)
Median educational levelb (range) 3 (1-5)
Median KPS scorec (range) 90 (70-100)
Diagnosis, no. 
ALL 1 
AML 2
CLL 2
MM 7
MDS 2
HD 3
NHL 4
SAA 4
Disease statusd, no. 
Low risk 15
High risk 10
Chemotherapy treatment history, no.
No previous treatment 5
1 course of chemotherapy 10
> 1 course of chemotherapy 10
ALL = acute lymphoblastic leukaemia; AML = acute myeloid leukaemia; CML = chronic myeloid leukaemia; MM = multiple myeloma; MDS =
myelodysplastic syndrome; HD = Hodgkin’s disease; NHL = non-Hodgkin’s lymphoma; SAA = severe aplastic anaemia;
a NART intelligence quotient; b level 1 ‘< high school degree’, level 2 ‘high school degree’, level 3 ‘vocational/trade school’, level 4
‘college/bachelors degree’, level 5 ‘graduate/professional degree’; c Karnofsky Performance Score; d Low risk = first remission, High risk = one
or more relapses and second remission
Materials
Neurocognitive functions The standardised neuropsychological test battery and procedures
have been described in detail elsewhere.1 In short, four cognitive domains were examined with
the following tests: Intelligence & Complex Tasks: short form of the Groninger Intelligence
Test12, National Adult Reading test13, copy of the Rey Complex Figure Test14,15; Memory: Digit
Span of the Wechsler Adult Intelligence Scale16, California Verbal Learning Test17, immediate
recall of the Rey Complex Figure Test14,15; Attention & Executive Functions: Stroop Colour Word
Test18, Trailmaking A and B19, Wordfluency Test12; Psychomotor Functions & Speed: Finger-
tapping Test20, Reaction Time Test.21 To help to control for practice effects, alternate versions
were used for the memory tests. Healthy populations norms, adjusted for age and sex, are
available for all tests. Before every neuropsychological assessment the Karnofsky Performance
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Score was rated.22 Additionally, the patients were interviewed by the neuropsychologist about
subjective cognitive complaints (memory and concentration) experienced in their daily life
activities.
QOL and psychological functioning Patients completed two standardised self-report ques-
tionnaires. QOL was assessed with the EORTC QLQ-C30.23 Psychological functioning was
measured with the Dutch version of the short Profile of Mood States (POMS) with the following
subscales: depression, tension, anger, fatigue and vigour.24
Data Analyses
The neuropsychological tests were scored according to standard procedures. Corrected test
indices scores of more than two standard deviations (z <= -2.0) below population norms (z = 0)
or below percentile 10 were classified as impaired.1 For the evaluation of neurocognitive
functions over time, the raw scores for each patient were transformed into T-scores based on
the performance at baseline (mean=50 and sd=10). The measure for that given time point was
T=50 + (10(x-m)/sd) in which x is the individual score, and m and sd are respectively the corre-
sponding group mean and standard deviation for the baseline score. For each of the four cog-
nitive domains, a mean cognitive domain index was calculated by using the sum of all T-scores
divided by the number of test indices in that domain. 
The large number of missing observations due to relapse or morbidity and mortality precluded
the use of traditional statistical approaches for longitudinal designs (eg, end-point analysis and
ANOVA models). Therefore, Random Regression Modelling (RRM) analyses were conducted,
using the mean cognitive domain indices, to assess changes in neurocognitive functions over
time.25-27 The RRM approach allows for missing observations, time-varying covariables
(psychological functioning) and invariant covariables (sex, age and education), and assessments
at different end points. RRM estimates both average time trends and individual time trends. The
individual time trend curves are based on available data for each patient, augmented by
information from data from all other patients in the sample. The general model assumes that
the individual response of each patient can be described by a line with intercept (baseline
response) and slope (change rate) that is specific to the individual. Spearman’s correlation
techniques were used to identify and evaluate potential determinants for treatment and
performance on neuropsychological testing. Nonparametric tests (Mann-Whitney U-test) were
used to compare different groups of individuals. The probability level for statistical significance
was set at 0.05 (two-tailed). All analyses were performed using the Statistical Package for Social
Sciences (SPSS), version 10.1 and the SAS System version 8.2.
RESULTS
Clinical Outcomes
SCT was cancelled in two patients because of relapse, and two patients were not approached
for follow-up because SCT was delayed severely due to medical complications. Table 2 presents
a summary of the SCT treatment characteristics for the remaining 21 patients. Pre-treatment
baseline testing was completed at a median of 23 (range 6-107) days before initiation of SCT-
conditioning. Most patients (16/21) had an allogeneic transplant, while five patients received
autologous stem cells, both following ablative high-dose chemotherapy. The majority of
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patients (18/21) received CY (60 mg/kg once daily iv for 2 days) as a conditioning regimen
followed by TBI up to a total dose of 12 Gy. Six patients experienced acute GVHD. Chronic
GVHD was not observed. Severe complications immediately after SCT occurred in two patients
(meningo-encephalitis and toxic pneumonitis). Twelve patients were included in the follow-up
evaluation at 6 months and nine at 12 months. Failure to complete the 6-months follow-up
evaluation was due to death (n = 3), long-term hospitalisation (n = 4; these patients were
hospitalised because of severe post-SCT complications and died before the last assessment)
and refusal (n = 2). Missing at the 12-months follow-up was caused by death (n = 1), long-term
hospitalisation (not related to SCT; n = 1) and relapse (n = 1). 
Table 2 SCT characteristics (n = 21)
Type of SCT, no. 
Autologous SCT 5
Related donor SCT 15
Unrelated donor SCT 1
Conditioning regimen, no.
CY / TBI 18
BU / CY 1
CBV 2
TBI dose , no.
2 x 5 Gy 6
2 x 6 Gy 12
CY = cyclophosphamide (60 mg/kg once daily iv. on days 1 & 2); BU = Busulphan (4 mg/kg p.o. in divided doses daily for 4 days); CBV =
(BCNU 300 mg/m2 once daily iv. on day 1, cyclophosphamide 1500 mg/m2 once daily on days 2-5, VP16 125 mg/m2 twice daily iv. on days 2-4)
Pre-Transplant Neurocognitive Functions Compared to Normative Data
Table 3 presents the mean scores of the neuropsychological tests and the percentages of
impaired scores compared to normative data at baseline and follow-up evaluations. Baseline
scores were examined for the entire patient sample (n = 25). Impaired test results were obser-
ved in the domains Intelligence & Complex Tasks, Attention & Executive Functions and Psycho-
motor Functions & Speed. The dropouts at 6 and 12 months did not differ from the non-
dropouts on any of the neuropsychological tests at baseline. 
Neurocognitive functions during the first year after SCT 
The performance of the RRM models is shown in Table 4. To examine the degree to which neuro-
cognitive functions varied across time and to explore the interaction of additional covariables,
the RRM analysis strategy was as follows. First of all, time trend was entered in all models as
linear and quadratic terms. Linear terms were introduced as random in half of the models and,
in addition, psychological functioning (POMS) was introduced in half of the models. In all models
the error variance was declared unstructured and the following variables were entered as
covariables: premorbid intelligence, sex, age and education. The results of the RRM analysis are
summarised in Table 5. The overall time effect was significant for the domain Memory, which
reflects improvement in test performance over time. Additionally, a negative effect of age was 
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Table 3 Means (SD) and percentages of impaired test scores for the neuropsychological 
tests over the three time points
Cognitive Domain Baseline 6-months FU 12-months FU
Neuropsychological test (n = 25) (n = 12) (n = 9)
Intelligence & Complex Tasks
Short-GIT (score 0-66) 35.6 (7.4) 4% 37.7 (6.5) -
CFT-copy (score 0-36) 35.4 (1.0) - 35.1 (1.1) - 35.3 (0.9) -
Memory
Digits (score 0-24) 12.6 (4.0) - 12.6 (3.7) - 13.8 (4.9) -
CVLT (score 0-75) 55.0 (8.3) - 59.9 (6.2) - 58.3 (7.2) 11%
CFT-recall (score 0-36) 23.5 (5.4) - 27.9 (5.7) - 27.0 (4.8) -
Attention & 
Executive Functions
Stroop-Colour 93.7 (21.8) 24% 95.8 (27.7) 25% 91.6 (16.0) 22%
Word Card (sec)
TMT-A (sec) 39.1 (15.6) 8% 33.2 (10.8) - 27.6 (6.1) -
TMT-B (sec) 74.9 (19.1) 8% 68.1 (20.6) - 71.0 (29.6) 11%
Wordfluency (in 1 min) 21.4 (4.2) - 20.1 (3.4) - 22.7 (3.3) -
Psychomotor Functions 
& Speed 
Tapping-dominant (in 1 min) 343.6 (48.3) 8% 350.2 (32.4) - 344.2 (34.3) -
Tapping-nondominant (in 1 min) 297.1 (47.1) 12% 302.3 (52.1) - 293.8 (54.9) 11%
Single Motor Speed (msec) 166.6 (47.8) 12% 161.7 (32.0) 8% 145.0 (33.2) -
Complex Motor Speed (msec) 166.8 (51.9) 12% 158.5 (36.0) - 160.0 (52.0) -
Single Decision Time (msec) 344.9 (37.5) 24% 341.1 (25.6) 8% 353.3 (34.7) 22%
Complex Decision Time (msec) 521.8 (65.3) 8% 498.8 (62.6) - 490.1 (93.5) -
Percentage of impaired test scores in italics; standard deviation values in parentheses; SD = standard deviation; FU = follow-up evaluation; GIT
= Groninger Intelligence Test; CFT = Rey Complex Figure Test; CVLT = California Verbal learning Test; TMT = Trailmaking Test; sec = seconds;
min = minutes; msec = milliseconds
observed, suggesting that the change in test performance on memory tasks varied by age (ie.
older patients showed less improvement). For the other three cognitive domains, there was no
evidence of any significant change over time or effects of the covariables.
Subjective cognitive problems, psychological functioning and QOL
At baseline the majority of patients (20/25) reported no subjective cognitive complaints (i.e.
memory and concentration problems). At the first follow-up, six patients reported light to
moderate cognitive problems (memory and concentration) and at the last assessment three out
of nine patients complained about memory problems. The differences in the scores of
subjective cognitive complaints over time were not significant. The percentage of impaired test
results correlated positively with the subjective concentration problems at the one-year follow-
up (r = .85, P = < .004), and no correlations were found at 6-months or at baseline. 
Analysis of the QLQ-C30 revealed that patients who only performed the baseline assessment
had lower scores on the emotional functioning scale of the QLQ-C30 (mean scores respectively 
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Table 4 Fit statistics for the four most plausible RRM models
RRM Models -2 res LL AICC BIC
Intelligence & Complex Tasks
Model 1 216.9 226.7 229.8
Model 2 219.1 223.6 225.6
Model 3 217.2 227.1 230.1
Model 4 218.9 223.4 225.4 
Memory
Model 1 260.2 264.5 266.6
Model 2 263.8 267.8 270.2
Model 3 260.8 265.1 267.2
Model 4 265.0 269.3 271.4 
Attention & Executive Functions
Model 1 267.8 276.9 280.6
Model 2 269.3 273.7 275.8
Model 3 264.2 270.9 273.8
Model 4 266.6 270.9 273.0 
Psychomotor Functions & Speed
Model 1 257.9 267.0 270.7
Model 2 259.9 264.2 266.3
Model 3 259.5 268.7 272.4
Model 4 261.5 265.9 268.0
-2 res LL = -2 restricted Log Likelihood; BIC = Bayesian Information Criterion (smaller is better) (Schwarz, 1978); AICC = small sample corrected
Akaike Information Criterion Corrected (Hurvich & Tsai, 1995)
71 and 85, P = .05; adjusted for sex and age). No other differences between dropouts and non-
dropouts were found. Similar RRM analysis strategies as described for the neurocognitive
performance were applied for further examination of the QLQ-C30 and the short-POMS. No
effects were found for the short-POMS or the QLQ-C30 symptoms scales or symptom items. A
time effect was found for the emotional functioning scale (P = < .005), indicating an improve-
ment at follow-up assessments. For global QOL, an effect of education was observed (P = .01);
higher educational level was associated with higher global QOL. Differences in scores between
sexes were observed for global health at the first follow-up assessment (females had higher
scores, P = .04). At baseline, none of the QLQ-C30 scores correlated with neurocognitive func-
tioning (although ‘emotional functioning’ reached an almost significant level; r = -.34, P = .10).
The subscales depression and anger of the short-POMS associated positively with neurocog-
nitive functions at baseline (respectively r = .40, P = .05; r = .47, P = .02). At both follow-up
assessments, a negative correlation was observed between neurocognitive functions and
‘emotional functioning’ of the QLQ-C30 (6-months evaluation r = -.60, P = .04; 12-months
evaluation r = -.75, P = .02), indicating that patients with more disturbed emotional functioning
had more impaired test results. 
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Table 5 Neurocognitive functions after SCT: modelling trends over time and effects of
covariables 
Effect Estimate SE t-value P-value 
Intelligence & Complex Tasks
Overall Time Effect 1.927 0.987 1.95 0.09
Premorbid IQ 0.025 0.205 0.12 0.91
Sex 0.370 3.578 0.10 0.92
Age 0.125 0.152 0.82 0.44
Education 9.094 4.481 2.03 0.08
Memory
Overall Time Effect 11.284 4.629 2.44 0.03
Premorbid IQ 0.166 0.140 1.18 0.25
Sex - 3.812 2.453 - 1.55 0.14
Age - 0.373 0.104 - 3.57 < 0.002
Education 3.825 3.077 1.24 0.23
Attention & Executive Functions
Overall Time Effect - 0.441 4.228 - 0.10 0.92
Premorbid IQ 0.098 0.177 0.51 0.61
Sex 2.538 3.076 0.83 0.42
Age - 0.061 0.131 - 0.47 0.65
Education 4.566 3.845 1.19 0.25
Psychomotor Functions & Speed
Overall Time Effect 5.184 4.247 1.22 0.24
Premorbid IQ - 0.198 0.138 - 1.43 0.17
Sex - 2.144 2.412 - 0.89 0.39
Age 0.120 0.103 1.16 0.26
Education 4.897 3.030 1.62 0.12
SE = standard error
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DISCUSSION
The present prospective and longitudinal pilot-study assessed neurocognitive functions and
QOL in 25 adult SCT recipients. Patients were evaluated in a prospective design and tested with
a comprehensive battery of neuropsychological tests and questionnaires of QOL and psycho-
logical functioning at six and twelve months after baseline. All patients completed the test
battery. 
The use of repeated evaluations enabled individual changes in neurocognitive functions and
QOL-related issues to be examined over time. During the first six months an attrition rate of
52% was observed caused by relapse before SCT, pre-treatment medical problems (pulmonary
or cardiac) and severe SCT treatment-related morbidity or mortality. Only two patients declined
to participate at the follow-up evaluations. The attrition rate increased to 64% at the last follow-
up evaluation one year after baseline. High percentages of dropouts are well known in
longitudinal studies of SCT patients as a result of the significant treatment-related morbidity or
mortality in the first months after SCT. Therefore, systematic measurements of neurocognitive
functions and QOL have proven difficult. We analysed our data with RRM, an adequate
statistical technique in handling missing data, in which the analysis is not limited to survivors
only or to those patients who were available for testing. Our data revealed that at the baseline
assessment, cognitive deficits were mainly found in 'Attention & Executive Function' in com-
parison to age-adjusted healthy population norms. Almost one-fourth of the patients had
impaired scores on the Stroop Colour Word Test, a measure for mental control, response
flexibility and perceptual interference.20 The percentage of impairment on this test remained
stable throughout the first year and associated strongly with subjective concentration problems
at the last follow-up. RRM analysis revealed no statistical differences in mean group scores
before and during follow-up up to one year after SCT for most cognitive domains. Only
performance on memory tests improved slightly across time, in particular for younger patients.
The influence of practice effects in performance on memory tasks cannot be completely ruled
out despite the use of alternate versions. Because of the regular follow-up assessments,
patients get familiar with the test procedures what may improve the test outcome. 
During the first year post-SCT, only minor statistical changes were found in QOL and psycho-
logical functioning. The level of psychological distress (depression and anger) affected neuro-
cognitive performance at baseline but not at follow-up, which is in line with results from
previous reports.6,8,10 They showed that mood disturbances at baseline, probably as a response
to the forthcoming SCT treatment, were followed by declining stress levels after hospitalisation.
Our findings show that before SCT many patients have impaired test results in several domains
of neurocognitive functions. This confirms other studies that focused on cognitive functioning in
the first year after SCT treatment.5,6,10,11 However, unlike some studies no significant decline in
neurocognitive functions was observed during the first year after SCT.6,7 The methodological
differences (ie, differences in methods and duration of follow-up) probably contribute to the
variability in results, but alternative explanations for these contradictory results should be con-
sidered. First of all, the effects of additional factors (eg, age and education) on decline or
improvement of neurocognitive functions were not reported because of limitations in
addressing group differences due to the small sample size. It is more likely that these effects
may be detected in al larger sample of patients and play a possible role in the rate and patterns
of cognitive changes. Furthermore, a potential selection bias needs to be considered given the
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high attrition rate, partly caused by the fact that patients with a relapse or severe medical
problems were excluded from further follow-up for ethical reasons. The current sample of
patients may not be representative for all SCT patients and, consequently, the neurocognitive
problems experienced by some patients could be underestimated. Therefore, our results should
be interpreted in the context of common limitations of pilot studies and replication of the
findings in a larger sample is essential. 
In conclusion, this pilot-study predominantly demonstrated the feasibility and relevance of a
prospective longitudinal design in studying neurocognitive functions in SCT patients. It also
emphasises the importance of a pre-treatment assessment as observed post-SCT cognitive
deficits may be due to impairment found before the SCT procedure. Furthermore, the results
implicate that, based on an expected dropout of at least 50% and the extensive battery of
neuropsychological tests, a sample size of approximately 100 patients at baseline is needed in
future research to obtain sufficient power. A study evaluating the neurocognitive functions in a
larger sample of SCT patients in comparison to other haematological cancer patients is cur-
rently ongoing.
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ABSTRACT
The aim of this study was to examine cognitive performance in patients prior to bone marrow or
haematopoietic stem cell transplantation (SCT) and in haematological patients who received
non-myeloablative cancer therapies. A consecutive sample of 101 SCT patients and 82
haematological patients completed a neuropsychological test battery and 5 questionnaires
assessing subjective cognitive complaints, psychological functioning, health-related quality of
life (HRQOL), and fatigue. Results were compared with normative data. Percentages of
cognitive impaired patients were equally divided between groups. Most deficits were observed
in visual memory, visuospatial and constructional ability and psychomotor functions. The SCT
group showed a higher rate of anxiety cases and reported lower cognitive functioning,
emotional functioning and social functioning. Results of neuropschychological testing were not
associated with outcome of the questionnaires. This study showed impaired cognitive
performance prior to SCT. Haematological patients treated with non-myeloablative cancer
therapies proved to be a reliable reference group for longitudinal studies. 
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INTRODUCTION
With more effective anticancer treatment, late side effects of treatment are an increasing source
of concern. This also holds for cognitive dysfunction. The most consistent cognitive deficits in
patients treated for advanced malignancies outside the central nervous system (CNS) involve
executive function, verbal memory and motor skills.1 Even though most of these cognitive
changes are mild or subtle, they can affect many aspects of patients’ lives and have serious
consequences for health-related quality of life (HRQOL), family role functions, and employment
status or vocational training. 
Bone marrow or haematopoietic stem cell transplantation (SCT) in adults with haematological
malignancies is a potential cause of cognitive dysfunction.2-12 SCT patients are exposed to a
variety of profound neurotoxic influences during a prolonged period of time. First of all, most
patients faced intensive treatment schedules before undergoing SCT, like high-dose systemic
chemotherapy, intrathecal chemotherapy or relapse therapies.13,14 This is followed by the
induction phase of SCT, which involves high-dose myeloablative chemotherapy with or without
total body irradiation (TBI).15 Finally post-engraftment, many patients need long-term immuno-
suppression with steroids or cyclosporin, they are at risk of opportunistic infections caused by
immunosuppression, and they experience acute or chronic graft versus host disease (GVHD).16
All these factors put SCT patients at an increased risk of CNS damage and result in possible
long-term cognitive deficits. In a retrospective study on cognitive functioning in adult survivors
of SCT, we observed that a significant proportion of patients experienced ongoing cognitive
problems several years after SCT treatment.11
The curative intent of SCT underscores the importance of evaluating long-term cognitive
performance in these patients. Better insight and understanding of the cognitive consequences
of SCT can be obtained by using a longitudinal repeated measurement design with a pre-SCT
assessment. A pre-treatment measurement is of pivotal importance because it allows for
differentiating between observed deficits due to the SCT procedure, the ensuing treatment and
complications on the one hand, and deficits induced by the disease itself, pre-SCT treatment or
confounding factors as psychological distress on the other hand. Previous prospective reports
showed cognitive deficits prior to SCT treatment in up 60% of patients.4,5,12 Although, most of
these studies used measures of psychological functioning, all failed to incorporate an
appropriate reference group, which is necessary to draw conclusions about the underlying
causes of the observed effects. However, there are inherent difficulties in selecting a reference
group. Differences in pre-SCT treatment schedules, in particular in the intensity of chemo-
therapy, may cause varying degrees of cognitive deficits prior to SCT. In the present study, we
therefore assessed cognitive performance, psychological functioning, fatigue and HRQOL in
SCT patients prior to SCT and in a group of patients with haematological malignancies who
were treated with systemic chemotherapy and/or involved-field radiotherapy. The objectives
were to study pre-SCT cognitive functioning in a sufficiently large sample of SCT patients and
its relation to potential confounding factors, and to investigate if a group of patients with
haematological malignancies treated with non-myeloablative cancer therapies can be used as a
clinically relevant reference group in future longitudinal studies.
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PATIENTS AND METHODS 
Patient accrual and study procedure
SCT study participants and patients of the reference group were recruited from the outpatient
clinics of the Departments of Haematology and Radiotherapy of the Erasmus Medical Center
(n=169) and the Department of Haematology of the Leiden University Medical Center (n=14).
Inclusion criteria were: completion of (pre-SCT) treatment for a haematological malignancy, age
16 to 65 years, and fluent in Dutch. Patients were excluded in case of previous or current
neurological or psychiatric disorders with known impact on cognitive and/or motor functions,
and in case of previous or current substance abuse. Patient accrual started in June 1999 and
lasted through December 2001. All patients were asked by their physician to take part in the
study. An appointment for assessment of the patient was scheduled before starting SCT
induction regimens. The institutional ethics committee for each participating center approved
the research protocol and all patients provided written informed consent. Medical data were
collected from the patients’ records. Performance status was assessed using the Karnofsky
performance status scale (KPS).17
Assessment of cognitive performance
A comprehensive test-battery was designed to assess four cognitive domains: Memory and
learning: the Dutch version of the California verbal learning test,18 the Rey complex figure test
and recognition trial,19 the Benton visual retention test;20 Attention and executive Functions:
Category wordfluency;21 Digit span,22 the abbreviated Stroop colour-word test,23,24 Trails A and
B,25 the D2 test;26 Visuospatial and constructional ability: the Rey complex figure test-copy
trial,19 Block design;22 Psychomotor functions: Digit symbol,22 Finger tapping;27 the Reaction
time test28. In addition, the Dutch version of the National Adult Rea-ding test 29 was used to
estimate the premorbid intelligence level. All tests were selected with regard to available
normative data and their sensitivity to measure specific cognitive deficits. The tests were
administered in the same order to each patient and the assessment took approximately 2 h to
complete. 
Assessment of subjective cognitive functioning
The Dutch version of the Cognitive Failure Questionnaire (CFQ) was administered to measure
the frequency of everyday cognitive failures in memory, attention, action and perception.30 It
has 25 items with a 5-point scale from 0 (never) to 4 (very often). Raw scores were transformed
and a total CFQ-score was computed by summing the item scores. The total CFQ scores range
from 0 to 100, with higher scores indicating more cognitive failures. Additionally, all patients
(except for those who reported no cognitive failures) indicated if they experienced an increase
in cognitive failures in the last year, if they were hindered, worried and annoyed about the
cognitive failures.
Assessment of psychosocial functioning, fatigue and HRQOL
The Hospital Anxiety and Depression Scale (HADS), comprising 14 items, was used to screen for
anxiety and depression.31 A cut-off level of >10 points for both subscales was used to identify
potential clinical cases.32 The severity of psychological reactions to disease and treatment was
evaluated with the Impact of Event Scale (IES).33 The IES relates to specific events associated
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with stress disorders and is based on a list of comments composed of commonly reported
experience of intrusion (7 items) and avoidance (8 items). Patients have to indicate how
frequently these comments applied to them during the past week on a 4-point scale with scores
ranging from 0 (not at all) to 5 (often). Separate scores of intrusion of disease, intrusion of
treatment, avoidance of disease and avoidance of treatment were computed, ranging from 0 to
35 for the intrusion scales and from 0 to 40 for the avoidance scales with higher scores
indicating more complaints.
The Multi-dimensional Fatigue Inventory (MFI) was used to measure fatigue.34 The MFI has five
subscales assessing general fatigue, physical fatigue, mental fatigue, reduced activity and
reduced motivation. The subscale scores range from 4 to 20 with higher scores representing
more symptoms. 
HRQOL was measured with the EORTC QLQ-C30.35 This instrument incorporates functional and
symptom scales, symptom items and two scales to assess health and global QOL. All scores
were transformed ranging from 0 to 100.36 The Leukaemia-BMT module (QLQ-LEU-BMT) was
added to evaluate somatic symptoms associated with SCT.37
Data analyses
The neuropsychological test scores were compared to normative data adjusted for age and
gender. Raw test scores were converted into standard (z-scores) scores. Patients were classified
as cognitive impaired when scores were more than 1.5 standard deviation (SD) below the mean
of the standard scores on at least 4 subtests.27 A measure of overall cognitive performance was
derived for each individual patient by summing the number of impaired test scores divided by
the number of completed tests and multiplied by 100. Descriptive statistics were used to
summarise the demographic and clinical characteristics, neuropsychological test scores and
questionnaires responses. Because of a large number of categorical potential confounding
variables, a multivariate confounder score (using gender, diagnosis, relapse, chemotherapy, and
radiotherapy) was calculated for each patient to reduce a bias in test results.38 Differences
between groups in raw neuropsychological test scores and the scores of the questionnaires
were tested by univariate analysis of covariance (ANCOVA) with the multivariate confounder
score as a covariate. Between-group differences in other variables were evaluated using Students'
t-tests for independent samples (two-sided) or chi-square tests. Pearson’s’ correlation coef-
ficients were calculated to assess the relations between various variables, test scores and
measure of overall cognitive performance. A 0.05 level of statistical significance was used in all
statistical procedures. Analyses were performed using the Statistical Package for the Social
Sciences (SPSS) Windows 11.0 software.
RESULTS
Patients characteristics
Of the 151 patients scheduled for SCT, 135 (89%) met the inclusion criteria. In the reference
group, 99 (83%) of the 119 consecutive patients were eligible for study. Main reasons for
exclusion in both groups were: age over 65, language difficulties, and concomitant neurological
disorders. Thirty-three (24%) SCT patients and 17 (17%) patients of the reference group refused
to participate. The primary reported reason for refusal in the SCT group was the burden of an
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Table 1 Demographic and clinical patients characteristics
SCT group (n=101) Reference group (n=82) P-value  
Gender, n (%) 0.02
Male 62 (61) 37 (45)
Female 39 (39) 45 (55)
Age in years, mean (SD) 42.0 (12.1) 39.2 (13.1) 0.14
Premorbid IQ level, mean (SD)a 104.6 (10.7) 102.9 (10.7) 0.28
KPS, mean (SD)b 83.7 (8.4) 85.2 (8.4) 0.20
Educational level, n (%) 0.90
Less than high school 5 (5) 4 (5)
High school 0 (30) 24 (29)
Vocational/trade school 37 (36) 31 (38)
College/bachelor degree 19 (19) 18 (22)
University degree 10 (10) 5 (6)
Civil status, n (%) 0.70
Married / living with partner 77 (76) 59 (72)
Single, divorced, widowed 24 (24) 23 (28)
Premorbid employment status, n (%) 0.78
Full-time work 51 (50) 43 (52)
Part-time work 25 (25) 21 (26)
Housewife or student 18 (18) 12 (14)
Disability benefits 1 (1) 3 (4)
Pension 6 (6) 3 (4)
Current employment status, n (%) 0.51
Full-time work 2 (2) 5 (6)
Part-time work 6 (6) 8 (10)
Housewife or student 18 (18) 14 (17)
Disability benefits 16 (16) 7 (8)
Pension 7 (7) 4 (5)
Sick-leave 52 (51) 44 (54)
Primary Diagnosis, n (%) <.001
Acute myelogenous leukaemia 19 (19) 1 (1)
Acute lymphocytic leukaemia 8 (8) 0
Chronic myelogenous leukaemia 16 (16) 1 (1)
Chronic lymphocytic leukaemia 1 (1) 1 (1)
Non-Hodgkin lymphoma 30 (29) 28 (34)
Hodgkin’s disease 4 (4) 49 (60)
Multiple myeloma 17 (17) 2 (3)
Myelodysplastic syndrome 3 (3) 0
Otherc 3 (3) 0
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Table 1 Continued
Relapse, n (%) <.001
No 58 (57) 74 (90)
Yes, first relapse 30 (30) 6 (7)
Yes, > 1 relapse 13 (13) 2 (3)
Chemotherapy, n (%) <.001
No previous chemotherapy 2 (2) 8 (10)
1 course of chemotherapy 47 (47) 71 (86) 
>1 course of chemotherapy 52 (51) 3 (4)
Intrathecal chemotherapy, n (%) 0.007
Yes 11 (11) 1 (1)
No 90 (89) 81 (99)
Radiotherapy (non-CNS), n (%) <.001
Yes 19 (19) 60 (73)
No 82 (81) 22 (27)
Time since diagnosis (yr), mean (SD) 1.6 (2.9) 1.1 (2.1) 0.16
Time since treatment (m), mean (SD) 2.7 (4.0) 2.0 (2.1) 0.15
SCT = bone marrow or haematopoietic stem cell transplantation
a Derived from the Dutch National Adult Reading Test, b KPS = Karnofsky Performance Score, c Other = Aplastic anaemia, Amyloidosis,
Waldenstrom’s macroglobulinemia
additional assessment along with many other medical examinations before long-term
hospitalisation for SCT. In the reference group the main reported reason for refusal was that
patients wished not to be confronted with their disease after the end of treatment. One SCT
patient was unable to complete the assessment and was excluded from the study. All remaining
101 SCT patients completed the pre-treatment assessment prior to the start of SCT induction
phase. Mean time between the assessment and start of SCT treatment was 21 days (SD = 23.0).
Thirty-five (34%) SCT patients were scheduled for autologous SCT, 42 (42%) for an allogeneic
related donor transplant and 24 (24%) for an unrelated donor transplant. The patients'
characteristics are described in Table 1. Gender was not equally distributed (P = 0.03) when
comparing both groups. 
Two SCT patients received no treatment prior to transplant. All other patients (98%) received
chemotherapy according to standard treatment protocols and 19 (19%) had additional (non-
cranial) radiotherapy. In the reference group, chemotherapy had been given to 74 (90%)
patients. Radiotherapy (mantle field and mediastinal fields) subsequent to chemotherapy was
administered to 52 (63%) patients. Eight (10%) patients of the reference group received
radiotherapy as primary treatment. Intrathecal chemotherapy was given to 11 (11%) SCT
patients as opposed to 1 (1%) patient of the reference group (P = 0.01). Forty-three percent of
SCT patients had been treated for a relapse in contrast to 10% in the reference group (P =
<.001). There was no between-group difference in time interval between last treatment and the
neuropsychological assessment. 
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Table 2 Neuropsychological results: raw means ± SD by group (adjusted meansa) and
percentage of impaired patients
SCT group (n=101) Reference group (n=82) P-value b
Memory and learning
Verbal learning
CVLT, total score list A 54.3 ± 9.9 (53.9) 8% 54.7± 9.9 (55.3) 11% 0.46
Verbal memory
CVLT, short-delay free recall 11.4 ± 2.6 (11.6) 11% 11.9 ± 2.6 (11.7) 14% 0.91
CVLT, consolidation 2.0 ± 2.8 (12.1) 8% 12.2 ± 2.6 (12.1) 10% 0.10
CVLT, recognition 14.9 ± 1.4 (15.0) 8% 15.1 ± 1.1 (15.0) 4% 0.10
CVLT, false-positives .9 ± 1.6 (0.9) 0% 9 ± 1.4 (0.9) 0% 0.91
Visual memory 
RCFT, short-delay recall 20.9 ± 6.2 (21.1) 15% 21.9 ± 5.9 (21.7) 13% 0.58
RCFT, long-delay recall 20.9 ± 6.3 (21.2) 18% 22.1 ± 5.7 (21.8) 15% 0.63
RCFT, recognition 20.2 ± 2.0 (20.2) 17% 20.5 ± 2.1 (20.5) 16% 0.42
BVRT, no. correct 7.4 ± 1.7 (7.4) 2% 7.6 ± 1.6 (7.6) 1% 0.52
BVRT, no. wrong 3.5 ± 2.7 (3.6) 11% 3.2 ± 2.4 (3.2) 5% 0.44
Attention and executive functions
Category wordfluency 20.5 ± 4.5 (20.3) 1% 20.5 ± 4.1 (20.7) 0% 0.68
Digit span, total score 12.9 ± 3.6 (12.8) 1% 13.0 ± 3.3 (13.1) 1% 0.65
Stroop colour-word card, total time 90.8 ± 35.9 (89.0) 11% 89.7 ± 19.8 (91.9) 13% 0.61
Trails A, total time 33.8 ± 13.9 (35.0) 4% 30.9 ±11.7 (29.4) 2% 0.03
Trails B, total time 72.2 ± 28.3 (71.9) 1% 66.4 ± 27.4 (66.8) 2% 0.35
D2 test, total score GZ 409.6 ± 76.8 (405.6) 3% 417.8 ± 77.9 (422.7) 2% 0.25
D2 test, total score F% 4.2 ± 3.7 (4.4) 0% 4.3 ± 3.2 (4.1) 0% 0.57
D2 test, total score KL 155.1 ± 34.4 (152.2) 10% 161.7 ± 40.8 (165.2) 10% 0.07
Visuospatial and constructional ability
RCFT, total score copy 34.0 ± 2.9 (34.0) 20% 34.4 ± 1.9 (34.3) 16% 0.59
Block design, total score 18.8 ± 6.2 (18.9) 0% 19.7 ± 5.6 (19.3) 0% 0.57
Psychomotor functions
Digit symbol, total score 54.2 ± 11.3 (54.3) 1% 56.7 ± 10.8 (56.6) 0% 0.29
FT, total score dominant hand 353.6 ± 51.1 (352.0) 13% 352.9 ± 46.3 (354.8) 16% 0.76
FT, total score non-dominant hand 305.6 ± 51.7 (305.6) 21% 302.9 ± 49.7 (302.9) 18% 0.78
RTT, decision time single stimuli 322.8 ± 39.1 (323.9) 6% 320.3 ± 42.1 (319.0) 7% 0.54
RTT, motor time single stimuli 146.5 ± 41.2 (150.8) 16% 144.3 ± 39.9 (139.2) 10% 0.15
RTT, decision time complex stimuli 515.4 ± 82.0 (515.8) 17% 509.5 ± 94.5 (509.0) 22% 0.70
RTT, motor time complex stimuli 150.1 ± 50.8 (152.2) 20% 148.2 ± 44.7 (145.7) 12% 0.49
RTT, error score 1.7 ± 2.4 (1.9) 11% 1.4 ± 1.5 (1.2) 7% 0.08
Percentage of impaired patients in italics
n/a = not available, CVLT = California verbal learning test, RCFT = Rey complex figure test and recognition trial, BVRT = Benton visual
retention test, GZ = total number of identified targets , F% = percentage of errors and omissions, KL = accuracy score , FT = Finger tapping,
RTT = Reaction time test
SCT = bone marrow or haematopoietic stem cell transplantation
a raw mean test scores adjusted for confounding factors
b adjusted P-values
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Table 3 Subjective cognitive complaints: mean scores ± SDa of the Cognitive Failure 
Questionnaire
SCT group (n=101) Reference group (n=82) P-value 
CFQ
Total score 26.2 ± 12.6 (26.6) 28.0 ± 14.1 (27.6) 0.69b
CFQ score-distributionc, n (%) 0.13
Very low score 14 (14) 9 (11)
Low score 20 (20) 19 (23)
Average score 57 (56) 36 (44)
High score 7 (7) 15 (18)
Very high score 3 (3) 3 (4)
Increase in cognitive failuresd 0.46 
No increase 49 (51) 31 (40)
Little increase 31 (32) 33 (42)
Moderate increase 11 (12) 9 (12)
Quite an increase 4 (4) 5 (6)
Very strong increase 1 (1) 0
Hindered by cognitive failuresd 0.30
No hindrance 33 (34) 23 (30)
Little hindrance 41 (43) 30 (38)
Moderate hindrance 20 (21) 19 (24)
Quite some hindrance 2 (2) 6 (8)
Very much hindrance 0 0
Worried by cognitive failuresd 0.39
No worries 55 (57) 38 (49)
Little worries 26 (27) 20 (26)
Moderate worries 13 (14) 16 (20)
Quite a lot worries 2 (2) 4 (5)
Very much worries 0 0
Annoyed about cognitive failuresd 0.15
No annoyance 42 (44) 31 (40)
Little annoyance 41 (43) 25 (32)
Moderate annoyance 8 (8) 14 (18)
Quite a lot annoyance 5 (5) 7 (9)
Very much annoyance 0 1 (1)
SCT = bone marrow or haematopoietic stem cell transplantation, CFQ = Cognitive Failure Questionnaire
a mean scores adjusted for confounding factors
b P = 0.69 (adjusted p-value of an ANCOVA)
c CFQ scores compared to normative data
d 96 SCT patients and 78 control patients completed these additional questions
COGNITIVE SEQUELAE OF INTENSIVE TREATMENT FOR HEMATOLOGICAL MALIGNANCIES |  107
Cognitive performance
Comparisons of the assessment prior to SCT showed minor group differences on neuropsycho-
logical tests (Table 2). The SCT group was slower on the Trails A than the reference group (P =
0.03). No differences between groups were found in percentages of impaired patients
(compared to normative data). Most deficits were seen in visual memory, visuospatial and
constructional ability, and psychomotor functions. The measure of overall cognitive perfor-
mance was not significantly different between groups (respectively 9.2 in the SCT group and 8.3
in the reference group; P = 0.47) No differences were observed between groups in the per-
centages of impaired test scores per cognitive domain. Twelve percent of the SCT patients and
8.5 percent of the patients in the reference group had impaired scores on more than 20% (ie, >
5 of the 26 subtests) of the neuropsychological tests. No associations were found between
cognitive performance and treatment parameters. 
Subjective cognitive functioning
Results of the CFQ are shown in Table 3. Comparisons of the mean CFQ scores with published
norms indicated that total scores fell within normal limits (ie, very low, low or average score) for
the majority of SCT patients and the reference group (respectively 90% and 78%). There was no
difference in the total score between groups. The percentages of patients reporting an increase
in cognitive failures or who were hindered, worried or annoyed about their cognitive failures
were small. The distributions of these scores were not different between groups. 
Psychological functioning, fatigue and HRQOL 
Table 4 shows the results of the questionnaires of psychological functioning and fatigue. No
differences in mean scores of anxiety and depression of the HADS were found between groups.
The number of anxiety cases (ie, scale score > 10) was higher in the SCT group, but no dif-
ferences were found in the number of depression cases between groups. In both groups, no
correlations were observed between the HADS and cognitive performance. No differences
between groups were found in mean subscale scores of the IES and the MFI. The scores of the
IES and the MFI were not associated with cognitive performance. 
Analysis of the EORTC QLQ-C30 and the QLQ-LEU-BMT revealed that the SCT patients had
lower scores (ie, lower level of functioning) on cognitive functioning, emotional functioning and
social functioning compared to the patients of the reference group (Table 5). Higher scores (ie,
more complaints) for the reference group were found on the symptom item dyspnoea. On the
QLQ-LEU-BMT, the SCT patients reported higher scores on chills, fever, weight loss, mouth
sores and functional status. The HRQOL scores were not related to cognitive performance.
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Table 4 Psychological functioning: Means ± SD (adjusted means) of the Hospital Anxiety
and Depression Scale, the Impact of Event Scale, and the Multi-dimensional Fatigue
Inventory
SCT group (n=101) Reference group (n=82) P-value b
HADSa
Anxiety 5.5 ± 4.0 (5.5) 4.7 ± 3.5 (4.7) 0.30
Depression 3.7 ± 3.4 (3.6) 3.7 ± 3.5 (3.8) 0.77
Anxiety > 10, n (%) 14 (13.9) 3 (3.7) 0.02
Depression >10, n (%) 5 (5.0) 7 (8.5) 0.34
IESa
Intrusion disease 11.0 ± 7.5 (10.9) 9.4 ± 6.7 (9.5) 0.90
Intrusion treatment 7.8 ± 6.9 (8.3) 8.5 ± 6.7 (7.9) 0.79
Avoidance disease 10.6 ± 8.9 (10.5) 7.4 ± 7.3 (7.5) 0.06
Avoidance treatment 8.3 ± 8.4 (8.8) 6.7 ± 7.3 (6.0) 0.06
MFIa
General fatigue 11.0 ± 4.7 (11.1) 12.1 ± 4.4 (12.0) 0.34
Physical fatigue 11.2 ± 5.0 (11.3) 12.2 ± 5.1 (12.0) 0.48
Reduced activity 10.5 ± 5.0 (10.6) 11.1 ± 5.0 (11.0) 0.71
Reduced motivation 8.0 ± 3.9 (7.6) 8.4 ± 4.1 (8.8) 0.14
Mental fatigue 9.6 ± 4.6 (9.7) 9.8 ± 4.3 (9.7) 0.94
SCT = bone marrow or haematopoietic stem cell transplantation, HADS = Hospital anxiety and depression scale, IES = Impact of event scale,
MFI = Multi-dimensional fatigue inventory
a mean scores adjusted for confounding factors 
b adjusted P-values 
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Table 5 EORTC QOL questionnaire and Leukemia-BMT module: means ± SD (adjusted
meansa)
SCT group (n=101) Reference group (n=82) P-value b
QLQ-C30 functioning scales c
Physical functioning 74.3 ± 23.2 (74.4) 77.1 ± 19.7 (77.1) 0.53
Role functioning 62.4 ± 31.1 (61.6) 69.5 ± 26.2 (70.4) 0.12
Cognitive functioning 76.5 ± 10.0 (75.0) 83.5 ± 17.6 (83.6) 0.02
Emotional functioning 70.2 ± 28.3 (68.9) 79.4 ± 18.8 (81.4) 0.009
Social functioning 69.2 ± 29.8 (68.0) 76.8 ± 23.4 (78.3) 0.05
Global health 66.7 ± 23.0 (65.5) 66.5 ± 18.8 (67.8) 0.58
Global quality of life 71.0 ± 21.5 (70.6) 72.4 ± 21.2 (72.9) 0.58
QLQ-C30 symptom scales and items d
Fatigue 31.9 ± 25.5 (34.4) 38.3 ± 25.4 (35.4) 0.82
Nausea/vomiting 5.1 ± 13.1 (5.0) 7.3 ± 16.2 (7.5) 0.39
Pain 16.8 ± 25.2 (18.7) 13.8 ± 20.3 (11.5) 0.10
Dyspnoea 15.3 ± 20.8 (13.0) 21.9 ± 25.8 (24.8) 0.009
Sleep disturbances 20.7 ± 28.3 (23.3) 19.9 ± 28.1 (16.8) 0.23
Appetite loss 7.0 ± 17.3 (7.5) 9.3 ± 19.1 (8.8) 0.71
Constipation 4.7 ± 14.3 (4.5) 3.3 ± 10.0 (3.5) 0.69
Diarrhoea 10.4 ± 18.8 (8.3) 5.7 ± 15.5 (8.3) 1.0
Financial impact 14.5 ± 25.7 (14.4) 9.8 ± 20.6 (9.8) 0.31
QLQ-LEU-BMT symptom scales and itemsd
Chills 17.5 ± 24.0 (18.1) 9.9 ± 17.0 (9.1) 0.03
Itchy skin 22.3 ± 30.7 (20.5) 20.6 ± 30.7 (23.0) 0.65
Dry skin 29.7 ± 28.4 (29.0) 28.4 ± 25.9 (29.5) 0.93
Stiff joints 24.9 ± 27.0 (21.9) 20.2 ± 24.0 (22.6) 0.89
Feeling cold 24.0 ± 26.8 (25.3) 21.4 ± 28.5 (20.2) 0.34
Flushes 10.4 ± 20.0 (9.6) 10.7 ± 21.6 (11.8) 0.59
Headache 12.8 ± 19.5 (13.5) 13.2 ± 19.5 (12.3) 0.76
Hearing loss 6.1 ± 18.7 (6.3) 3.3 ± 10.0 (3.0) 0.26
Pain during sex 7.1 ± 17.4 (7.8) 6.2 ± 16.8 (5.3) 0.44
Fever 15.2 ± 25.8 (16.1) 4.9 ± 13.0 (3.8) 0.003
Infection 15.5 ± 24.9 (16.2) 9.5 ± 18.4 (8.6) 0.08
Weight loss 10.4 ± 19.4 (12.4) 6.6 ± 17.0 (4.2) 0.02
Abdominal pain 11.5 ± 21.9 (12.1) 12.8 ± 20.1 (12.0) 0.98
Mouth sores 11.8 ± 23.5 (12.4) 3.3 ± 12.5 (2.5) 0.009
Pain during urination 1.0 ± 5.7 (1.7) 2.1 ± 8.1 (1.2) 0.73
Blood in urine 1.3 ± 8.1 (1.5) 0.4 ± 3.7 (.3) 0.36
Sensory loss 18.0 ± 22.5 (17.9) 13.2 ± 19.7 (13.3) 0.26
Functional status 4.4 ± 12.0 (4.7) 0.6 ± 3.2 (.2) 0.01
SCT = bone marrow or haematopoietic stem cell transplantation, QLQ-C30 = EORTC QOL que-stionnaire, QLQ-LEU-BMT = Leukemia-BMT module
a mean scores adjusted for confounding factors
b adjusted P-values 
c scores on functioning scales range from 0 to 100 with a higher score indicating better functioning
d scores on the symptoms scales and items range from 0 to 100 with higher scores meaning more bothered by complaints
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DISCUSSION
This comparative study constitutes the largest published sample of SCT patients evaluated with
a comprehensive battery of neuropsychological tests prior to SCT treatment and is the first to
compare the results to a reference group of haematological patients. It revealed that up to
around 20% of SCT patients showed deficits in visual memory, visuospatial and constructional
ability, and psychomotor functions before undergoing SCT treatment. No significant correlations
were found between patients' subjective estimations of cognitive performance in daily-life
functioning and the results of objective neuropsychological testing.
Our findings are in line with 3 other reports despite differences in design and methods.4,5,12
Andrykowski and colleagues found cognitive impairment in 56% of 55 SCT candidates.4 Meyers
and colleagues observed cognitive dysfunction in 20% of 61 SCT candidates by using a self-
reporting instrument to identify cognitive problems.5 Recently, Sostak and colleagues found
abnormal results in a neuropsychological examination in 58% of 71 allogeneic SCT patients.12
To date, research has centred on cognitive functions in SCT patients only. By using a reference
group, we were able to examine differences in cognitive functioning prior to SCT between SCT
candidates and haematological patients treated with chemotherapy, radiotherapy, or a
combination of these. Our results showed no between-group differences in degree or patterns
of cognitive impairment. Patients in the reference group scored slightly higher in only one out
of 26 neuropsychological subtests. Using a different threshold for statistical significance (P =
0.01) to correct for multiple testing would not have altered our findings. In both groups correla-
tions between cognitive performance and specific treatment parameters were lacking. There-
fore, the observed cognitive dysfunctions in our patients can possibly be attributed to the
undergone treatment (ie, chemotherapy, radiotherapy, and adjuvant drugs), the underlying
disease or a combination of these factors. 
Between 90% and 98% of all patients in our study were treated with at least one course of
systemic chemotherapy at an average time interval of 2 - 3 months before the neuropsycho-
logical assessment. Most cytotoxic agents, although some more than others, are known to
affect both the CNS and the peripheral nerves.39 A variety of treatment induced neurological
complications have been described, including peripheral neuropathies, leukoencephalopathies,
and cerebellar symptoms.40 In some instances, these complications are persistent and involve
structural changes in the brain, in particular white matter lesions (mainly in the subcortical
areas), brain atrophy and ventricular dilation. 
Support for the hypothesis that systemic chemotherapy has a negative impact on cognitive
functioning comes from research comparing systemic chemotherapy with local therapy (ie,
surgery and local radiotherapy) in breast cancer and lymphoma patients.41 Patients in
chemotherapy groups showed more cognitive impairment compared with those treated with
local therapy only. In contrast, we observed no significant differences between patients treated
with systemic chemotherapy or local radiotherapy only. Furthermore, there was an absence of
significant differences between patients treated with one course of chemotherapy or those who
received multiple courses. The similarities of the cognitive dysfunctions found in our patient
groups suggest that differences in treatment intensity between groups play no prevailing role in
the development of cognitive impairment. Thus, it is unlikely that chemotherapy-related neuro-
toxicity is the only cause of the observed cognitive deficits in our patient population.
Besides chemotherapy, other factors could be involved in the aetiology of cancer-related
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cognitive impairment. Systemic chemotherapy is often given in combination with adjuvant
drugs (eg, corticosteroids) or other treatment modalities. High doses of exogenous cortico-
steroids might well affect CNS structure and functioning. Reduced hippocampal volume and
memory deficits in patients receiving chronic corticosteroid therapy have been reported
previously.42 Similarly, synergistic effects of combined treatment have been noted to play a role
in impaired cognitive functioning of primary CNS lymphoma patients.43 Lastly, cytokines
released from the tumour issue or exogenous cytokines used in immunotherapy (eg, interferon
alpha), could affect CNS functioning and have a sizeable effect on cognitive performance.44
Further research on the identification of specific cytotoxic agents, combined effects of drugs
and other additional factors responsible for CNS damage is required and should increase the
understanding of the specific mechanisms involved in the development of cognitive deficits
after cancer treatment. 
This assessment of psychological functioning, HRQOL and fatigue prior to SCT confirms earlier
findings that anxiety, depression, sleep disturbances, or fatigue are common complaints in
patients before undergoing SCT.4-6 The number of anxiety cases in our sample of SCT patients
was indeed substantial higher than in the reference group and we also observed distinct
differences between the two groups on a number of HRQOL functioning scales and symptom
items. The between-group differences in the symptom items suggest a relationship with adverse
effects of previous treatment, either radiotherapy with mantle and mediastinal fields or pre-SCT
chemotherapy schedules. Of particular importance is the finding that none of the between-
group differences in psychological functioning or HRQOL affected cognitive performance. A
contributing effect of psychological distress, related to either the disease itself or its treatment,
on cognitive performance in our patient groups, is probably not significant.
The present findings indicated that physicians or health care practitioners preparing patients for
the transplantation and its complications should be aware of a wide range of cognitive and
emotional problems associated with treatment prior to SCT. More importantly, they should be
sensitive to further functional declines in these particular areas. For the moment, greater effort
should be directed to translate the outcome of the assessments into the development of
educational interventions, and perhaps cognitive rehabilitation programs. Preventive rehabili-
tation programs, in particular, could minimise further functional loss, facilitate recovery after
SCT treatment, and thereby retard the patient’s well being and enhance HRQOL. 
In conclusion, this study has provided additional information about pre-transplant cognitive
performance in SCT patients and its relation to confounding factors, in part by being the first to
specifically evaluate this in comparison to a reference group. The results confirm that cognitive
performance is impaired prior to SCT treatment. Also, they showed that cognitive impairment
was not associated with confounding psychological factors, nor that it was different to patients
treated with conventional cancer therapies. More research is needed to identify whether these
observed effects are reversible or persist over time, and to investigate if SCT patients develop
further deterioration after additional SCT treatment. A longitudinal study in SCT patients is now
being undertaken to explore these critical issues. Our data emphasise that prospective longi-
tudinal designs using a similar reference group of patients with haematological malignancies
are required for future trials on the cognitive impact of SCT. 
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ABSTRACT
Previous research demonstrates poor cognitive performance prior to and following bone
marrow or hematopoietic stem cell transplantation (HSCT). This prospective study examined
latent cognitive changes in 101 adult patients undergoing HSCT in comparison to 82
hematological reference patients treated with systemic chemotherapy and/or radiotherapy.
Serial extensive neuropsychological testing was performed at baseline before HSCT and after 8
and 20 months. Additional measures included questionnaires of subjective cognitive function,
health-related quality of life, fatigue and psychological function. Baseline assessment showed
no between-group differences and indicated mild impairment in visual memory, visuospatial
function, and psychomotor function in both patient groups. Follow-up showed no significant
changes over time for the entire sample. Performance in attention and executive function (P =
.01) and psychomotor function (P = .03) over time was reduced in HSCT patients, which was in
part related to total body irradiation. Female gender and older age negatively affected
outcome, while education had a positive effect. Results indicate that mild cognitive impairment
is apparent in a subset of patients before transplant. HSCT has only a limited adverse effect on
tasks measuring attention and executive function, and psychomotor function when compared to
a disease-specific reference group.
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INTRODUCTION
Bone marrow or hematopoietic stem cell transplantation (HSCT) is an accepted therapeutic
option for various malignant hematological disorders. Improved patient selection and
development of new treatment regimens and transplant techniques have expanded its use.
HSCT is preceded by high-dose cytotoxic treatment with or without total body irradiation (TBI)
to eradicate the malignant disease and suppress the immune system to allow engraftment of
donor or autologous stem cells or bone marrow.1 Complications related to HSCT treatment are
generally due to toxicity associated with the myeloablative chemoradiotherapy, the period of
profound immunodeficiency, and graft-versus-host disease (GVHD).2-4 As many of these
complications are now better controlled, delayed central nervous system (CNS) toxicity might
become a relevant long-term side-effect in HSCT. Indeed, several studies using cross sectional
retrospective designs have given evidence of poor cognitive performance following HSCT.5-9
Recently, two prospective longitudinal studies reported on cognitive functions up to 14 months
after allogeneic HSCT.10,11 Sostak et al found impaired function in half of patients evaluated with
a brief neuropsychological assessment at baseline and at 14 months after HSCT.10 A decline of
cognitive function after HSCT treatment was most apparent in executive function. Risk factors
for cognitive decline included acute GVHD, prolonged immunosuppression and metabolic
disturbances. Syrjala et al found a generalized cognitive decline at 80 days, with recovery to
pre-transplant levels at one year after HSCT in most cognitive domains, except for motor
dexterity and grip strength.11 Chemotherapy prior to HSCT and drug treatment for GVHD at
one year were associated with impairment.
Longitudinal research on cognitive changes is difficult due to a high attrition rate, and because
administration of the neuropsychological assessment is time-intensive and requires specialized
training. Most longitudinal studies have focused on the impact of HSCT before and during
hospitalization and, consequently, have a limited duration of follow up.12-15 Perhaps even more
importantly, there are at present no longitudinal data documenting cognitive changes following
HSCT in comparison to a disease-specific reference group. Concurrent neuropsychological
evaluation in reference patients is important for discerning cognitive changes related to disease
and/or previous treatment from effects related to HSCT and its complications.
To establish if HSCT is associated with cognitive decline over time, we conducted a prospective
longitudinal study to examine patterns of neuropsychological changes over 20 months in adult
hematological patients undergoing HSCT in comparison with a reference group with hemato-
logical disorders. The primary objective was to assess the effect of HSCT on neuropsychological
function in comparison to standard treatment regimens. The relationship between
neuropsychological function and subjective cognitive complaints, health-related quality of life
(HRQL), fatigue, psychological functioning, treatment-related variables, and work attendance
were measured as secondary end points.
PATIENTS, MATERIALS, AND METHODS
Patients and procedure
Serial neuropsychological assessments were carried out in a consecutive group of
hematological patients before undergoing HSCT (time 1 [T1]), and at intervals of 8 months (time
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2 [T2]) and 20 months (time 3 [T3]) after baseline. Reference patients (REF) were assessed at
similar time points. Patients were accrued from the Erasmus Medical Center (Rotterdam, the
Netherlands) and Leiden University Medical Center (Leiden, the Netherlands). Eligible patients
(HSCT, REF) were between 16 and 65 years of age, diagnosed with a hematological disorder
and had completed (pretransplant) treatment, fluent in Dutch, and without overt psycho-
pathology, neurological disorders or substance abuse. The study protocol was reviewed and
approved by the institutional ethics and research committees. Written informed consent was
obtained before study participation.
Study measures
Demographical and clinical information. Information was extracted from chart review and the
transplant-database and reviewed at baseline and prior to follow up.
Neuropsychological function. A comprehensive battery of neuropsychological tests was
designed to assess a wide range of functions. Tests were selected on availability of normative
data and sensitivity to detect cognitive impairment. The following cognitive domains were
assessed: Verbal memory: California verbal learning test16 (CVLT); Visual memory: Rey complex
figure test and recognition trial17 (RCFT), Benton visual retention test18 (BVRT); Attention and
executive function: Category wordfluency19 (CF), WAIS Digit span20 (WD), Trailmaking A and B21
(TMTA, TMTB), abbreviated Stroop color-word test22 (SCWT), D2-test23 (D2); Visuospatial
function: RCFT-copy trial,17 WAIS Block design20 (WBD); Psychomotor function: WAIS Digit
symbol20 (WDS), Finger tapping24 (FT), Reaction time test25 (RTT). Premorbid intelligence was
estimated with the National Adult Reading test26. Alternate forms were used when possible to
minimize practice effects.
Subjective Cognitive Functioning. The Cognitive Failure Questionnaire (CFQ)27 was used to
assess the frequency of everyday cognitive failures.
HRQL. Measures included the EORTC QLQ-C3028 and the MRC/EORTC QLO Leukemia-BMT
module (QLQ-LEU).28
Fatigue. The Multi-dimensional Fatigue Inventory (MFI)29 was used to address general fatigue,
physical fatigue, mental fatigue, reduced activity, and reduced motivation.
Psychological Functioning. Measures included the Hospital Anxiety and Depression Scale
(HADS)30 and the Impact of Event Scale (IES).31 A dichotomized index was used for the HADS to
define potential cases of anxiety and depression based on a cutoff score of > 10.32
Statistical analysis
Raw neuropsychological test scores were compared to normative data adjusted for age and
gender and converted into standardized scores (z scores; mean = 0, standard deviation [SD] =
1.0) to facilitate comparisons among measures. Cognitive impairment was defined as a test
score of 2.0 SD below the mean of healthy controls. Composite test scores were calculated for
each cognitive domain by adding z scores for each subtest and dividing the sum by the number
of subtests. A measure of overall neuropsychological function was computed based on the
number of impaired subtests.
Descriptive statistics were generated for demographic and clinical characteristics and study
measures. Because of a large number of categorical potential confounding demographic and
clinical variables, a multivariate confounder score (using gender, diagnosis, relapse,
pretransplant treatment) was calculated to reduce the potential bias in test results.33 Between
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group differences for continuous variables were evaluated using Students' t-tests for
independent samples (two-sided). Similarly, X2-analysis was used to compare distributions of
categorical variables. Group differences in neuropsychological function were tested by
univariate analysis of covariance (ANCOVA) with the multivariate confounder score as a
covariate. To determine changes in neuropsychological function over time, random regression
models (RRM) analyses were conducted for all cognitive domains.34,35 The RRM approach allows
for missing observations, time-varying covariables, invariant covariables and assessments at
unequal end-points. RRM estimates both average time trends and individual time trends. The
individual time trend curves are based on available data for each patient, augmented by
information from data from the entire sample. The approach allows for modeling changes of
variances in neuropsychological function and changes in correlations between neuro-
psychological function and covariables. Pearson’s correlation techniques were used in survivors
to evaluate associations between measures and treatment-related variables. The two-sided
probability level for statistical significance was set at 0.05 for primary end points and at 0.01 for
secondary end points. Analyses were performed using the Statistical Package for Social Sciences
(version 10.1) and RRM models were implemented using PROC MIXED (SAS System, version 8.2).
RESULTS
Patients and treatment
Figure 1 summarizes the flow of patients through the study. Fifty-four percent of HSCT patients
completed the neuropsychological assessment at each time point opposed to 72% of REF
patients. Table 1 lists the demographic and clinical characteristics. Various HSCT conditioning
regimens were used. The most common regimen was high-dose cyclophosphamide followed by
TBI (74%). GVHD prophylaxis consisted of cyclosporine-A and T-cell depletion of the donor
graft. GVHD ratios were considered for allogeneic HSCT recipients who underwent follow up
assessment. Four patients (11%) developed acute GVHD (grade III-IV). Chronic GVHD was
observed in 41% (15 of 37) and 27% (9 of 34) of patients at T2 and T3 respectively, of which 24%
(9 of 37) and 12% (4 of 34) had extensive disease. Most patients with chronic GVHD (90%)
received immunosuppressive medication at follow up. Seventeen HSCT patients died of
transplant-related complications and six HSCT patients died of recurrent disease.
Neuropsychological function at baseline
The results of the baseline assessment were reported in detail previously.36 In short, mean z
scores of all neuropsychological tests were classified as non-impaired for both groups (Table 2).
Between group differences in mean z scores were not observed. Evidence of impairment on ≤ 3
tests was found in 53 (53%) HSCT and 40 (49%) REF patients, while 14 (14%) HSCT and 7 (9%)
REF patients were impaired on ≥ 4 tests (P = .33). In both groups, impairment was most
frequently seen in visual memory, visuospatial function and psychomotor function. No dif-
ference was found in overall neuropsychological function between groups (P = .26).
Changes in neuropsychological function over time
Mean z scores in the HSCT group were significantly lower at follow up for several measures of
attention and executive function, and psychomotor function (Table 2). Mean z scores of verbal
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Enrollment
270 hematological pts assessed for eligibility after completion of pre-HSCT chemotherapy
and/or radiotherapy: 151 HSCT pts, 119 REF pts
Informed consent
151 registered HSCT pts
50 pts not entered: 
• 17 pts ineligible
• 33 pts declined consent
Baseline
101 HSCT pts completed baseline
Follow up
64 HSCT pts completed 8-month follow-up
37 pts not evaluated:
• 18 pts died
• 16 pts relapsed (2 prior to HSCT)
• 3 pts refused
55 HSCT pts completed 20-month follow up
9 pts not evaluated:
• 3 pts died
• 4 pts relapsed
• 2 pts missingb
119 registered REF patients
37 pts not entered:
• 20 pts ineligible
• 17 pts declined consent
82 REF pts completed baseline
70 REF pts completed 8-month follow-up
12 pts not evaluated:
• 8 pts relapsed
• 2 pts refused
• 2 pts not availablea
59 REF pts completed 20-month follow up
13 pts not evaluated:
• 3 pts relapsed
• 2 pts refused
• 8 pts missingb
a Two patients were not available for T2 because of work commitments; 
b ten patients could not be evaluated at T3 because of end of the study.
Figure 1 Flow of patients through the study
120 |  COGNITIVE SEQUELAE OF INTENSIVE TREATMENT FOR HEMATOLOGICAL MALIGNANCIES
Table 1 Demographic and clinical characteristics for the HSCT patients and the reference patients
Characteristic HSCT (n=101) REF (n=82) P-value
Gender, no. (%) .02
Male 62 (61) 37 (45)
Female 39 (39) 45 (55)
Age .14
Mean, y (SD) 42.0 (12.1) 39.2 (13.1)
Performance statusa .20
Mean (SD) 83.7 (8.4) 85.2 (8.4)
Estimated IQ .28
Mean (SD) 104.6 (10.7) 102.9 (10.7)
Diagnosis, no. (%) <.001
Lymphoma 30 (29) 28 (35)
Hodgkin’s disease 4 (4) 49 (60)
Acute Leukemia 27 (27) 1 (1)
Chronic Leukemia 17 (17) 2 (2)
Multiple myeloma 17 (17) 2 (2)
Myelodysplasia 3 (3) 0 (0)
Otherb 3 (3) 0 (0)
Relapse, no. (%) 43 (43) 8 (10) <.001
Pretransplant treatment, no. (%)
Chemotherapy only 84 (84) 22 (27) <.001
Chemotherapy and 15 (14) 52 (63) <.001
radiation therapy
Radiation therapy only 0 (0) 8 (10) .001
No previous treatment 2 (2) 0 (0) .20
Intrathecal chemotherapy, no. (%) 11 (11) 1 (1) .007
HSCT conditioning regimenc, no. (%) NA
Cyclophosphamide and TBId 73 (74)
Cyclophosphamide and Busulphan 6 (6)
BEACe 10 (10)
BEAMf 7 (7)
Otherg 3 (3)
Type of transplant, no. (%) NA
Autologous 34 (34)
Allogeneic related 41 (42)
Allogeneic unrelated 24 (24)
SD = standard deviation; IQ = intelligence quotient; NA = not applicable; TBI = total body irradiation
a Karnofsky Performance Score
b Aplastic anemia, Amyloidosis, Waldenstrom’s macroglobulinemia 
c 2 HSCT patients died before transplant (n=99)
d TBI dose: 5 Gy or 6 Gy daily for 2 days, or 9 Gy for 1 day
e BEAC, Busulphan (300 mg/m2 for 1 day, Etoposide 100 mg/m2 twice per day for 4 days, Ara-C 100 mg/m2 twice per day for 4 days, f
Cyclophosphamide 15 mg/kg per day for 4 days)
f BEAM, Busulphan (300 mg/m2 for 1 day, Etoposide 125 mg/m2 twice per day for 4 days, Ara-C 100 mg/m2 twice per day for 4 days Melfalan 
140 mg/ m2 for 1 day)
g CBV , Busulphan (300 mg/m2 for 1 day), Cyclophosfamide (1500 mg/m2 per day for 4 days) and Etoposide (250 mg/m2 per day for 3 days);
Fludarabine (30 mg/m2 per day for 6 days), Methotrexate (10 mg/m2 per day for 3 days); induction with 3 cycles of VAD (Vincristine 0.4 mg;
Doxorubicine 9 mg/m2, Dexamethasone 40 mg) followed by high-dose Melphalan (100 mg/m2 per day for 2 days)
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Table 2 Neuropsychological test scores (z-scores) and percentages of impaired test
scores over time
Measures Baseline 8-month follow up 20-month follow up
HSCT (n=101) REF (n=82) HSCT (n=64) REF (n=70) HSCT (n=55) REF (n=59)
M  (SD)  % M (SD)  % M  (SD)  % M  (SD)  % M  (SD)  % M  (SD)  %
Verbal memory
CVLTT 0.12 (1.0) 5 -0.06 (1.0) 6 -0.00 (0.0) 5 0.04 (1.0) 3 0.45 (1.0) 4 0.42 (0.9) 2
CVLTSD 0.04 (1.2) 5 -0.14 (1.1) 5 -0.06 (1.0) 6 0.10 (1.0) 3 0.19 (1.0) 0 -0.14 (1.2) 5
CVLTLD -0.12 (1.0 4 -0.19 (0.9) 7 0.02 (0.9) 0 0.16 (1.0) 3 0.04 (1.0) 0 -0.19 (0.9) 7
CVLTC 0.01 (1.1) 4 -0.11 (1.1) 6 -0.15 (1.1) 3 -0.10 (1.0) 3 0.18 (1.0) 4 0.12 (1.1) 5
CVLTR -0.02 (1.0) 6 0.12 (0.8) 2 0.50 (0.9)* 0 0.13 (0.9)* 0 0.15 (0.8) 2 -0.04 (1.0) 9
Nonverbal memory
RCFTSD 0.00 (1.3) 10 0.09 (1.2) 6 0.84 (1.2) 2 0.57 (1.4) 4 0.86 (1.2) 4 1.03 (1.3) 3
RCFTLD -0.03 (1.3) 15 0.09 (1.2) 6 0.72 (1.2) 3 0.49 (1.5) 6 0.82 (1.2) 4 0.95 (1.3) 3
RCFTR -0.35 (1.1) 10 -0.19 (1.1) 10 -0.09 (1.2) 6 0.15 (1.0) 3 0.10 (1.3) 6 0.36 (1.0) 5
BVRTC -0.06 (0.7) 2 0.01 (0.7) 1 0.00 (0.7) 0 0.02 (0.7) 3 0.00 (0.8) 4 0.12 (0.6) 0
BVRTE 0.00 (1.0) 8 0.10 (0.8) 2 0.03 (0.8) 2 0.05 (0.9) 6 0.02 (1.0) 10 0.20 (0.8) 2
Attention/executive function
CF 0.61 (0.8) 0 0.65 (0.7) 0 0.70 (0.8) 0 0.76 (0.8) 0 0.78 (0.8) 0 0.68 (0.7) 0
WD 0.74 (1.0) 1 0.75 (0.9) 1 0.75 (1.0) 1 0.83 (1.0) 1 0.91 (1.1) 0 0.96 (1.1) 0
TMTA 0.47 (1.3) 4 0.81 (1.4) 2 0.48 (0.9)** 0 1.07 (1.3)** 1 0.87 (1.4)* 2 1.51 (1.3)* 0 
TMTB 0.64 (1.2) 1 0.84 (1.3) 2 0.64 (1.3)* 3 1.13 (1.3)* 1 0.57 (1.5)** 6 1.35 (1.4)** 2
SCWT 0.14 (1.1) 0 -0.01 (1.0) 1 0.10 (1.2)* 3 0.59 (1.5)* 4 0.51 (1.6) 9 0.82 (1.2) 0
D2GZ 0.35 (1.0) 0 0.56 (1.0) 2 0.48 (1.0)* 0 0.91 (1.1)* 0 0.71 (1.1) 2 1.05 (1.2) 0 
D2F 1.12 (1.4) 0 0.91 (1.3) 0 1.12 (1.3) 0 1.13 (1.6) 6 1.33 (1.4) 2 1.56 (1.3) 0
D2KL 0.42 (1.7) 10 0.60 (1.8) 10 0.79 (1.6) 5 1.23 (1.7) 4 1.21 (1.6) 4 1.47 (1.8) 5
Visuospatial function
RCFTC 0.56 (2.0) 9 0.83 (1.8) 4 0.45 (1.7) 5 0.36 (1.9) 9 0.10 (1.6) 7 0.04 (1.5) 7
WBD 1.20 (1.0) 0 1.20 (0.8) 0 1.55 (1.0) 0 1.49 (0.9) 0 1.54 (1.0) 0 1.62 (0.9) 0
Psychomotor function
WDS 1.02 (0.9) 0 1.10 (0.8) 0 1.04 (1.0)* 0 1.37 (0.8) * 0 0.91 (1.1) 0 1.43 (0.9) 0
FTD -0.22 (1.3) 9 -0.14 (1.2) 6 -0.47 (1.3) 14 -0.31 (1.2) 9 -0.56 (1.4) 13 -0.22 (1.2) 7
FTND -0.47 (1.4) 15 -0.45 (1.3) 13 -0.83 (1.4) 21 -0.56 (1.2) 17 -1.06 (1.4)* 18 -0.47 (1.2)* 7
RTTSDT -0.17 (0.9) 3 -0.24 (1.0) 5 -0.37 (0.9) 10 -0.34 (1.0) 7 -0.84 (2.4) 17 -0.56 (1.1) 10
RTTSMT -0.39 (1.3) 11 -0.31 (1.1)  7 -0.39 (1.4) 7 -0.23 (1.0) 6 -0.70 (3.8) 11 -0.13 (1.0) 3
RTTCDT -0.36 (1.3) 10 -0.38 (1.5) 12 -0.60 (1.3) 8 -0.44 (1.1) 10 -0.64 (1.3) 19 -0.53 (1.3) 14
RTTCMT -0.64 (1.5) 13 -0.41 (1.1) 7 -0.67 (1.5) 14 -0.38 (1.0) 6 -0.70 (2.2) 15 -0.29 (1.0) 7
RTTE -0.31 (2.0) 11 -0.03 (1.3) 7 -0.00 (1.2) 6 0.14 (1.0) 4 -0.29 (1.2)** 11 0.22 (0.8)** 2
*P < .05; ** P < .01 for between groups differences
CVLTT, California Verbal Learning Test, total score; CVLTSD, California Verbal Learning Test, short delay recall; CVLTLD, California Verbal
Learning Test, long delay recall; CVLTC, California Verbal Learning Test, consolidation; CVLTR, California Verbal Learning Test, recognition;
RCFTSD, Rey Complex Figure Test and Recognition Trial, short delay recall; RCFTLD, Rey Complex Figure Test and Recognition Trial, long delay
recall; RCFTR, Rey Complex Figure Test and Recognition Trial, recognition; BVRTC, Benton Visual Retention Test, correct score; BVRTE, Benton
Visual Retention Test, error score; CF, Category Fluency; WD, WAIS Digit span; TMTA , Trailmaking A; TMTB, Trailmaking B; SCWT, abbreviated
Stroop Color Word Test, color-word card; D2GZ, D2 Test, total score; D2F, D2 Test, error score; D2KL, D2 Test, concentration score; RCFTC, Rey
Complex Figure Test and Recognition Trial, copy trial; WBD, WAIS Block design; WDS, WAIS Digit symbol; FTD, Fingertapping dominant;
FTND, Fingertapping nondominant; RTTSDT, Reaction time test–single decision time; RTTSMT, Reaction time test–single motor time; RTTCDT,
Reaction time test–complex decision time; RTTCMT, Reaction time test–complex motor time; RTTE, Reaction time test, error score
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memory recognition were higher in the HSCT group at T2, indicating an improvement in long-
term word retrieval during a recognition procedure when compared a free recall procedure.
Four RRM models were generated to evaluate changes in neuropsychological function over
time. Composite scores of the cognitive domains were entered as dependent variables. Time
trend was entered as linear and quadratic time (time2) terms. Error variance was declared
unstructured and age, gender and education were entered as covariables. Interaction terms
(time x group, time x gender, time x age, time x dropouts, time2 x dropouts, group x dropouts)
were considered as random, and only maintained when the models significantly improved.
Based on fit statistics, the model that included covariables and interaction terms was selected
for interpretation. Intercepts represent neuropsychological function at baseline and slopes
characterize change in neuropsychological function over time. Linear time terms assume a
constant rate of change over time, while quadratic time terms reflect curvature in the slope of
the function. For all cognitive domains, linear and quadratic time terms were not significant,
suggesting no changes in functioning over time for the entire sample. Interactions between
time and group showed significant negative slopes for attention and executive function (P =
.01) and for psychomotor function (P = .03), indicating a mild time-dependent decline in
functioning over time for the HSCT group compared to the REF group (Table 3). An interaction
between time and age was also observed for attention and executive function (P = .01),
suggesting poorer functioning over time for older patients for the entire group. An interaction
between group and dropouts was seen in visuospatial function (P = .04) suggesting that impro-
vement within the domain was related to attrition of patients. Significant negative slopes were
also observed for older age in verbal and visual memory, attention and executive function and
visuospatial function and for female gender in visual memory, visuospatial function and
psychomotor function. Lastly, positive effects of education were observed for all cognitive
domains.
Subjective cognitive complaints and neuropsychological function
No significant differences in mean scores of subjective cognitive complaints (CFQ) were
observed between groups at any time point (Table 4). Overall neuropsychological function was
associated with subjective cognitive complaints at T2 in the HSCT group (r = .26; P = .04) and at
all time points in the REF group (r = .29, P =.009; r = .25, P =.04; r = .34, P = .009).
Effects of health-related quality of life, fatigue and psychological function
Poorer emotional function and functional status (respectively P = .05 and P < .01) and more
symptoms of fever and mouth sores were reported by HSCT patients at baseline (P < .01; data
not tabulated). At follow up, HSCT patients had lower scores on several functioning scales
(physical, role and social functioning, global health and quality of life) and more symptoms
compared to REF patients. In the HSCT group, overall neuropsychological function was
associated with global health at T3 (r = -.41; P = .002). Overall neuropsychological function in
the REF group was related to physical function at baseline and T3 (respectively r = -.30; P < .01
and r = -.27; P = .04) and to cognitive functioning at all time points (r = -.22, p = .05; r = -.32, P
= .007; r = -.38, P = .003).
Similar levels of fatigue were reported by HSCT and REF patients at baseline (data not tabulated).
Physical fatigue levels were higher in HSCT patients at follow up (P < .05). Reduced motivation
in HSCT patients was associated with overall neuropsychological function at baseline. Overall
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neuropsychological function was associated with mental fatigue at follow up in REF patients (r =
.24, P = .04; r = .32, P = .02).
No significant differences between groups were found in mean scores of anxiety and depression
or in the number of depression cases as defined by the HADS at any time point. At baseline, the
number of anxiety cases was higher in the HSCT group than in the REF group (14% v 4%; P =
.02). Impairment levels in both groups were higher in patients defined as anxiety cases at
baseline (HSCT P < .01; REF P = .05). Overall neuropsychological function in HSCT patients was
associated with anxiety at baseline (r = .21; P = .04) and T3 (r = .32; P = .02), and to depression
(r = .28; P = .04) at T3.
HSCT patients reported feelings of avoidance of disease (IES) more frequently than REF
patients at baseline. At baseline, overall neuropsychological function was associated with
avoidance of disease in the HSCT group (r = .23; P = .02) and with intrusion of treatment (r =
.23; Ps = .04) in the REF group. Overall neuropsychological function at follow up was associated
with intrusion in the HSCT group (r = .30, P = .02; r = .31, P = .01) and avoidance in the REF
group (r = .30, P = .01; r = .29; P = .02).
Table 3 Estimated intercepts and slopes of time X group effects of the cognitive domains
Domain Intercept Slope P-value
Estimate SE Estimate SE
Verbal memory 49.03 4.35 -0.57 0.60 .35
Visual memory 59.32 4.00 0.09 0.56 .87
Attention/executive function 54.03 3.42 -0.98 0.37 .01
Visuospatial function 62.03 4.78 -0.41 0.61 .50
Psychomotor function 56.58 3.15 -1.31 0.58 .03
Intercepts represent neuropsychological function at baseline (estimate in T-scores with a mean of 50 and standard deviation of 10), and slopes
characterize change in neuropsychological function over time. SE indicates standard error
Table 4 Overview of subjective cognitive complaints over time 
Measures Baseline 8-month follow up 20-month follow up
HSCT (n=101) REF (n=82) HSCT (n=64) REF (n=70) HSCT (n=55) REF (n=59)
M (SD)  M (SD) M (SD)  M (SD)  M (SD) M  (SD)  
Total raw scorea 26.2 (12.9) 28.0 (14.1) 27.4 (14.3) 30.5 (16.6) 28.4 (15.3) 30.2 (16.4)
Increase in cognitive failuresb .7 (.9) .9 (.9) .9 (1.0) 1.1 (1.1) 1.1 (1.0) 1.2 (1.3)
Hindered by cognitive failuresb .9 (.8) 1.1 (.9) .9 (.8) 1.1 (1.0) 1.0 (.9) 1.3 (1.0)
Worried by cognitive failuresb .6 (.8) .8 (.9) .6 (.8)* 1.0 (1.0)* .7 (.9) 1.0 (1.0)
Annoyed by cognitive failuresb .8 (.8) 1.0 (1.0) .7 (.9)** 1.3 (1.2)** .8 (.9)* 1.2 (1.0)*
*P< .05; ** P< .01
a Mean raw total scores (range, 0 to 100) are indicated. Higher scores indicate more subjective cognitive complaints.
b Mean raw scores (range, 0 to 4) are indicated. Higher scores indicate more problems.
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Effects of treatment-related factors 
TBI had a negative effect on psychomotor function at T3 (P = .02), while the effect on overall
neuropsychological function reached a trend level significance (P = .07). Overall neuropsy-
chological function at follow up was not affected by any other treatment-related factors, like
pretransplant treatment (intrathecal chemotherapy), type of HSCT (autologous v allogeneic
transplantation, related v unrelated donor status), HSCT conditioning regimen (myeloablative v
non-myeloablative), acute GVHD, chronic GVHD, prolonged immunosuppressive therapy and
infections (acute or long term).
Occupational status and neuropsychological function
Most HSCT patients (86%) and REF patients (79%) were not working or studying at baseline (P =
.24). Occupational status was not associated with HRQL, fatigue or psychological function in
HSCT patients. At follow up, work attendance was lower in HSCT patients (respectively 14% v
50%, P < .001; 40% v 66%, P = .008). A positive association between overall neuropsychological
function and work attendance was found in REF patients (P = .01). HSCT patients who resumed
their activities at follow up reported better cognitive function on the QLQ-C30 (T2, P = .05; T3,
P = .005). No associations between occupational status and subjective cognitive complaints
measured by the CFQ were observed at any time point in either group.
DISCUSSION
The present study is one of the few prospective reports on neuropsychological function in HSCT
patients using a pretreatment baseline assessment and the first to compare performance over
time to a disease-specific reference group. Our data demonstrate that neuropsychological
function prior to HSCT was similar in both patient groups. Before HSCT, subsets of patients
show cognitive deficits in visual memory, visuospatial function, and psychomotor function. No
significant changes were observed compared to baseline function during a follow up period of
20 months. Only mild differences in performance over time were seen within two cognitive
domains in comparison to the reference group. HSCT patients showed poorer performance on
attention and executive function, and psychomotor function. Regarding the covariate
adjustment used in the RRM analysis, function over time decline was significantly influenced by
sociodemographic factors, and older patients and females were found to be especially at risk. In
contrast, a higher educational level had a positive effect on performance in all cognitive
domains. 
These findings are in accordance with previous reports.5,8-11 In our retrospective study in long-
term survivors of HSCT, late cognitive deficits more than two years following HSCT were found
in attention and executive function, information processing speed, and memory. Current data
lack evidence of significant impairment in memory function, which may be explained by slight
differences in measures and normative data and patients groups. Also, and again contrary to
previous studies, we found no evidence for recovery to pretransplant levels at follow up as
function over time remained stable.10,11
In the present study, objective and subjective measures of neuropsychological function were
only weakly associated in HSCT patients. Recently, Booth-Jones et al did not find a relationship
between patients’ subjective estimation of function in every day life and objective cognitive
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impairment following HSCT, but both subjective and objective cognitive function were related
to depression and fatigue.9 Further analysis of our results showed that patients who complained
about cognitive problems, indeed achieved more cognitive test scores within the impaired
range. It is important to note, however, that some test instruments may be insufficiently
sensitive to detect mild deficits, which may result in an underestimation of subtle differences in
function. Moreover, subjective self-reported questionnaires and neuropsychological test
batteries might not be measuring the same function, as questionnaires may not necessarily
relate directly to cognitive problems encountered by patients in everyday lives. Consequently,
studies evaluating cognitive function in HSCT patients should not be based on questionnaires
only.
The physical and emotional effects of the HSCT procedure play an important role in the general
well-being in patients before and after undergoing transplant.37,38 Previous studies on
neuropsychological function in HSCT patients found that HRQL factors may contribute to
observed cognitive deficits or to changes over time.8,9 Main predictors of cognitive impairment
after HSCT in our previous retrospective study were global health and fatigue. Our current
results show weak correlations between HRQL factors and objective neuropsychological
function, despite significant between group differences on several HRQL functioning scales and
symptoms at all time points. In addition, in the present study no effect was found of fatigue at
follow up. The inconsistency between these results could be related to differences in the
duration of follow up because mean time between HSCT and the assessment in our
retrospective study was almost four years.
The current study provides evidence that affective status has only a minor impact on
neuropsychological function before and after HSCT. Because of the intensive nature of the
transplant procedure, HSCT patients experience high levels of emotional distress. In the present
study, more anxiety cases were found in the HSCT group together with more feelings of
avoidance of disease at baseline. However, only a weak association between depression and
neuropsychological function was observed at follow up, and in REF patients, similar levels of
correlations were observed. The observed differences in neuropsychological function between
HSCT and REF patients can therefore not be solely explained by psychological factors.
TBI for conditioning contributed to poorer psychomotor function at follow up which is
consistent with previous findings.5,10 No other treatment-related factors were found to relate to
impairment. In future studies, risk factors for cognitive impairment may need to be further
identified by MRI techniques.
Several factors may have confounded this study. First, we did not observe our patients from
diagnosis onwards and before the start of any treatment. Subject attrition is another common
problem in longitudinal studies in HSCT patients, but our data were collected from a sufficiently
large sample of HSCT patients. Attrition was related to death and recurrent disease, and refusal
after consenting to the baseline assessment was less than five percent in both patient groups. It
is therefore unlikely that attrition affected our study significantly.
In conclusion, this first longitudinal study on HSCT with a disease-specific reference group
shows the absence of significant treatment-related changes in neuropsychological function up
to 20 months after treatment. Neuropsychological function remained stable and is, in general,
comparable to functioning in hematological patients not treated with HSCT. The observed
differences in performance are subtle, and domain specific because they are limited to
attention and executive function, and to psychomotor function. Further long-term follow up of
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this patient cohort is essential as it may show changes in functioning within these particular
domains. At this point in time, however, it seems legitimate to consider HSCT as a treatment
with no significant additional effect on neuropsychological functioning compared to the
standard therapies for hematological malignancies.
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ABSTRACT
Objective: To evaluate the cognitive status and quality of life (QOL) in a cohort of 19 con-
secutive patients treated in a prospective European Organization for Research and Treatment of
Cancer study (20962) for primary CNS lymphoma (PCNSL). All patients were in complete
remission after combined-modality treatment with intravenous and intrathecal high-dose
methotrexate (MTX)-based chemotherapy followed by whole brain radiotherapy (WBRT).
Methods: An extensive neuropsychological assessment, including QOL measures, was
conducted in 19 patients with PCNSL. The results were compared to matched controls with
systemic hematological malignancies treated with systemic chemotherapy or non-CNS
radiotherapy. In addition, a neuroradiological evaluation was carried out in 18 patients with
PCNSL. 
Results: Cognitive impairment was found in 12 patients with PCNSL (63%), despite a complete
tumor response. Four patients (21%) showed severe cognitive deficits, and the percentage of
impaired test-indices correlated with age. In comparison, only two controls (11%) showed
cognitive dysfunction (p = .002). Forty-two percent of the patients with PCNSL, in contrast to
81% of the controls resumed work. White matter abnormalities were observed in 14 patients
with PCNSL, and 14 had cortical atrophy. Cortical atrophy correlated with cognitive functioning,
age and, Karnofsky performance score. Group differences in cognitive status and QOL could
not be explained by anxiety, depression, or fatigue. 
Conclusions: Combined-modality treatment for PCNSL is associated with cognitive impairment
even in patients aged < 60.
Treatment protocols for primary CNS lymphoma (PCNSL) have changed over the past years.
Intensified therapeutic regimens, particularly those with high-dose methotrexate (MTX)-based
chemotherapy followed by whole brain radiotherapy (WBRT) have resulted in long-term
remissions and improved survival rates.1 Consequently, late neurotoxicity has become a serious
problem with important implications for cognitive functions and quality of life (QOL). The
reported incidence of late neurotoxicity in PCNSL patients varies from 5% to 32%, and is more
common in patients aged > 60 years.2-4 However, most studies have addressed late neuro-
toxicity with clinical data, sometimes in combination with radiological findings.5,6 A well-
conducted study assessing cognitive status and QOL in patients in complete response to
combined-modality treatment is lacking, and the incidence of late neurotoxicity is probably
underestimated. The objective of the current study was to evaluate systemically cognitive status
and QOL in PCNSL patients in complete remission to combined-modality treatment. The results
were compared to controls and neuroradiological data.
METHODS
Patients
From July 1997 to March 2002, a phase II trial to confirm the feasibility of high-dose MTX-based
chemotherapy followed by WBRT in non-AIDS related PCNSL was carried out by the European
Organization for Research and Treatment of Cancer (EORTC). Patients received two cycles of
MBVP chemotherapy (Methylprednisolone 60 mg/m2 PO day 1-5, MTX 3 g/m2 IV days 1 and 15,
Teniposide 100 mg/m2 IV day 2-3, BCNU 100 mg/m2 IV day 4) and two intrathecal injections of
chemotherapy (MTX 15 mg, Cytarabine 40 mg and Hydrocortisone 25 mg, days 1 and 15).
WBRT was given at a total dose of 39 to 40 Gy. Inclusion criteria were: aged 16 to 65 years,
Karnofsky performance score (KPS) 40 to 100, neurological function status 0 to 3, histological or
cytological proven non-Hodgkin Lymphoma (NHL) of the CNS including the leptomeninges and
the spinal cord and at least one measurable lesion for response evaluation. Fifty-two patients
were included.7 To be eligible for the neuropsychological evaluation, patients had to meet the
following supplementary criteria: treated for intracranial tumor localization only, at least 6
months post treatment and in complete remission, no presence or history of drug abuse or
psychiatric or neurological disorders, and fluent in Dutch. The medical ethics committee ap-
proved the study and written informed consent was obtained from all patients.
The results were compared to the results of controls selected from a database of an ongoing
longitudinal cognitive study among patients with a hematological malignancy. The control
patients were treated at a single institution for Hodgkin disease or systemic Non-Hodgkin
Lymphoma (NHL) with systemic chemotherapy or radiotherapy, or both. Patients were matched
for sex, age, education, and time since the end of treatment.
Measures
Neuropsychological evaluation. All patients underwent a formal neuropsychological assessment
using standardized psychometric testing procedures. The neuropsychological test battery (12
tests, 18 test indices) measured a broad range of cognitive domains and is described in detail
elsewhere.8 Normative data were available for all tests. The assessment took place in the
hospital where the patient was treated or at home.
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Assessment of Quality of Life. The EORTC QLQ-C30 (QLQ-C30) was used to measure subjective
health-related QOL.9 It evaluates five functioning scales (physical, role, cognitive, emotional,
social), global health status, global QOL, and several QOL symptom scales or items. In addition,
the EORTC Brain Cancer Module (BCM20) was used to assess neurological functioning.10
Fatigue was assessed with the Multidimensional Fatigue Inventory (MFI), which has five scales:
general fatigue, physical fatigue, mental fatigue, reduced motivation and reduced activity.11
Current mood was evaluated using the Hospital Anxiety and Depression Scale (HADS).12 The
recommended cut-off score for cancer populations (total score >10) was used as an indication
for increased levels of anxiety or depression.13 
Clinical data and evaluation of neuroradiological data. Data on medical status, tumor charac-
teristics, and treatment history were derived from the EORTC Data Center in Brussels. The
pretreatment and the last follow-up brain scans (MRI or CT) were obtained from the treating
specialist. The presence of white matter abnormalities (WMA) and cortical atrophy was scored
blind to clinical and neuropsychological data. The WMA were separately evaluated in the
anterior and posterior white matter on three subsequent MRI/CT slices according to a semi-
quantitative method.14 The changes were scored on a 3 - point grading system for each region:
grade 0 ‘no lesions’; grade 1 ‘multiple focal lesions restricted to the region adjoining the
ventricles’; grade 2 ‘multiple confluent lesions scattered throughout the white matter’. The
overall atrophy score ranged from 0 (no atrophy) to 2 (moderate-severe atrophy). 
Data analysis 
The raw scores of the neuropsychological tests were converted to standard (z-scores) or
percentile scores, depending on normative data. Based on a commonly accepted categori-
zation of cognitive performance levels, standard scores < 2 SD below average or percentile
scores < 10 were classified as impaired.15 Subsequently, for each individual the total number
and the percentage of impaired test-indices were calculated (for the statistical analyses the
percentage was used because not all patients completed the neuropsychological test battery).
The severity of cognitive impairment was defined as follows: mild to moderate impairment: ≥ 4
test-indices in the impaired range; severe impairment: > 6 test-indices in the impaired range.
Non-parametric analyses (Mann-Whitney U tests for independent samples, Spearman’s rho test)
were used because of small samples. For all statistical analyses with the neuropsychological
tests, a Bonferroni alpha adjustment (P=. 01) was used because of multiple testing.
RESULTS
Patients and treatment
Twenty-five of the 38 patients who had been treated in the Netherlands and Belgium were still
alive. Six patients were ineligible (two had recurrent disease, two had tumor localization in the
spinal cord only, one suffered from severe psychiatric problems, and one was lost to follow up),
leaving 19 patients. All patients agreed to participate in the study. Patient characteristics and
main clinical features are summarized in the table 1. Median age was 44 years (range 24 to 63),
only two patients were > 60. In two patients the second cycle of MBVP was omitted because of
insufficient tumor response. Eighteen patients received intrathecal chemotherapy. All patients
were treated with WBRT, and most received 39 to 40 Gy in 22 to 26 fractions. In the control
group, six patients were treated with systemic chemotherapy or involved-field radiotherapy
only. Thirteen patients received radiotherapy up to 42 Gy in 15 to 28 fractions after systemic
chemotherapy.
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Table 1 Patient characteristics
PCNSL Controls
Male/female 15/4 15/4
Mean ± SD age, y 44 ± 12 45 ± 12
Education level, no. (%)
High school degree or less 5 (26) 4 (21)
Vocational/trade school 6 (32) 8 (42)
College/bachelor degree 4 (21) 4 (21)
Graduate/professional degree 4 (21) 3 (16)
Mean ± SD time since treatment, mo 23 ± 14 16 ± 7
Mean ± SD pre-treatment KPS 75 ± 19 NA
Mean ± SD KPSa 87 ± 8 94 ± 6
Diagnosis, no. (%)
PCNSL 19 (100)
Hodgkin disease 8 (42)
NHL 11 (58)
Extension CNS lesion, no. (%)
Single mass lesion 13 (68)
Multifocal lesion 6 (32)
Pre RT meningeal infiltration, no. (%)b
Negative 13 (68)
Positive 2 (11)
Not done 4 (21)
Tumor lateralization, no. (%)
Left-sided 6 (32)
Right-sided 6 (32)
Bilateral 6 (32)
Central 1 (5)
Tumor Localization no. (%)
Frontal 3 (16)
Temporal 3 (16)
Parietal 1 (5)
Occipital 1 (5)
Cerebellum 1 (5)
Otherc 10 (53)
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Table 1 (continued)
Chemotherapy, no. (%)d
MBVP 19 (100)
ABVD 5 (31)
CHOP 4 (25)
MOPP/ABV 3 (19)
BEACOPP 2 (13)
LEUKERAN 1 (6)
Other 1 (6)
Radiotherapy, no. (%)
WBRT 39-40 Gy 17 (89)
WBRT 45-50 Gy 2 (11)
IF-RT 30 Gy 1 (6)
IF-RT 36-42 Gy 15 (94)
KPS = Karnofsky performance score; NA = not available; PCNSL = primary CNS lymphoma; NHL = non-Hodgkin lymphoma; WBRT = whole
brain radiotherapy; IF-RT = involved-field radiotherapy
a P-value is .005
b Lymphoma cells identified in cerebrospinal fluid
c Other = deep lesions (basal ganglia and thalamus, n=4) and tumor lesion(s) in: frontal regions and corpus callosum (n=1), septum pellucidum
(n=1), 3rd ventricle (n=1), foramina of Monroe and 4th ventricle (n=1), frontal and deep regions (n=1), and temporal and frontal areas and
basal ganglia (n=1)
d MBVP (methylprednisolone, methotrexate, teniposide, carmustine); CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone or
dexamethasone); ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine); MOPP/ABV (chloormethine, vincristine, procarbazine,
prednisone, doxorubicin, bleomycin, vinblastine); BEACOPP (doxorubicin, cyclophosphamide, procarbazine, prednisone, etoposide,
bleomycin, vincristine); LEUKERAN (chlorambucil); other= CVP (cyclophosphamide, vincristine, prednisone), DHAP (dexamethasone,
cisplatine, cytarabine) and EMP (etoposide, mitoxantrone, prednisone)
Neuropsychological assessment
Two patients with PCNSL did not complete the neuropsychological test battery (due to
insufficient knowledge of the Dutch vocabulary and a disease-induced hemi-paresis). Almost two-
third (63%) showed mild to moderate impairment (Table 2). Four patients (21%) were severely
impaired. In contrast, only 11% of the controls showed mild to moderate cognitive impairment
and none were severely impaired. Compared to the controls, the patients with PCNSL had lower
scores on some or all of the neuropsychological tests of the following domains: verbal and
nonverbal memory (California Verbal Learning Test, Rey Complex Figure Test), attention (Digit
Symbol, Trailmaking A), executive function (Trailmaking B), and motor speed (Fingertapping
Task and motor times of the Reaction Time Test). For the patients with PCNSL cognitive
impairment was positively correlated with age (r=. 56; P=. 013). 
Impaired cognitive status was not related to work-attendance. Eight patients with PCNSL (42%)
attended work. Four of them worked on a lower level, and 2 worked less than before diagnosis.
Additionally, 10 patients were on disability benefits of which four were slowly re-entering the
workplace. One patient retired early, but required intensive nursing care due to severe physical
disabilities and cognitive deficits. Out of the 16 controls working before diagnosis, 13 (81%)
resumed work. Only three controls were on disability benefits.
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Table 2 Neuropsychological data: mean (SD) raw scores and percentile-scores, including
percentage of impaired patients
PCNSL Controls P-valuea
Intelligence
GIT IQ 99 (16) / 50 (29) 0% NA -
Verbal Ability
Word Fluency 19 (5) / 53 (28) 0% 22 (4) / 72 (16) 0% .06
Memory
Digit Span 11 (3) / 54 (27) 0% 13 (3) / 73 (23) 0% .04
California Verbal Learning Test 37% 5%
Total learning 41 (15) / 24 (25) 58 (7) / 67 (21) <.001
Immediate free recallb 7 (4) / 62 (33) 12 (2) / 56 (32) <.001
Delayed free recallb 8 (5) / 63 (24) 13 (2) / 42 (33) .001
Recognition 14 (1) / 68 (25) 15 (1) / 64 (27) .05 
Rey Complex Figure Test-recallc,d 17 (7) / 28 (31) 17% 24 (7) / 71 (36) 11% .004
Visual Reproduction Ic 30 (7) / 46 (27) 0% NA -
Visual Reproduction IIc 23 (12) / 40 (37) 11% NA -
Attention
Digit Symbolc 39 (15) / 43 (31) 11% 58 (9) / 88 (12) 0% <.001
Trailmaking Ae 52 (33) / 39 (30) 21% 25 (8) / 85 (14) 0% <.001
Stroop Color Word Test Ie 20 (5) / 37 (31) 32% 18 (4) / 62 (30) 5% .07
Stroop Color Word Test IIe 27 (7) / 32 (32) 44% 22 (4) / 60 (31) 11% .02
Executive functions
Trailmaking Be 122 (75) / 38 (22) 26% 62 (24) / 78 (19) 0% .007
Stroop Color Word Test IIIe 46 (20) / 35 (29) 37% 33 (8) / 67 (30) 11% .04
Visuoconstructive abiliy
Rey Complex Figure Test-copyc 33 (2) / 60 (23) 39% 34 (2) / 67 (27) 32% .33
Motor Speed
Fingertapping Test dominantf 286 (67) / 10 (16) 47% 351 (46) / 36 (32) 16% .002
Fingertapping Test non-dominantf 245 (59) / 8 (13) 58% 310 (40) / 32 (28) 5% .001
Single Motor timeg 192 (55) / 15 (24) 37% 130 (38) / 54 (28) 11% .001
Complex Motor timeg 204 (75) / 17 (23) 47% 136 (37) / 44 (22) 11% .003
Speed of information processing
Single Decision timeg 358 (50) / 31 (25) 27% 327 (52) / 38 (27) 16% .03
Complex Decision timeg 559 (113) / 31 (34) 32% 527 (77) / 33 (24) 11% .31
Error rate 2 (2) / 43 (35) 11% .7 (1) / 67 (15) 0% .05
SD in parentheses
Percentile-scores: in a normal population a percentile score of 50 (SD=34) is an average score
GIT IQ = Intelligence quotient of the abbreviated Groninger Intelligence Test; NA = not available
a P-value for mean raw test scores
b percentile-scores are based on the differences between free recall and cued recall 
c n =18 for PCNSL patients
d the 3-minute Immediate Recall score
e scores in sec
f total number of hits in 1 minute
g scores in msec
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Table 3 QLQ-C30 and BCM20; mean ± SD
PCNSL Controls P-value
QLQ C30
Functioning scales
Physical functioning 82 ± 27 92 ± 17 .25
Role functioning 63 ± 33 80 ± 25 .10
Cognitive functioning 62 ± 28 81 ± 21 .04
Emotional functioning 64 ± 27 82 ± 15 .03
Social functioning 70 ± 32 88 ± 21 .03
Global health 68 ± 17 78 ± 16 .05
Global quality of life 67 ± 24 80 ± 17 .07
Symptom scales and items
Fatigue 35 ± 25 22 ± 21 .13
Nausea/vomiting 4 ± 9 2 ± 5 .29
Pain 16 ± 20 6 ± 12 .06
Dyspnea 2 ± 8 16 ± 20 .01
Sleep disturbances 33 ± 35 19 ± 26 .22
Appetite loss 9 ± 19 0 .04
Constipation 9 ± 16 2 ± 8 .08
Diarrhea 4 ± 14 2 ± 8 .16
Financial impact 16 ± 30 11 ± 19 .84
BCM20 
Symptom scales
Future uncertainty 28 ± 22
Visual disorder 17 ± 22
Motor dysfunction 13 ± 16
deficit 17 ± 18
Items
Headaches 14 ± 26
Seizures 5 ± 23
Drowsiness 18 ± 23
Bothered by hair loss 4 ± 11
Bothered by itching skin 16 ± 28
Weakness of both legs 9 ± 19
Trouble controlling bladder 9 ± 22
Scores range from 0 to 100. Functioning scales, global health and global QOL: higher scores denote better function. Symptom scales and
items: higher scores denote higher symptom levels
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Evaluation of neuroradiological data
Brain scans were available for review in 18 patients with PCNSL. WMA were observed in 14
patients (78%). Fourteen patients had cortical atrophy, of which six (33%) severely. One patient
had a mild atrophy before the start of treatment. Twelve patients (67%) showed WMA and
cortical atrophy. Cortical atrophy was associated with cognitive impairment (r=. 60, P =. 008),
age (r=. 50; P=. 035), and KPS (r=-. 66, P =. 003). WMA and cortical atrophy were not related to
tumor size before treatment, extent of the lesion, total dose of WBRT, or time since the end of
treatment.
QOL assessment
Nine patients with PCNSL (47%) reported well to excellent QOL (‘global QOL’ score > 5; Table 3).
However, they had significant lower scores than the controls on the following QOL functioning
scales: ‘cognitive functioning’, ‘emotional functioning’, ‘social functioning’ and ‘global health’.
The scores of ’cognitive functioning’ and ‘global QOL’ were not related to cognitive
performance. Patients who attended work had higher scores on the ‘global QOL’ scale. 
Two patients with PCNSL scored above the cut-off point on the anxiety and the depression
scale of the HADS (Table 4). Differences between groups on the MFI were not found. The scores
on the HADS and the MFI were not related to cognitive performance. The patients with PCNSL,
who resumed work, had lower scores on ‘general fatigue’ and ‘reduced activity’ of the MFI.
Table 4 MFI and HADS; mean ± SD and percentage of impaired patients
PCNSL Controls P-value
MFI
General Fatigue 11 ± 5 11 ± 5 .86
Physical Fatigue 11 ± 5 9 ± 5 .45
Reduced Activity 11 ± 5 8 ± 5 .06
Reduced Motivation 9 ± 5 7± 3 .22
Mental Fatigue 12 ± 5 10 ± 5 .11
HADSa
Anxiety 7 ± 5 5 ± 3 .16
% > 10 (22) (5) .14
Depression 6 ± 4 3 ± 3 .08
% > 10 (11) (0) .14
Percentages range from 4 to 20; higher scores indicate more symptoms
HADS: scores range from 0 to 21; higher scores denote more complaints
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DISCUSSION
Our cohort of patients represents a relatively young group of patients compared to other
PCNSL series.16 Nevertheless, the expected better outcome that younger patients tend to have,
was not reflected in our study and only less than half of the patients resumed work. The
incidence of white matter abnormalities and cortical atrophy in our study is similar to earlier
findings.5 Cerebral damage from chemotherapy or cranial radiation usually affects the white
matter tracts devoted to higher cortical function.17 Especially tasks that involve psychomotor
speed, attention and concentration, memory and learning abilities, and executive functions
appear to be affected by white matter abnormalities.18 The observed differences between our
patient groups on these particular cognitive tasks cannot be explained by confounding factors
related to the psychological effects of the diagnosis or treatment of cancer because the controls
were also treated with systemic chemotherapy or radiotherapy or both.
There are several possible causes for the observed cognitive deficits and the neuroradiological
changes in these patients with PCNSL. The first is the neurotoxic effect of combined-modality
treatment with intravenous and intrathecal MTX-based chemotherapy before WBRT. Each
treatment modality independently is potential neurotoxic, but once combined the risk to
develop neurological and cognitive deficits increases in more than an additive way.19,20 Apart
from treatment side effects, the cognitive deficits could also be attributed to cerebral scarring
as a result of prior tumor infiltration of the brain. Most studies on cognitive functioning in brain
tumor patients addressed patients with gliomas who suffer from significant residual tumor. In
those patients, treatment with cranial irradiation and chemotherapy is related to cognitive
deficits, but coexistence of residual tumor, influence of surgery and tumor lateralization make
interpretation difficult.21-24 In our study the effects of residual tumor are negligible because all
patients had a complete tumor response without evidence of tumor activity. However, due to
the absence of a pre-treatment evaluation, the effect of other tumor characterizations (eg, site
and number of lesions) on cognitive functioning cannot be ruled out.
Our findings are in contrast with previous studies investigating cognitive functioning in patients
with PCNSL with standardized psychometric methods.25-32 All evaluated patients treated with
chemotherapy alone, which was associated with a low risk of late neurotoxicity. Cognitive
impairment was only found in those patients who received cranial radiotherapy as first-line
treatment or in a later stage for refractory disease.25,28,31
Our results indicate that the difficult balance between prolongation of disease-free survival and
the risk of increased neurotoxicity needs to be carefully monitored. Assessment of cognitive
status and QOL should be considered as endpoints in new clinical trials, and future trials should
particularly aim at reducing these side effects. Further follow-up of our cohort of patients is
needed to show whether the prolonged and complete remissions are lasting over time and, in
particular, whether a possible progressive cognitive decline can be detected. 
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10 | Summary and concluding remarks
With more active treatments becoming available, cancer is increasingly becoming a more
chronic illness. The side-effects of cancer treatment, including potential neurotoxic effects are a
major concern. The number of long-term cancer survivors will further increase in the near future,
as will the number of survivors with cognitive and neurobehavioral impairment. Both chemo-
therapy and cranial irradiation may induce cognitive impairment.1 Research on cognitive
functioning following cancer treatment started in the early 1980s,2 but still there is a paucity of
systematic prospective, longitudinal and large-scale studies using objective psychometric
measures. Up till recently, most clinical trials investigating new treatment approaches focused
on survival, time to tumor progression, physical side-effects and its impact on quality of life
(QOL), rather than on potential cognitive side-effects.
This thesis reports on the cognitive sequelae of intensive treatment for hematological malig-
nancies. The central aim of this thesis was to examine the prevalence and the characteristics of
cognitive impairment in patients treated with or undergoing bone marrow or hematopoietic
stem cell transplantation (HSCT), and in patients treated for primary central nervous system
lymphoma (PCNSL). Additional goals were to study the relationship between cognitive
functioning and subjective cognitive complaints, general QOL-related issues, and psychological
functioning. This chapter presents and discusses the main findings, the limitations of the studies
and recommendations for future research.
SUMMARY
In chapter 2 the toxic effects of cancer treatment on the central nervous system (CNS), including
the putative underlying mechanisms and its effect on cognitive functioning, were described.
Severe delayed treatment-induced neurological complications are radiation necrosis, and
delayed leukoencephalopathy which is characterized by neurological abnormalities and
progressive cognitive decline. The incidence and risk of chemotherapy- and radiotherapy-
induced neurotoxicity depends on the capillary permeability of the blood-brain barrier (BBB),
the dosage and route of administration of antineoplastic agents, total dose and fraction dose,
and volume of the brain irradiated, and administration of other treatment modalities.
Immunotherapy with cytokines and adjunctive medications like corticosteroids and immuno-
suppressive agents may also induce neurotoxic effects. The pathogenesis of neurotoxicity is an
unknown and complex process of direct and indirect effects on neurons and glial cells that leads
to disruption of genetic, metabolic or neurotransmitter-related processes, to secondary inflam-
matory or autoimmune responses, and to cerebrovascular damage, particularly in the capillary
microvasculature and the capillary permeability of the BBB. 
Chapter 3 focused on the available literature data on cognitive dysfunction in HSCT patients.
Results of this review suggest that cognitive dysfunction in HSCT patients includes diffuse
impairment of motor function, executive function, and memory prior to and following the
transplant procedure. The reported prevalence of cognitive impairment varies from 20 to 58%
prior to HSCT and 37 to 79% after completion of treatment; this large range is in part explained
by the use of different criteria for cognitive impairment. Risk factors for poorer cognitive out-
come include demographical factors (ie, old age, male gender, low educational level, low
estimated premorbid intelligence) and disease and/or treatment-related factors (ie, cranial
irradiation, history of previous chemotherapy, intrathecal treatment, disease duration and
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disease stage at transplant, total dose of total body irradiation (TBI), and graft-versus-host-
disease). Methodological limitations, including small sample size, diversity in patient selection
and lack of an appropriate reference group, greatly limit the interpretation of currently available
results.
Chapter 4 presented a literature review of cognitive dysfunction associated with PCNSL and its
treatment with whole brain radiotherapy, high-dose chemotherapy, combined modality therapy,
and blood-brain barrier disruption chemotherapy. Most neuropsychological studies on PCNSL
are prospective and embedded in clinical trials. A broad range of cognitive deficits is observed,
including deficits in attention, executive functions, memory, language (eg, naming), and psy-
chomotor speed. Cognitive impairment is usually already apparent before treatment. PCNSL
patients treated with combined modality therapy demonstrate generally more pronounced
cognitive impairment than those who received chemotherapy alone. Treatment with chemo-
therapy alone is associated with either stable or improved cognitive performance after
completion of treatment. Further large-scale systematic clinical and neuropsychological studies
are needed. 
The results of a retrospective study in adult long-term survivors of HSCT were described in
chapter 5. We evaluated a cohort of 40 progression-free patients with hematological
malignancies who received HSCT at least two years before study participation. The induction
regimen consisted of high-dose chemotherapy and TBI, followed by an allogeneic transplant for
most patients. Mild to moderate cognitive impairment was found in 60% of patients compared
to normative data. Impairment involved deficits in selective attention, executive function,
information processing speed, and verbal and visual memory. Performance on tasks of infor-
mation processing speed was significantly lower when compared to expected scores of a
healthy population (p = .001). Fatigue, global health, and educational level accounted for the
variance in impaired test scores. A brief mental status evaluation (the Mini-Mental Status
Examination)3 revealed no abnormalities. The findings emphasized the importance of including
cognitive functioning as an outcome parameter in HSCT trials. 
In chapter 6, the results of a pilot study on changes in cognitive functioning in HSCT candidates
during the first year following transplant were presented. Less than half of the 25 patients
included in the pre-treatment baseline assessment were evaluated at follow-up. Attrition was
caused by death and relapse (both before and after transplant), and to severe post-HSCT
complications. Cognitive impairment prior to HSCT was observed in up to 24% of patients,
predominantly in selective attention and information processing speed. Random regression
modeling revealed a slight improvement in mean group scores of memory tasks over time,
particularly for younger patients, which may be related to practice effects. Emotional
functioning improved over time. Depression and anger affected performance at baseline, and
emotional functioning was correlated with cognitive performance at follow-up. We concluded
that future research requires a pre-treatment assessment together with a sufficient large sample
of patients to overcome an expected drop-out of at least 50%.
We examined cognitive performance in HSCT candidates prior to transplant in comparison to a
reference group of patients with hematological malignancies who received conventional non-
myeloablative cancer therapy in chapter 7. The baseline results of this prospective comparative
study in a large-scale and representative cohort of 101 HSCT patients and 82 reference patients
indicated that up to 20% of HSCT candidates experienced cognitive impairment before
undergoing HSCT. Deficits were observed in visual memory, visuospatial and constructional
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ability, and psychomotor functions. There were no differences in degree or pattern of cognitive
impairment between groups. We also observed no associations between cognitive performance
and treatment parameters. In the transplant group, a higher rate of anxiety cases was observed,
and levels of subjective cognitive functioning, emotional functioning, and social functioning
were significantly lower. However, this was not related to cognitive performance. 
The same cohort of patients was assessed at eight months and 20 months after baseline to
investigate whether cognitive functioning would change over time and may be affected by the
transplant procedure. The results of this study were described in chapter 8. As predicted in our
pilot-study, only 54% of the HSCT patients completed follow-up in contrast to 72% of the
reference patients. Random regression modeling indicated that there were no significant
changes in cognitive functioning over time. However, performance on several measures of
attention and executive function (p = .01), and psychomotor function (p = .03) in the HSCT
group was reduced when compared to the reference group. This was partly related to TBI.
Further analyses demonstrated adverse effects of female gender and older age on cognitive
functioning. Moreover, physical fatigue levels were significantly higher in HSCT patients at
follow-up, and weak correlations were found between cognitive functioning, and global health
and psychological functioning. Work attendance in the transplant group was considerably lower
in comparison to the reference group. So far, almost two years after transplant, HSCT has no
significant additional effect on cognitive functioning. These results may suggest that cytotoxic
treatment before HSCT may play a prevailing role in the development of treatment-related
cognitive impairment. We recommended further long-term follow-up to evaluate whether
cognitive functioning, particularly within the domains of attention and executive function, and
psychomotor function improves, stabilizes or progresses over time.
In chapter 9, we presented the results of a study on cognitive functioning in a relatively young
cohort (median age was 44 years) of disease-free survivors of PCNSL who were treated in a
prospective European Organization for Research and Treatment of Cancer study (EORTC
20962). All 19 patients received intravenous and intrathecal high-dose MTX-based
chemotherapy followed by consolidating whole brain radiotherapy. The results were compared
with matched control subjects with systemic hematological malignancies and were related to
neuroradiological findings. Mild to moderate cognitive impairment was observed in 63% of
PCNSL patients in comparison to 11% of control subjects (p = .002). Impairment predominantly
involved verbal and visual memory, attention, executive function, and motor speed. We found
that impairment rate was positively correlated with older age. Group differences could not be
explained by confounding factors like psychological functioning or fatigue. Evaluation of
neuroradiological findings revealed white matter abnormalities and cortical atrophy in 78% of
patients. Cortical atrophy was associated with a higher rate of cognitive impairment, older age
and lower performance status. We concluded that combined modality treatment for PCNSL is
associated with cognitive impairment, even in patients under 60 years.
CONCLUDING REMARKS
Discussion of main findings
In line with other studies on the cognitive side-effects of cancer treatment,4 we found evidence
for cognitive impairment in a number of patients who received intensive treatment for
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hematological malignancies. Our studies revealed that particularly patients with CNS tumors
experience cognitive impairment, whereas in hematological patients with non-CNS cancer only
a subgroup of patients displayed cognitive dysfunction. 
In our first cross-sectional study on cognitive dysfunction associated with HSCT, we observed
mild to moderate cognitive deficits in 60% of long-term survivors,5 particularly in information
processing speed. Two prospective trials showed that some of these cognitive problems
predate the transplantation procedure.6,7 The data from our ensuing prospective study indeed
indicated that approximately a quarter of patients experience cognitive deficits before under-
going transplant. However, neuropsychological assessments following transplant demonstrated
no significant change in cognitive functioning compared to the baseline evaluation. Moreover,
when compared to reference patients who had not received HSCT, only mild differences in
attention and executive function, and psychomotor function were detected.8
Based on literature data, and in view of the results of our first cross-sectional study, we had
anticipated coming across a higher rate of cognitive deficits after HSCT and more profound
changes in cognitive functioning over time. HSCT patients undergo an intensive preparative
conditioning regimen with high-dose chemotherapy and often TBI, and they are submitted to
long-term use of immunosuppressive drugs and treatment-related complications like GVHD and
infectious diseases due to the immunodeficient state. In comparison to patients of the reference
group, therefore, they are not only exposed to additional anti-cancer treatment but also to
more potential risks of CNS toxicity as a result of severe post-transplant complications. 
A possible explanation for this lower than expected prevalence of cognitive dysfunction could
be that the patients in our large-scale longitudinal study were assessed at an earlier time point
following HSCT than the patients in the retrospective study. The last neuropsychological
assessment in the longitudinal study took place at a mean time of 19 months after transplant,
while in the retrospective study patients were assessed between 22 and 82 months after HSCT.
It is well-known that some adverse effects of cytotoxic agents or other treatment modalities may
take substantial time to evolve (chapter 2). They can appear years after actual exposure and
cause CNS toxicity and cognitive dysfunction. Together with late effects of HSCT including a
greater number of health problems and persistent fatigue,9 this may have contributed to
differences in impairment rates.
An alternative hypothesis is that the discrepancy in post-HSCT cognitive functioning is related
to differences in HSCT conditioning regimens and treatment group assignment. In our
retrospective study, all patients were treated with high-dose chemotherapy followed with TBI,
whereas in the longitudinal study almost 25% of patients received no TBI. The majority of the
included patients was recruited from a single cancer center and received similar pre-HSCT
conditioning regimens. However, the conditioning regimens have changed slightly over the last
years, and more patients received non-myeloablative treatment regimens followed by an
autologous graft. These treatment regimens could be associated with lower risks of neuro-
toxicity and consequently a less profound impact on cognitive functioning. However, this remains
speculative as our data revealed no differences in cognitive performance between patients with
autologous grafts and allogeneic grafts.
In addition, the results of our large-scale longitudinal study suggest that treatment prior to
transplant may play an important role in the development of cognitive sequelae because almost
two years after baseline, no significant changes in functioning could be detected. 
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Our study in PCNSL patients is one of the first investigations on the cognitive side-effects of
combined modality treatment in a large clinical trial.10 We used an extensive neuropsycho-
logical test battery to investigate long-term effects of treatment. In contrast to the HSCT
studies, we encountered a significant number of cognitive problems in a relatively young group
of PCNSL survivors. Our data suggest that combined modality treatment but also the disease
itself is associated with substantial cognitive impairment and has a negative impact on daily-life
functioning as less than half of these young patients resumed work. The immediate priority for
future research in PCNSL patients is to confirm these observed effects in the setting of large,
well-designed longitudinal studies. Such a study is currently underway.
In our studies we could not find consistent associations between subjective cognitive func-
tioning or complaints and actual performance assessed by objective neuropsychological
testing. This may be in part related to the diverse use of measures of subjective cognitive func-
tioning. In our retrospective study and pilot study in HSCT patients, the extent of subjective
cognitive problems was rated by the neuropsychologist during a short interview before testing.
This is a common procedure in a clinical practice, and inter-rating problems were avoided by
using the same neuropsychologist for all assessments. In the other studies, patients were asked
to fill in a questionnaire to measure the frequency of everyday cognitive failures in memory,
attention, action and perception.11,12 Both instruments could measure different concepts,
leading to inconsistent findings. 
Additional suggestions for the lack of association between subjective and objective cognitive
measures might be that patients misjudge their actual performance state (eg, patients with
brain tumors often have diminished appreciation of their cognitive problems as a result of their
impairment), or that patients somehow adapt to cognitive deficits and problems, or cope
differently with them. In addition, long-term survivors may get used to a new way of life, which
makes fewer demands on their cognitive abilities, so that a decline in cognitive function as
assessed by formal objective neuropsychological testing is not an issue for these patients in
their daily life. This seems a plausible explanation, because large numbers of survivors do not
regain their premorbid role function, as many have not (yet) fully returned to their professional
careers or academic performance, or are unable to take part abundantly in social or familial
activities. Another explanation for the lack of association between subjective and objective
cognitive measures might be found in the concept of response-shift, in which individuals, in the
course of time, change their internal standards by which they judge their quality of life. For
example, a cancer survivor might judge the same cognitive deficits after his illness differently –
in this case, less bothersome - as he would have done before. Having survived, the survivor may
be inclined to attach less value to - and to underreport - his cognitive complaints because other
concepts (eg, being alive, family bonds) have become more important.
An important area of research that remains to be investigated is the identification of specific
cytotoxic agents, treatment regimens or combinations of therapeutic modalities that may have
caused the cognitive deficits. Our studies do not provide an answer to this cause-and-effect
issue. Our PCNSL study presents however a first step towards unraveling potential causes of
treatment-related cognitive dysfunction. We compared overall cognitive functioning with
evidence of neuroradiological abnormalities manifested on MRI. In the majority of patients,
white matter abnormalities and/or cortical atrophy were found. Only one of these patients had
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signs of a mild atrophy before the start of treatment, suggesting a direct relationship between
treatment and cognitive impairment. However, the aim to unveil the structural, metabolic, and
functional consequences of cancer therapies goes beyond the field of clinical neuropsycho-
logical research and beyond the scope of the thesis. 
Limitations and methodological considerations
The studies presented in this thesis have some methodological limitations. First of all, there is a
possibility of selection bias in the HSCT studies despite the use of similar in- and exclusion
criteria. In contrast to our retrospective study, about 20% of patients declined to participate to
the longitudinal HSCT study. In the light of a fully scheduled and intensive pre-transplant check-
up-scheme and distance to the hospital, this was not unexpected. Our patient groups may
therefore not resemble the entire patient population which may have contributed to the
disparities in the results. 
A limitation of the longitudinal study is that outcome differences in our studies could be
attributable to pre-existing group disparities rather than treatment effects. Given the fact that
we did not observe differences between HSCT candidates and reference patients in our
baseline assessment, this does not seem likely. In addition, using patients as their own controls
by measuring cognitive function before and at various times after HSCT, was an important
advantage of the longitudinal study. As such, pre-treatment baseline testing showing group
equality and the use of an appropriate reference group is the next best alternative to a true
random assignment. However, a ‘true’ baseline time-point prior to the start of the disease is
impossible, as patients cannot be identified before their cancer diagnosis. Assessing hemato-
logical patients immediately after being diagnosed with a malignancy (and often life-threatening
disease) before the start of any treatment is, regardless of ethical considerations associated with
major supplementary difficulties. One is that the psychological effect of a recent cancer
diagnosis would most likely result in a lower, rather than higher true baseline measurement of
cognitive functioning.
Lastly, the assessment of cognitive impairment in the studies presented in this thesis involved a
comparison between patients’ test scores on measures of cognitive skills and published
normative data. This is a common approach in clinical neuropsychology.13,14 Test performance
scores for a group of healthy individuals (ie, without cancer) comprise a valid control for the
purpose of the studies, especially because patients diagnosed with non-CNS cancer are not
commonly believed to experience overt neurological dysfunction and related cognitive
impairment. So, their performance should be in a similar range to that of healthy controls with a
comparable demographical background, in terms of age, gender and possibly educational
level. The use of normative data has the advantage that it represents a larger sample than a
control group recruited for a study, and it gives a more accurate and valid estimate of a so-
called true score for the control group with which the study cohort is compared. Nonetheless,
there are two problems with this method of comparison. Firstly, each neuropsychological test
has its own set of published test norms; consequently there is a wide variance within normative
test data, including differences in sample sizes and selection of healthy controls. This may lead
to inconsistency in interpreting results. The other reason for critique is its failure to control for
potential differences in emotional well-being and psychological distress that may accompany
being diagnosed with a medical illness, in particular cancer. Thus, a similar affected reference
group is desirable to control for this potentially confounding influence. We used therefore a
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reference group of patients with hematological malignancies in the longitudinal study and the
PCNSL study. Moreover, in each trial our neuropsychological assessment was supplemented
with measures of psychological functioning, QOL and fatigue, to investigate the correlation
between emotional and psychological distress and cognitive functioning. 
Implications for clinical practice
Despite a growing recognition that cancer and its treatment may be associated with cognitive
impairment, and that cognitive evaluations are valuable for patient care, there is still a shortage
of practical contributions, like directions to provide better information, and to guide treatment
decisions and therapeutic interventions. 
Cognitive complaints should not be dismissed as being ‘all in your head’ or minimized as
insubstantial. This is especially relevant given the lack of concordance between objective and
subjective measures of cognitive functioning in existing literature and in our studies. Regardless
of the level of cognitive difficulty experienced by cancer patients, it is essential for professionals
to bear in mind that even minor cognitive deficits can have an impact on QOL. It is also
important to identify the effects of the cognitive deficits in terms of everyday living. Neuro-
psychological expertise should be readily available in oncology clinics, and patients should be
referred for a comprehensive evaluation if necessary. 
Nurses and nurse practitioners, but also mental health professionals as psychologists and
psychiatrists working in clinical settings, may play an important role in informing patients not
only about their diagnoses and treatment, but also about potential side–effects and cognitive
dysfunction interfering with daily-life routine, and assist in coping with them. For some patients
the knowledge that cognitive dysfunction following treatment is not unique and the reassurance
that deficits may possibly dissolve over time, is sufficient. In other cases, a neuropsychological
assessment may be necessary to assess the extent of problems and monitor changes over time. 
Final considerations and future perspectives
It is crucial for oncologists and other health professionals to recognize the cognitive sequelae of
cancer and cancer treatment, and to intervene to minimize long-term effects. This issue has
been underestimated in the past given that most studies focused on survival rates, adequate
disease control or the physical side-effects of treatment. Though, it is also fair to mention that,
particularly in the last five years, this area of research has received increased attention, and that
the psychometric quality of the studies undertaken has improved immensely. Yet, there are still
issues that need further investigation. 
Despite our HSCT study, longitudinal data on the persistence of the observed deficits remain
very scarce. It is world-wide recognized that patients’ recovery from HSCT is a lengthy process
that takes much longer than one year. Further long-term follow-up of our HSCT survivors and
reference patients is necessary to investigate whether the observed deficits persist over time.
As negative side-effects of HSCT on cognition are confirmed in future longitudinal studies,
arguments should be made for a routine incorporation of objective cognitive measures as part
of the neurotoxicity evaluation in clinical trials, simultaneously methods of intervention and
preventing should be developed. Incorporating cognitive testing as a primary end point in
clinical trials will help to determine the risks versus benefits of different treatment approaches. 
Future research in PCNSL patients should focus on prospective and longitudinal studies to
investigate the extent and changes associated with the different treatment regimens for this
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malignancy. Age-related co-morbidity in PCNSL patients and the contribution of the disease
itself (eg, the microscopally diffuse lesions, the angiopathic growth pattern and the wide spread
infiltration) in cognitive decline, need further attention. Difficulties within this area of research
are the low incidence of the disease and the absence of a standard neuropsychological test
battery that could be included in clinical trials. A test battery that is useful in clinical trials should
have the following characteristics: it should be brief, to reduce patient and clinical burden;
standardized and simple to administer; have good psychometric properties (eg, good validity,
reliability and populations norms); and, include tests that measure cognitive effects of the tumor
and of treatment.15 
It is promising that very recently guidelines for the assessment of cognitive functions in PCNSL
patients have been developed in cooperation with the International PCNSL Collaborative
Group, and that a standardized and core battery of neuropsychological and QOL measures for
prospective clinical trials will be introduced internationally in the near future.16 Incorporation of
formal and systematic cognitive evaluations in PCNSL studies will increase our understanding of
treatment-related toxicity in this population.
In conclusion, the consistent findings of cognitive impairment in the studies discussed in this
thesis suggest a measurable and sustained effect of intensive treatment regimens for
hematological malignancies on cognitive functioning, although all studies had multiple
confounding factors as noted in each chapter. The relationship between intensive treatment
schedules and cognitive functioning is complicated. There are a number of factors which may
influence cognitive performance and it is difficult to establish which of these factors play a
central role. The present findings point out that treatment-related cognitive changes are not
universal among cancer patients. Some patients are able to tolerate therapy with no obvious
impairments, while others will develop significant toxicities that seriously compromise their
QOL and prevent them from social and occupational roles. The challenge to date has been to
convincingly demonstrate the existence of this subgroup of cancer patients through
methodologically sound longitudinal neuropsychological studies. This thesis highlighted some
aspects of a complex puzzle; nevertheless many pieces are still missing. 
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11 | Dutch summary
Door intensievere behandelingen wordt de diagnose kanker in toenemende mate een
chronische aandoening. De betekenis van bijwerkingen van kankerbehandelingen op de lange
termijn, waaronder neurotoxiciteit, wordt daardoor een belangrijker probleem. Naar ver-
wachting zal het aantal overlevenden dat succesvol behandeld is voor kanker toenemen en
daarmee ook het aantal patiënten dat te maken heeft met cognitieve en gedragsmatige
beperkingen. Chemotherapie en radiotherapie op de hersenen kan leiden tot cognitieve
beperkingen.1 Onderzoek naar cognitieve functies na kankerbehandeling vindt zijn oorsprong
in het begin van de jaren 80.2 Er is echter nog steeds een tekort aan systematische, prospec-
tieve en longitudinale studies waarin gebruik is gemaakt van grote steekproeven en objectieve
psychometrische methoden. Tot voor kort richtten de meeste klinische studies zich op de over-
levingsduur, de tijd tot progressie van de ziekte, de fysieke bijwerkingen of de gevolgen voor
de kwaliteit van leven; de mogelijke cognitieve bijwerkingen van kankerbehandeling zijn
onderbelicht gebleven.
In dit proefschrift worden de cognitieve gevolgen van intensieve behandeling voor hemato-
logische maligniteiten besproken. De nadruk ligt op de prevalentie en de kenmerken van
cognitieve beperkingen van patiënten die behandeld zijn met een beenmerg- of stamcel-
transplantatie (HSCT) en patiënten met een primair centraal zenuwstelsel lymfoom (PCNSL).
Daarnaast wordt de relatie tussen cognitieve functies en subjectieve cognitieve klachten,
kwaliteit van leven en psychologisch functioneren belicht. Dit hoofdstuk beschrijft de belangrijkste
bevindingen van de studies uit dit proefschrift, de methodologische overwegingen en aan-
bevelingen voor vervolgonderzoek.
Hoofdstuk 2 geeft een overzicht van de bijwerkingen (toxiciteit) van kankerbehandelingen op
het centraal zenuwstelsel (CNS), waaronder de mogelijke oorzaken en de gevolgen van deze
bijwerkingen op cognitieve functies. Ernstige ‘late’ neurologische complicaties die samen-
hangen met de behandeling zijn radiatienecrosis en leukencefalopathie; beide worden geken-
merkt door neurologische afwijkingen en progressieve cognitieve achteruitgang. De incidentie
en het risico van neurotoxiciteit is afhankelijk van een aantal factoren, zoals de doorlaatbaarheid
van de bloed-hersenbarriére (BBB) voor chemotherapeutica, de dosis en de wijze van toe-
diening van chemotherapeutica, de totale dosis en fractiedosis van de radiotherapie, de
omvang van het bestralingsveld en andere aanvullende behandelingen die gelijktijdig worden
gegeven. Immunotherapie met cytokines en behandeling met bepaalde medicamenten zoals
corticosteroiden of middelen tegen immuunsuppressie, kunnen ook leiden tot neurotoxiteit. De
onderliggende pathogenese van neurotoxiciteit is een onbegrepen en complex proces. Het is
een aaneenschakeling van directe en indirecte effecten op neuronen en gliacellen waarbij
waarschijnlijk sprake is van een verstoring in genetische, metabolische en neurotransmitter-
processen, van secundaire inflammatie of auto-immunologische reacties en van cerebrova-
sculaire beschadigingen, vooral in de capillaire microvasculatuur en de doorlaatbaarheid van de
BBB.
Hoofdstuk 3 beschrijft een literatuuronderzoek naar cognitieve disfuncties bij HSCT patiënten.
Deze bestaan vooral uit diffuse afwijkingen in de motorische functies, de executieve functies en
het geheugen, zowel voorafgaand aan de transplantatie als na afloop van de behandeling. De
gerapporteerde prevalentie loopt uiteen van 20%-78% voor de behandeling en van 37%-79%
na de transplantatie. Deze discrepantie kan ondermeer verklaard worden door verschillen in de
definitie van cognitief disfunctioneren. Risicofactoren voor een slechtere uitkomst zijn demo-
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grafische factoren (resp. hogere leeftijd, mannelijk geslacht, lager opleidingsniveau en lagere
premorbide intelligentie) en factoren gerelateerd aan ziekte en/of behandeling (resp.
schedelbestraling, chemotherapie vóór de transplantatie, intrathecale behandeling, duur en
stadium van de ziekte bij transplantatie, dosis van de totale lichaamsbestraling [TBI] en graft-
versus-host-ziekte). De methodologische tekortkomingen van de studies (resp. relatief kleine
steekproeven, diversiteit in patiëntenselectie en het ontbreken van een controlegroep)
beperken de interpretatie van de huidige onderzoeksresultaten.
In hoofdstuk 4 wordt een literatuuroverzicht gegeven van de studies op het gebied van het
cognitief functioneren na behandeling voor PCNSL met totale schedelbestraling, hoge-dosis-
chemotherapie, combinatiebehandeling (chemo- en radiotherapie) of intra-arteriële chemo-
therapie met verstoring van de BBB. Het merendeel van de neuropsychologische studies is
prospectief en veelal opgenomen in een klinische studie. De geobjectiveerde cognitieve
beperkingen bestaan uit stoornissen in de aandacht, de executieve functies, het geheugen, de
taal (benoemen) en de psychomotorische snelheid. Vaak is al voor de behandeling sprake van
cognitieve beperkingen. Patiënten die een combinatiebehandeling hebben ondergaan lijken
meer nadrukkelijke stoornissen te vertonen, terwijl bij chemotherapie sprake is van een stabiel
of verbeterd functioneren na afloop van de behandeling. Meer grootschalig en systematisch
klinisch en neuropsychologisch onderzoek is wenselijk.
De resultaten van een retrospectieve studie bij langdurige overlevenden van HSCT worden
weergegeven in hoofdstuk 5. We onderzochten een cohort van 40 ziektevrije patiënten met
hematologische maligniteiten die minstens twee jaar voorafgaand aan de studie waren
behandeld met HSCT. De inductie bestond uit hoge-dosis-chemotherapie en TBI waarna de
meeste patiënten een allogeen transplantaat kregen toegediend. In vergelijking met
normgegevens werden milde tot matige cognitieve beperkingen geobjectiveerd bij 60% van de
patiënten. Deze bestonden uit stoornissen in de selectieve aandacht, de executieve functies, de
snelheid van informatieverwerking en het verbale en visuele geheugen. De snelheid van infor-
matieverwerking was significant lager vergeleken met verwachte scores van een gezonde
normpopulatie (p = .001). Vermoeidheid, algehele gezondheid en opleidingsniveau droegen bij
aan de spreiding van de afwijkende scores. Een korte cognitieve screening test (de Mini-Mental
State Examination)3 liet geen afwijkingen zien. Onze bevindingen benadrukken de waarde van
het gebruiken van cognitieve functies als een uitkomst-variabele in HSCT studies.
In hoofdstuk 6 staan de resultaten beschreven van een pilotstudie naar mogelijke verande-
ringen in de cognitieve functies van HSCT patiënten gedurende het eerste jaar na de
transplantatie. Minder dan de helft van een groep van 25 patiënten die geïncludeerd waren
voor de baselinemeting, kon deelnemen aan het vervolgonderzoek. Uitval werd veroorzaakt
door overlijden, progressie van de ziekte (voor en na HSCT) en ernstige complicaties na de
transplantatie. Bij 24% werden cognitieve beperkingen geobjectiveerd voorafgaand aan de
transplantatie, voornamelijk in de selectieve aandacht en de snelheid van de informatie-
verwerking. Random regression modeling (RRM) analyse liet een kleine verbetering zien in de
gemiddelde groepscores van de geheugentaken, vooral bij jongere patienten. Dit kan
samenhangen met leereffecten. Er was sprake van een verbetering van het emotioneel func-
tioneren in de loop van de tijd. Depressie en woede beïnvloedden de cognitieve prestaties van
de baselinemeting. Het emotioneel functioneren had invloed op de prestaties bij het vervolg-
onderzoek. We concludeerden dat een baselinemeting voorafgaand aan HSCT noodzakelijk is,
evenals een voldoende grote onderzoeksgroep vanwege de 50% uitval.
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We vergeleken de cognitieve functies van HSCT patiënten voor de transplantatie met die van
een referentiegroep van patiënten met hematologische maligniteiten die een standaard (niet-
myeloablatieve) behandeling ondergingen in hoofdstuk 7. De resultaten van de baselinemeting
van deze prospectieve en vergelijkende studie met een groot en representatief cohort van 101
HSCT patiënten en 82 referentie-patiënten gaven weer dat bijna 20% van de HSCT patiënten
cognitieve beperkingen ondervindt voorafgaand aan de transplantatie. Deze bestaan uit
stoornissen in het visuele geheugen, de visuospatiële- en constructieve vaardigheden en de
psychomotorische functies. Tussen beide groepen bestonden geen verschillen met betrekking
tot de ernst en de aard van de cognitieve beperkingen. Ook vonden we geen verband tussen
de cognitieve functies en behandelingsfactoren. In de transplantatiegroep was sprake van een
hoger percentage patiënten dat geclassificeerd kon worden als een patiënt met een angst-
stoornis. Daarnaast was sprake van een significant lager niveau van subjectief-cognitief, emo-
tioneel en sociaal functioneren in deze groep. Deze bevindingen waren niet gerelateerd aan de
cognitieve prestaties.
We onderzochten of de cognitieve functies in deze patiëntengroepen veranderden in de loop
van tijd met vervolgonderzoek na 8 en 20 maanden. De resultaten van deze studie worden
beschreven in hoofdstuk 8. Zoals voorspelt in de pilotstudie, was slechts 54% van de HSCT
patiënten in staat om aan het vervolgonderzoek deel te nemen in tegenstelling tot 72% van de
referentie-patiënten. Bij RRM analyse was geen sprake van significante veranderingen in de
cognitieve functies in de loop van de tijd. Echter, de prestaties op tests voor de aandacht en
executieve functies en de psychomotorische functies waren lager in de HSCT groep (resp. p =
.01, p = .03). Dit werd gedeeltelijk verklaard door TBI. De analyse wees uit dat vrouwelijke en
oudere patiënten lagere resultaten behaalden. Bij de vragenlijsten was sprake van meer fysieke
vermoeidheidsklachten in de HSCT groep en een matig verband tussen de cognitieve functies
en globale gezondheid en psychologisch functioneren. Het percentage patiënten dat weer
deelnam aan het arbeidsproces was lager in de HSCT groep. Er lijkt echter anderhalf jaar na de
transplantatie geen sprake van aanzienlijke bijkomende negatieve effecten van HSCT op de
cognitieve functies. Onze resultaten suggereren dat vooral de cytotoxische behandeling voor
de transplantatie een belangrijke rol lijkt te spelen in de ontwikkeling van behandeling-
geïnduceerde cognitieve beperkingen. We benadrukten dat nader onderzoek in dit cohort op
de lange termijn geïndiceerd is om te onderzoeken of de cognitieve functies, in het bijzonder
de aandacht en executieve functies en de psychomotorische functies, zullen verbeteren,
stabiliseren of verminderen.
In hoofdstuk 9 zijn de resultaten beschreven van een studie naar de cognitieve functies van een
relatief jonge (mediane leeftijd is 44 jaar) groep ziektevrije patiënten die behandeld waren voor
PCNSL in een prospectieve ‘European Organization for Research and Treatment of Cancer’
studie (EORTC studie 20962). Alle 19 patiënten kregen intraveneuze en intrathecale hoge-
dosis-chemotherapie (MTX), gevolgd door totale schedelbestraling. De resultaten werden
vergeleken met controlepersonen (geselecteerd op leeftijd, geslacht en duur na behandeling)
met systemische hematologische maligniteiten en met neuroradiologische bevindingen. Bij
63% van de patiënten werden milde tot matige cognitieve beperkingen gevonden, terwijl dit
percentage in de controlegroep slechts 11% was (p = .002). Deze beperkingen bevonden zich
vooral op het gebied van het verbale en visuele geheugen, de aandacht en executieve functies
en de motorische snelheid. Er was een positieve correlatie tussen de ernst van de stoornissen
en oudere leeftijd. De verschillen tussen beide patiëntengroepen konden niet verklaard worden
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door ‘storende’ factoren, zoals het psychologisch functioneren en vermoeidheid. Bij 78% van de
patiënten was sprake van witte stof afwijkingen en corticale atrofie. De aanwezigheid van
corticale atrofie correleerde met een hoger percentage cognitieve afwijkingen, oudere leeftijd
en een lagere performance status. Uit onze studie kan geconcludeerd worden dat PCNSL patiënten
die behandeld zijn met deze combinatiebehandeling cognitieve beperkingen hebben, zelfs
indien deze patiënten jonger zijn dan 60 jaar.
CONCLUSIES
Discussie van de belangrijkste bevindingen
In onze studies vonden we aanwijzingen voor cognitieve beperkingen bij een deel van de
patiënten die een intensieve behandeling ondergaan voor hematologische maligniteiten. Deze
bevindingen komen overeen met eerdere onderzoeksresultaten.4 Cognitieve beperkingen
werden vooral gevonden bij patiënten met een tumorlokalisatie in het CNS, en slechts in een
deel van de patiënten met andere hematologische maligniteiten. 
In een cross-sectionele studie naar cognitief disfunctioneren bij HSCT patiënten bleek 60%
milde tot matige cognitieve beperkingen te hebben, in het bijzonder met betrekking tot de
snelheid van informatieverwerking.5 De resultaten van twee prospectieve studie wezen uit dat
een aantal van deze problemen al voor de transplantatie aanwezig zijn; ongeveer een kwart van
de patiënten heeft cognitieve beperkingen voor de behandeling.6,7 Neuropsychologisch
onderzoek na de transplantatie liet geen significante veranderingen zien ten opzichte van de
baselinemeting en er was sprake van kleine verschillen in vergelijking met patiënten die geen
transplantatie hadden ondergaan met betrekking tot de aandacht, de executieve functies en de
psychomotorische functies.8
Op basis van literatuurgegevens en de cross-sectionele studie hadden we een groter aantal
cognitieve problemen verwacht na de transplantatie, evenals veranderingen in de cognitieve
functies door de tijd heen. HSCT patiënten ondergaan een intensieve behandeling met hoge-
dosis-chemotherapie en vaak ook TBI. Daarnaast is deze patiëntengroep onderhevig aan
langdurig gebruik van medicatie voor immunosuppressie en complicaties die samenhangen
met de behandeling, zoals graft-versus-host-ziekte en infectieziekten die ontstaan door
immunodeficiëntie. De patiënten hebben naast een aanvullende kankerbehandeling ook meer
risico’s op neurotoxiciteit vooral door ernstige complicaties na de transplantatie.
Een mogelijke verklaring voor deze lagere prevalentie van cognitieve disfuncties is dat de
patiënten in de longitudinale studie op een eerder tijdstip na de transplantatie werden
onderzocht dan de patiënten in de cross-sectionele studie. Het laatste neuropsychologisch
onderzoek werd gemiddeld 19 maanden na de transplantatie afgenomen terwijl de patiënten
van de retrospectieve studie tussen 22 en 82 maanden na de behandeling werden onderzocht.
Het is algemeen bekend dat de nadelige effecten van kankerbehandeling zich soms pas in de
loop van de tijd ontwikkelen. De bijwerkingen kunnen jaren na de feitelijke blootstelling
ontstaan waardoor neurotoxiciteit en cognitieve disfuncties optreden. Samen met de late
effecten van de transplantatie, zoals een groot aantal gezondheidsproblemen en aanhoudende
vermoeidheid,9 kan dit hebben bijgedragen aan verschillen tussen de studies. 
Ook kan deze discrepantie zijn ontstaan door verschillen in de transplantatie-inductie schema’s
en indicatiestelling. Alle patiënten in onze cross-sectionele studie kregen hoge-dosis-
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chemotherapie en TBI, terwijl in onze longitudinale studie bijna een kwart van de patiënten niet
werd behandeld met TBI. De meerderheid van de patiënten was afkomstig van één oncologisch
behandelcentrum en kregen vergelijkbare inductieschema’s. De inductie behandeling is in de
afgelopen jaren enigszins gewijzigd met een lager risico op neurotoxiciteit en mogelijk minder
invloed op de cognitieve functies. Deze verklaring blijft echter speculatief, zo werden er geen
aanwijzingen gevonden voor verschil in functioneren bij autologe en allogene transplantatie-
patiënten. Daarnaast suggereren de resultaten van de longitudinale studie dat de behandeling
voorafgaand aan de transplantatie mogelijk een belangrijke rol speelt in de ontwikkeling van
cognitieve beperkingen aangezien bijna twee jaar na de baselinemeting geen significante
veranderingen werden gevonden.
Onze PCNSL-studie is één van de eerste onderzoeken naar de cognitieve gevolgen van een
combinatiebehandeling uit een klinische trial.10 We gebruikten een uitgebreide neuropsycho-
logische testbatterij om de lange-termijn effecten te onderzoeken. In tegenstelling tot de
transplantatie studies bleek sprake van een fors aantal cognitieve problemen bij patiënten met
een relatief jonge leeftijd. Onze bevindingen wijzen uit dat de combinatiebehandeling en de
ziekte zelf leidt tot substantiële cognitieve beperkingen die een negatieve invloed hebben op
het alledaags functioneren omdat minder dan de helft van de patiënten was teruggekeerd in
het arbeidsproces. Een aandachtspunt voor verder onderzoek op dit gebied is de boven-
staande bevindingen te verifiëren in een grootschalige en longitudinale studie. Momenteel is er
een internationale studie in voorbereiding.
Er bleek in onze HSCT-studies geen consistent verband te zijn tussen het subjectief cognitief
funcioneren (cognitieve klachten) en de prestaties van het neuropsychologisch onderzoek. Dit
kan samenhangen met de verschillende meetinstrumenten die gebruikt werden om deze
klachten te meten. In de cross-sectionele studie en de pilotstudie werd de aanwezigheid en
ernst van de klachten gemeten door de neuropsycholoog tijdens een korte anamnese voor het
onderzoek. Dit is een algemene procedure in de klinische praktijk en mogelijke problemen werden
voorkomen door alle onderzoeken af te laten nemen door één individu. In de andere studies
werden patiënten gevraagd om een vragenlijst in te vullen waarmee de frequentie van
alledaagse cognitieve beperkingen over geheugen, aandacht, uitvoering en perceptie werd
gemeten.11,12 Beide instrumenten kunnen verschillende concepten meten en de aanleiding zijn
voor inconsistente bevindingen.
Een andere verklaring voor het ontbreken van een verband tussen de subjectieve en de
objectieve meetinstrumenten kan zijn dat patiënten hun eigen prestaties niet goed kunnen
beoordelen (patiënten met een hersentumor kunnen bijvoorbeeld een beperkt ziekte-inzicht
hebben door de hersenbeschadiging), zich aanpassen aan de beperkingen, of er op een andere
wijze mee om leren gaan. Ook is het mogelijk dat patiënten zich aanpassen aan een ‘nieuwe
manier van leven’ en minder een beroep doen op hun cognitieve mogelijkheden waardoor een
achteruitgang in functioneren niet meer van belang is. Dit lijkt plausibel omdat een groot deel
van de patiënten niet meer kan terugkeren op het premorbide niveau of volledig kan deel-
nemen aan beroepsmatige, opleidings- of sociale activiteiten. Daarnaast speelt mogelijk een
zogenaamde ‘response-shift’ een rol omdat patiënten de standaard waarmee ze de kwaliteit
van leven beoordelen in de loop van de tijd veranderen. Zo kan bijvoorbeeld iemand die
behandeld is voor kanker anders (minder belastend) tegen cognitieve beperkingen aankijken.
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De patiënt kan zich min of meer gedwongen voelen om minder waarde te hechten aan en
minder te klagen over cognitieve klachten omdat andere concepten (zoals ‘nog in leven zijn’,
familiecontacten) een belangrijkere plaats hebben ingenomen.
Een belangrijk punt voor verder onderzoek is het vaststellen van de specifieke cytotoxische
middelen, behandelingsmethoden en combinaties van behandelingen die verantwoordelijk zijn
voor het ontstaan van de cognitieve beperkingen. Onze studies leveren geen antwoord op dit
oorzaak-en-gevolg-vraagstuk. De PCNSL studie is een eerste stap naar de zoektocht naar even-
tuele oorzaken. Het cognitief functioneren werd vergeleken met neuroradiologische afwijkingen
op de MRI. Witte stof afwijkingen en/of corticale atrofie werden gevonden in de meerderheid
van de patiëntengroep. Bij slechts één van de patiënten was sprake van een milde atrofie voor
de behandeling; dit suggereert dat er een directe relatie bestaat tussen de behandeling en de
geobjectiveerde cognitieve beperkingen. Tumor effecten valen echter niet uit te sluiten.
Onderzoek naar de structurele, metabolische en functionele gevolgen van kankerbehan-
delingen gaat echter verder dan de klinische neuropsychologie en voorbij aan het doel van dit
proefschrift.
Beperkingen en methodologische overwegingen
De studies die in dit proefschrift zijn beschreven hebben een aantal methodologische
beperkingen. Allereerst is in de HSCT-studies mogelijk sprake van een selectie-bias ondanks het
gebruik van inclusie- en exclusiecriteria. In de longitudinale studie weigerden ongeveer 20%
van de patiënten om deel te nemen aan de studie. Dit is niet onverwacht gezien het intensieve
behandelingsschema voorafgaand aan de transplantatie. Het is daardoor mogelijk dat de
patiëntengroepen uit de studies niet vergelijkbaar zijn met de totale patiëntenpopulatie.
Een beperking van de longitudinale studie is dat discrepanties in de resultaten kunnen
samenhangen met verschillen die reeds bestonden voor de behandeling, en niet met effecten
van de behandeling. De invloed van deze vorm van test-bias lijkt echter klein gezien het feit dat
er geen verschillen werden gevonden tussen de patiëntgroepen bij de baselinemeting. Ook
fungeerden de patiënten als eigen controlepatiënt doordat het cognitief functioneren door de
tijd heen werd gemeten op verschillende meetmomenten. Een baselinemeting voor de behan-
deling en het gebruik van een referentiegroep zijn een goed alternatief voor randomisatie. Een
‘echte’ baselinemeting voor de aanvang van de ziekte is echter niet mogelijk. Het afnemen van
een neuropsychologisch onderzoek vlak nadat men op de hoogte is van een maligne
aandoening (en veelal levensbedreigende ziekte) en voor aanvang van de behandeling, gaat
naast allerlei ethische bezwaren samen met andere methodologische beperkingen. Eén hiervan
is dat het psychologische effect kort na het vernemen van een maligne diagnose zeer
waarschijnlijk resulteert in lagere testresultaten. 
Onderzoek naar cognitieve functies in dit proefschrift werd uitgevoerd door de testresultaten
van patiënten te vergelijken met normscores. Dit is een gebruikelijke benadering in de klinische
neuropsychologie.13,14 De prestaties van gezonde personen kunnen dienen als een controle,
temeer omdat bij patiënten zonder tumorlokalisatie in het CNS geen neurologische disfuncties,
- en hieraan gerelateerde cognitieve beperkingen - worden gevonden. Het gebruik van
testnormen heeft ook het voordeel dat gebruik gemaakt kan worden van een grotere
steekproef. Hierdoor kan een accurate schatting worden gemaakt van de prestaties van de
controlegroep waarmee de patiëntengroep wordt vergeleken. Er zijn echter een tweetal
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nadelen aan het gebruik testnormen. Elke neuropsychologische test heeft veelal afzonderlijke
normscores waardoor variatie bestaat in de steekproefgrootte en de selectie van de proef-
personen. Hierdoor kan sprake zijn van inconsistentie in de interpretatie van de resultaten.
Daarnaast kan bij het gebruik van testnormen niet gecontroleerd worden voor verschillen ten
aanzien van emotioneel en psychologisch disfunctioneren waarmee een medische aandoening
vooral kanker, vaak gepaard gaat. Om hiervoor te controleren is het gebruik van een vergelijk-
bare groep patiënten wenselijk. In de longitudinale HSCT studie en in de PCNSL studie werd
derhalve gebruik gemaakt van een referentiegroep met patiënten met hematologische maligni-
teiten. Daarnaast werden in elke studie instrumenten opgenomen om het psychologisch
functioneren, de kwaliteit van leven en vermoeidheid te meten om het verband tussen de
verschillende functies vast te stellen.
Implicaties voor de klinische praktijk
Ondanks de erkenning dat kanker en kankerbehandeling kunnen samengaan met cognitieve
beperkingen en dat cognitieve evaluaties belangrijk zijn voor de patiëntenzorg, is er nog steeds
een tekort aan praktische bijdragen zoals bijvoorbeeld instructies voor betere patiënten-
informatie, begeleiding van beslissingen voor de behandeling en therapeutische interventies.
Cognitieve klachten van patiënten dienen serieus genomen te worden vooral omdat een
verband tussen objectieve en subjectieve cognitieve meetinstrumenten ontbreekt. Onafhankelijk
van de ernst van mogelijke stoornissen bij kankerpatiënten, is het essentieel dat men begrijpt
dat zelfs milde cognitieve beperkingen invloed kunnen hebben op de kwaliteit van leven. Ook
is het belangrijk om de effecten van cognitieve beperkingen op het alledaags functioneren te
onderzoeken. Expertise op neuropsychologisch gebied dient aanwezig te zijn in oncologische
behandelcentra en patiënten zouden indien nodig doorgestuurd moeten worden voor een
uitgebreid testonderzoek.
Diverse medewerkers uit de klinische setting (verpleegkundigen, verpleegkundig-specialisten,
psychologen en psychiaters) hebben een invloedrijke rol in de voorlichting van patiënten, niet
alleen ten aanzien van de diagnose en behandeling, maar ook over mogelijke bijwerkingen en
cognitieve beperkingen die kunnen interfereren met de dagelijkse routine. Tevens spelen ze
een rol in het leren omgaan met eventuele beperkingen. Voor sommige patiënten voldoet de
kennis dat cognitieve beperkingen na de behandeling kunnen voor komen en dat de stoor-
nissen mogelijk kunnen verminderen in de loop van de tijd. Voor andere patiënten kan een
neuropsychologisch onderzoek noodzakelijk zijn om de omvang van de beperkingen te meten
en veranderingen in de tijd te volgen.
Beschouwing en toekomstperspectieven
Het is cruciaal dat oncologen en andere medewerkers uit de kliniek de cognitieve gevolgen van
kanker en kankerbehandeling herkennen en ingrijpen om de lange termijn gevolgen te
minimaliseren. In het verleden is dit onderschat en hebben de meeste studies zich op over-
levingsduur, controle van de ziekte en de fysieke bijwerkingen gericht. Vooral de laatste vijf jaar
is de belangstelling voor dit onderzoeksgebied toegenomen en is de psychometrische kwaliteit
van de ondernomen studies sterk verbeterd. Desondanks zijn er een aantal aandachtspunten
voor verder onderzoek.
Longitudinale gegevens over de persistentie van de geobjectiveerde cognitieve beperkingen
blijft beperkt. Men erkent dat de herstelperiode na HSCT een langdurig proces is dat langer
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dan een jaar kan duren. Vervolgonderzoek is noodzakelijk om te bepalen of de geobjectiveerde
cognitieve beperkingen blijven bestaan in de loop van de tijd. Indien bij vervolgonderzoek
aanwijzingen worden gevonden voor persisterende stoornissen dan is het belangrijk om
objectieve cognitieve meetinstrumenten op te nemen als een onderdeel van de evaluatie naar
toxiciteit in klinische trials. Ook dienen dan interventie en preventiemogelijkheden te worden
overwogen. Neuropsychologisch onderzoek in klinische trials kan een bijdrage leveren in het
onderzoek naar de voor- en nadelen van verschillende behandelingsmethoden.
Vervolgonderzoek bij PCNSL patiënten dient zich te richten op prospectieve en longitudinale
studies die de aard en veranderingen bestuderen van de verschillende behandelingsmethoden
voor deze aandoening. De leeftijdsafhankelijke co-morbiditeit en de bijdrage van de ziekte zelf
(die kan resulteren in parenchym schade) aan de cognitieve achteruitgang dient meer aandacht
te krijgen. Problemen binnen dit onderzoeksgebied zijn de lage incidentie van de ziekte en het
ontbreken van een standaard neuropsychologische testbatterij. Zo’n testbatterij dient aan de
volgende eisen te voldoen: kort, voor patiënt en medewerker van de kliniek; goede psycho-
metrische eigenschappen (validiteit, betrouwbaarheid en normatieve data); en inclusie van tests
die de effecten van de tumor en de behandeling te meten.15
Het is veelbelovend dat zeer recent richtlijnen voor onderzoek naar cognitieve functies bij
PCNSL patiënten zijn ontwikkeld in samenwerking met ‘the International PCNSL Collaborative
Group’ en dat een gestandaardiseerde kernbatterij van neuropsychologische tests en kwaliteit
van leven meetinstrumenten wordt geïntroduceerd in de nabije toekomst.16 Het opnemen van
formele en systematische evaluaties in PCNSL studies zal de kennis van de toxiciteit van de
behandeling voor deze aandoening doen toenemen.
Concluderend, de consistente bevindingen voor de aanwezigheid van cognitieve beperkingen
in de studies die in dit proefschrift zijn beschreven suggereren een meetbare en aanhoudende
invloed van intensieve behandelingen voor hematologische maligniteiten op het cognitief
functioneren, ondanks de verschillende beperkende factoren die in elk hoofdstuk zijn aange-
geven. Het verband tussen intensieve behandeling en de cognitieve functies blijft gecompli-
ceerd. Er zijn verschillende factoren van invloed op de cognitieve functies en het is bijna
onmogelijk om te bepalen welke factor de meest centrale rol speelt. De huidige bevindingen
geven aan dat cognitieve veranderingen na een kankerbehandeling niet universeel zijn.
Sommige patiënten zijn in staat een behandeling te doorstaan zonder aantoonbare stoornissen,
terwijl anderen neurotoxiteit ontwikkelen die de kwaliteit van leven aanzienlijk beperkt en hen
weerhoudt om sociale en beroepsmatige activiteiten te ondernemen. Tot op heden was het een
uitdaging om het bestaan van deze subgroep van patiënten te bewijzen met behulp van goede
methodologische en longitudinale studies. Dit proefschrift heeft een aantal aspecten van de
complexe puzzel belicht, echter er zijn nog veel stukken die onvindbaar blijven. 
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